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REAMBLE
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures and
herapies as they are introduced in the detection, management,
r prevention of disease states. Rigorous and expert analysis of
he available data documenting the absolute and relative
enefits and risks of those procedures and therapies can
roduce helpful guidelines that improve the effectiveness of
are, optimize patient outcomes, and favorably affect the overall
ost of care by focusing resources on the most effective strategies.
The American College of Cardiology (ACC) and the
merican Heart Association (AHA) have jointly engaged in
he production of such guidelines in the area of cardiovascular
isease since 1980. This effort is directed by the ACC/AHA
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesask Force on Practice Guidelines, whose charge is to develop,
pdate, or revise practice guidelines for important cardiovas-
ular diseases and procedures. Writing committees are charged
ith the task of performing an assessment of the evidence and
cting as an independent group of authors to develop or update
ritten recommendations for clinical practice.
Experts in the subject under consideration are selected
rom both organizations to examine subject-specific data
nd write guidelines. The process includes additional rep-
esentatives from other medical practitioner and specialty
roups where appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers, co-
orbidities, and issues of patient preference that might
nfluence the choice of particular tests or therapies are
onsidered, as well as frequency of follow-up. When avail-
ble, information from studies on cost will be considered;
owever, review of data on efficacy and clinical outcomes
ill be the primary basis for preparing recommendation in
hese guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflicts of interest that might arise as a result of an
utside relationship or personal interest of a member of the
riting committee. Specifically, all members of the writing
ommittee and peer reviewers of the document are asked to
rovide disclosure statements of all such relationships that
ight be perceived as real or potential conflicts of interest.
riting committee members are also strongly encouraged
o declare a previous relationship with industry that might
e perceived as relevant to guideline development. If a
riting committee member develops a new relationship
ith industry during his or her tenure, he or she is required
o notify guideline staff in writing. The continued partici-
ation of the writing committee member will be reviewed.
hese statements are reviewed by the parent task force,
eported orally to all members of the writing panel at each
eeting, and updated and reviewed by the writing commit-
ee as changes occur. Please refer to the methodology
anual for ACC/AHA guideline writing committees for
urther description of the relationships with industry policy,
vailable on ACC and AHA World Wide Web sites
http://www.acc.org/clinical/manual/manual_introltr.htm
nd http://circ.ahajournals.org/manual/). Relationships
ith industry pertinent to these guidelines are listed in
ppendixes 1 and 2 of the full-text Guidelines for members
f the writing committee and peer reviewers, respectively.
These practice guidelines are intended to assist healthcare
roviders in clinical decision making by describing a range
f generally acceptable approaches for the diagnosis, man-
gement, and prevention of specific diseases or conditions.
hese guidelines attempt to define practices that meet the
eeds of most patients in most circumstances. These guide-ine recommendations reflect a consensus of expert opinion after a thorough review of the available, current scientific
vidence and are intended to improve patient care. If these
uidelines are used as the basis for regulatory/payer deci-
ions, the ultimate goal is quality of care and serving the
atient’s best interests. The ultimate judgment regarding
are of a particular patient must be made by the healthcare
rovider and patient in light of all of the circumstances
resented by that patient. There are circumstances in which
eviations from these guidelines are appropriate.
The “ACC/AHA 2006 Practice Guidelines for the Man-
gement of Patients With Valvular Heart Disease” was
pproved for publication by the ACC Foundation (ACCF)
oard of trustees in May 2006 and the AHA Science
dvisory and Coordinating Committee in May 2006. The
xecutive summary and recommendations are published in
he August 1, 2006 issue of the Journal of the American
ollege of Cardiology and the August 1, 2006 issue of
irculation. The full-text guideline is e-published in the
ame issues of each journal and is posted on the World
ide Web sites of the ACC (www.acc.org) and the AHA
www.americanheart.org). The guidelines will be reviewed
nnually by the ACC/AHA Task Force on Practice Guide-
ines and will be considered current unless they are updated,
evised, or sunsetted and withdrawn from distribution.
opies of the full text and the executive summary are
vailable from both organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA,
Chair, ACC/AHA Task Force on Practice Guidelines
. INTRODUCTION
his guideline focuses primarily on valvular heart disease in
he adult, with a separate section dealing with specific
ecommendations for valve disorders in adolescents and
oung adults. The diagnosis and management of infants and
oung children with congenital valvular abnormalities are
ignificantly different from those of the adolescent or adult
nd are beyond the scope of these guidelines.
The committee emphasizes the fact that many factors
ltimately determine the most appropriate treatment of
ndividual patients with valvular heart disease within a given
ommunity. These include the availability of diagnostic
quipment and expert diagnosticians, the expertise of inter-
entional cardiologists and surgeons, and notably, the
ishes of well-informed patients. Therefore, deviation from
hese guidelines may be appropriate in some circumstances.
hese guidelines are written with the assumption that a
iagnostic test can be performed and interpreted with skill
evels consistent with previously reported ACC training and
ompetency statements and ACC/AHA guidelines, that
nterventional cardiological and surgical procedures can be
erformed by highly trained practitioners within acceptable
afety standards, and that the resources necessary to perform
hese diagnostic procedures and provide this care are readily
vailable. This is not true in all geographic areas, which
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ACC/AHA Practice Guidelines August 1, 2006:598–675urther underscores the committee’s position that its recom-
endations are guidelines and not rigid requirements.
All of the recommendations in this guideline revision
ere converted from the tabular format used in the 1998
uideline to a listing of recommendations that has been
ritten in full sentences to express a complete thought, such
hat a recommendation, even if separated and presented
part from the rest of the document, would still convey the
ull intent of the recommendation. It is hoped that this will
ncrease the readers’ comprehension of the guidelines. Also,
he level of evidence, either A, B, or C, for each recom-
endation is now provided. See Figure 1 for further details
n the classification and level of evidence schema.
I. GENERAL PRINCIPLES
. Evaluation of the Patient With a Cardiac Murmur
ardiac auscultation remains the most widely used method
f screening for valvular heart disease. The production of
urmurs is due to 3 main factors: 1) high blood flow rate
hrough normal or abnormal orifices, 2) forward flow
hrough a narrowed or irregular orifice into a dilated vessel
r chamber, and 3) backward or regurgitant flow through an
ncompetent valve.
A heart murmur may have no pathological significance
r may be an important clue to the presence of valvular,
ongenital, or other structural abnormalities of the heart.
ost systolic heart murmurs do not signify cardiac
isease, and many are related to physiological increases in
lood flow velocity. In other instances, a heart murmur
ay be an important clue to the diagnosis of undetected
ardiac disease that may be important even when asymp-
omatic or that may define the reason for cardiac symp-
oms. In these situations, various noninvasive or invasive
ardiac tests may be necessary to establish a firm diagno-
is and form the basis for rational treatment of an
nderlying disorder. Echocardiography is particularly
seful in this regard, as discussed in the “ACC/AHA/
SE 2003 Guidelines for the Clinical Application of
chocardiography” (1). Diastolic murmurs virtually al-
ays represent pathological conditions and require fur-
her cardiac evaluation, as do most continuous murmurs.
ontinuous “innocent” murmurs include venous hums
nd mammary souffles.
. Electrocardiography and Chest Roentgenography
lthough echocardiography usually provides more spe-
ific and often quantitative information about the signif-
cance of a heart murmur and may be the only test
eeded, the electrocardiogram (ECG) and chest X-ray
re readily available and may have been obtained previ-
usly. The absence of ventricular hypertrophy, atrial
nlargement, arrhythmias, conduction abnormalities,
rior myocardial infarction, and evidence of active isch-
mia on the ECG provides useful negative information at erelatively low cost. Abnormal ECG findings in a patient
ith a heart murmur, such as ventricular hypertrophy or
prior infarction, should lead to a more extensive
valuation that includes echocardiography.
Chest roentgenograms often yield qualitative information
n cardiac chamber size, pulmonary blood flow, pulmonary
nd systemic venous pressure, and cardiac calcification in
atients with cardiac murmurs. When abnormal findings are
resent on chest X-ray, echocardiography should be per-
ormed.
. Echocardiography
lass I
. Echocardiography is recommended for asymptomatic
patients with diastolic murmurs, continuous murmurs,
holosystolic murmurs, late systolic murmurs, murmurs
associated with ejection clicks or murmurs that radiate
to the neck or back. (Level of Evidence: C)
. Echocardiography is recommended for patients with
heart murmurs and symptoms or signs of heart failure,
myocardial ischemia/infarction, syncope, thrombo-
embolism, infective endocarditis, or other clinical
evidence of structural heart disease. (Level of Evi-
dence: C)
. Echocardiography is recommended for asymptomatic
patients who have grade 3 or louder midpeaking
systolic murmurs. (Level of Evidence: C)
lass IIa
. Echocardiography can be useful for the evaluation of
asymptomatic patients with murmurs associated with
other abnormal cardiac physical findings or murmurs
associated with an abnormal ECG or chest X-ray.
(Level of Evidence: C)
. Echocardiography can be useful for patients whose
symptoms and/or signs are likely noncardiac in origin
but in whom a cardiac basis cannot be excluded by
standard evaluation. (Level of Evidence: C)
lass III
Echocardiography is not recommended for patients
who have a grade 2 or softer midsystolic murmur
identified as innocent or functional by an experienced
observer. (Level of Evidence: C)
chocardiography with color flow and spectral Doppler
valuation is an important noninvasive method for assessing
he significance of cardiac murmurs. Information regarding
alve morphology and function, chamber size, wall thick-
ess, ventricular function, pulmonary and hepatic vein flow,
nd estimates of pulmonary artery pressures can be readily
ntegrated.
Although echocardiography can provide important infor-
ation, such testing is not necessary for all patients with
ardiac murmurs and usually adds little but expense in the
valuation of asymptomatic younger patients with short
Figure 1. Applying classification of recommendations and level of evidence. *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history
of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many
important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular
test or therapy is useful or effective. †In 2003 the ACC/AHA Task Force on Practice Guidelines provided a list of suggested phrases to use when writing recommendations. All recommendations in this
guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets
of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual
recommendation level. 603
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ACC/AHA Practice Guidelines August 1, 2006:598–675rade 1 to 2 midsystolic murmurs and otherwise normal
hysical findings. At the other end of the spectrum are
atients with heart murmurs for whom transthoracic echo-
ardiography proves inadequate. Depending on the specific
linical circumstances, transesophageal echocardiography
TEE), cardiac magnetic resonance, or cardiac catheteriza-
ion may be indicated for better characterization of the
alvular lesion.
It is important to note that Doppler ultrasound devices
re very sensitive and may detect trace or mild valvular
egurgitation through structurally normal tricuspid and
ulmonic valves in a large percentage of young, healthy
ubjects and through normal left-sided valves (particularly
he mitral valve [MV]) in a variable but lower percentage of
atients (2–6).
General recommendations for performing echocardiog-
aphy in patients with heart murmurs are provided. Of
ourse, individual exceptions to these indications may exist.
. Cardiac Catheterization
ardiac catheterization can provide important information
bout the presence and severity of valvular obstruction,
alvular regurgitation, and intracardiac shunting. It is not
ecessary in most patients with cardiac murmurs and
ormal or diagnostic echocardiograms, but it provides
dditional information for some patients in whom there is a
iscrepancy between the echocardiographic and clinical
ndings. Indications for cardiac catheterization for hemo-
ynamic assessment of specific valve lesions are given in
ection III, “Specific Valve Lesions.” Specific indications
or coronary angiography to screen for the presence of
oronary artery disease (CAD) are given in Section X-B.
. Exercise Testing
xercise testing can provide valuable information in patients
ith valvular heart disease, especially in those whose symp-
oms are difficult to assess. It can be combined with
chocardiography, radionuclide angiography, and cardiac
atheterization. It has a proven track record of safety, even
mong asymptomatic patients with severe aortic stenosis
AS). Exercise testing has generally been underutilized in
his patient population and should constitute an important
omponent of the evaluation process.
. Approach to the Patient
he evaluation of the patient with a heart murmur may vary
reatly depending on the timing of the murmur in the
ardiac cycle, its location and radiation, and its response to
arious physiological maneuvers. Also of importance is the
resence or absence of cardiac and noncardiac symptoms
nd other findings on physical examination that suggest the
urmur is clinically significant.
Echocardiography is indicated for patients with diastolic
r continuous heart murmurs not due to a cervical venous
um or a mammary souffle during pregnancy, for those with polosystolic or late systolic murmurs, for those with mid-
ystolic murmurs of grade 3 or greater intensity, and for
hose with softer systolic murmurs in whom dynamic
ardiac auscultation suggests a definite diagnosis (e.g.,
ypertrophic cardiomyopathy). Echocardiography is also
ndicated in certain patients with grade 1 or 2 midsystolic
urmurs, including patients with symptoms or signs con-
istent with infective endocarditis, thromboembolism, heart
ailure, myocardial ischemia/infarction, or syncope.
It must be re-emphasized that trivial, minimal, or phys-
ological valvular regurgitation, especially affecting the mi-
ral, tricuspid, or pulmonic valves, is detected by color flow
maging techniques in many otherwise normal patients,
ncluding many patients who have no heart murmur at all
2,5,6). This observation must be considered when the
esults of echocardiography are used to guide decisions in
symptomatic patients in whom echocardiography was used
o assess the significance of an isolated murmur.
Characteristics of innocent murmurs in asymptomatic
dults that have no functional significance include the
ollowing:
grade 1 to 2 intensity at the left sternal border
a systolic ejection pattern
normal intensity and splitting of the second heart
sound
no other abnormal sounds or murmurs
no evidence of ventricular hypertrophy or dilatation
and the absence of increased murmur intensity with
the Valsalva maneuver or with standing from a squat-
ting position.
Throughout these guidelines, treatment recommenda-
ions will often derive from specific echocardiographic
easurements of left ventricular (LV) size and systolic
unction. Accuracy and reproducibility are critical, particu-
arly when applied to surgical recommendations for asymp-
omatic patients with mitral regurgitation (MR) or aortic
egurgitation (AR). Serial measurements over time, or
eassessment with a different imaging technology (radionu-
lide ventriculography or cardiac magnetic resonance), are
ften helpful for counseling individual patients. Lastly,
lthough handheld echocardiography can be used for
creening purposes, it is important to note that its accuracy
s highly dependent on the experience of the user. The
recise role of handheld echocardiography for the assess-
ent of patients with valvular heart disease has not been
lucidated.
As valuable as echocardiography may be, the basic car-
iovascular physical examination is still the most appropri-
te method of screening for cardiac disease and will establish
any clinical diagnoses. Echocardiography should not re-
lace the cardiovascular examination but can be useful in
etermining the cause and severity of valvular lesions,
articularly in older and/or symptomatic patients.
B
C
T
t
r
E
q
T
T
A
J
M
V
V
M
P
V
Q
Q
A
Q
Q
A
S
S
S
S
*
M
t
c
605JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:598–675 ACC/AHA Practice Guidelines. Valve Disease Severity Table
lassification of the severity of valve disease in adults is listed in
able 1. The classification for regurgitant lesions is adapted from
he recommendations of the American Society of Echocardiog-
able 1. Classification of the Severity of Valve Disease in Adults
. Left-Sided Valve Disease
Indicator Mild
et velocity (m per second) Less than 3.0
ean gradient (mm Hg)* Less than 25
alve area (cm2) Greater than 1.5
alve area index (cm2 per m2)
M
ean gradient (mm Hg)* Less tha
ulmonary artery systolic pressure (mm Hg) Less tha
alve area (cm2) Greater
Mild
ualitative
Angiographic grade 1
Color Doppler jet width Central jet, width less than
25% of LVOT
Doppler vena contracta width (cm) Less than 0.3
uantitative (cath or echo)
Regurgitant volume (ml per beat) Less than 30
Regurgitant fraction (%) Less than 30
Regurgitant orifice area (cm2) Less than 0.10
dditional essential criteria
Left ventricular size
Mild
ualitative
Angiographic grade 1
Color Doppler jet area Small, central jet (less than
4 cm2 or less than 20%
LA area)
Doppler vena contracta width (cm) Less than 0.3
uantitative (cath or echo)
Regurgitant volume (ml per beat) Less than 30
Regurgitant fraction (%) Less than 30
Regurgitant orifice area (cm2) Less than 0.20
dditional essential criteria
Left atrial size
Left ventricular size
B. Right-Sided Valve Disease
evere tricuspid stenosis: Valve
evere tricuspid regurgitation: Vena
evere pulmonic stenosis: Jet ve
Hg
evere pulmonic regurgitation: Color
Dense
Valve gradients are flow dependent and when used as estimates of severity of valve ste
odified from the Journal of the American Society of Echocardiography, 16, Zoghbi Wwo-dimensional and Doppler echocardiography, 777–802, Copyright 2003, with permissio
ath, catheterization; echo, echocardiography; LA, left atrial/atrium; LVOT, left ventriculaaphy (7). For full recommendations of the American Society of
chocardiography, please refer to the original document. Subse-
uent sections of the current guidelines refer to the criteria in
able 1 to define severe valvular stenosis or regurgitation.
Aortic Stenosis
Moderate Severe
3.0–4.0 Greater than 4.0
25–40 Greater than 40
1.0–1.5 Less than 1.0
Less than 0.6
Mitral Stenosis
Moderate Severe
5–10 Greater than 10
30–50 Greater than 50
1.5 1.0–1.5 Less than 1.0
Aortic Regurgitation
Moderate Severe
2 3–4
Greater than mild but no signs
of severe AR
Central jet, width greater than
65% LVOT
0.3–0.6 Greater than 0.6
30–59 Greater than or equal to 60
30–49 Greater than or equal to 50
0.10–0.29 Greater than or equal to 0.30
Increased
Mitral Regurgitation
Moderate Severe
2 3–4
of MR greater than
ld present but no
teria for severe MR
Vena contracta width greater than 0.7 cm with
large central MR jet (area greater than 40%
of LA area) or with a wall-impinging jet of
any size, swirling in LA
.69 Greater than or equal to 0.70
9 Greater than or equal to 60
9 Greater than or equal to 50
.39 Greater than or equal to 0.40
Enlarged
Enlarged
Characteristic
less than 1.0 cm2
acta width greater than 0.7 cm and systolic flow reversal in hepatic veins
greater than 4 m per second or maximum gradient greater than 60 mm
lls outflow tract
inuous wave Doppler signal with a steep deceleration slope
should be assessed with knowledge of cardiac output or forward flow across the valve.
ecommendations for evaluation of the severity of native valvular regurgitation withild
n 5
n 30
than
Signs
mi
cri
0.3–0
30–5
30–4
0.2–0
area
contr
locity
jet fi
cont
nosis
A, Rn from American Society of Echocardiography (7). AR indicates aortic regurgitation;
r outflow tract; and MR, mitral regurgitation.
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he following information is based on recommendations
ade by the AHA in 1997 (8). These recommendations are
urrently under revision and subject to change. Recommen-
ations for prophylaxis against and treatment of nonvalvular
ardiac device–related infections have been published pre-
iously (9).
. Endocarditis Prophylaxis
lass I
rophylaxis against infective endocarditis is recom-
ended for the following patients:
Patients with prosthetic heart valves and patients with a
history of infective endocarditis. (Level of Evidence: C)
Patients who have complex cyanotic congenital heart
disease (e.g., single-ventricle states, transposition of
the great arteries, tetralogy of Fallot). (Level of Evi-
dence: C)
Patients with surgically constructed systemic-pulmonary
shunts or conduits. (Level of Evidence: C)
Patients with congenital cardiac valve malformations,
particularly those with bicuspid aortic valves, and pa-
tients with acquired valvular dysfunction (e.g., rheumatic
heart disease). (Level of Evidence: C)
Patients who have undergone valve repair. (Level of
Evidence: C)
Patients who have hypertrophic cardiomyopathy when
there is latent or resting obstruction. (Level of Evi-
dence: C)
Patients with MV prolapse (MVP) and auscultatory
evidence of valvular regurgitation and/or thickened
leaflets on echocardiography.* (Level of Evidence: C)
lass III
rophylaxis against infective endocarditis is not recom-
ended for the following patients:
Patients with isolated secundum atrial septal defect.
(Level of Evidence: C)
Patients 6 or more months after successful surgical or
percutaneous repair of atrial septal defect, ventricular
septal defect, or patent ductus arteriosus. (Level of
Evidence: C)
Patients with MVP without MR or thickened leaflets
on echocardiography.* (Level of Evidence: C)
Patients with physiological, functional, or innocent
heart murmurs, including patients with aortic valve
sclerosis as defined by focal areas of increased echo-
genicity and thickening of the leaflets without restric-
tion of motion and a peak velocity less than 2.0 m per
second. (Level of Evidence: C)
Patients with echocardiographic evidence of physio-
logic MR in the absence of a murmur and with
structurally normal valves. (Level of Evidence: C) rPatients with echocardiographic evidence of physio-
logical tricuspid regurgitation (TR) and/or pulmonary
regurgitation in the absence of a murmur and with
structurally normal valves. (Level of Evidence: C)
Patients with MVP without regurgitation require addi-
ional clinical judgment. Indications for antibiotic prophy-
axis in MVP are discussed in Section III-E-2. Patients
ho do not have MR but who do have echocardiographic
vidence of thickening and/or redundancy of the valve
eaflets, and especially men 45 years of age or older, may
e at increased risk for infective endocarditis (10). Addi-
ionally, approximately one third of patients with MVP
ithout MR at rest may have exercise-induced MR (11).
ome patients may exhibit MR at rest on one occasion and
ot on another. There are no data available to address this
atter issue, and at present, the decision must be left to
linical judgment, taking into account the nature of the
nvasive procedure, the previous history of endocarditis,
nd the presence or absence of valve thickening and/or
edundancy.
. Rheumatic Fever Prophylaxis
lass I
Patients who have had rheumatic fever with or with-
out carditis (including patients with MS) should
receive prophylaxis for recurrent rheumatic fever.
(Level of Evidence: B)
heumatic fever is an important cause of valvular heart
isease worldwide. In the United States (and Western
urope), cases of acute rheumatic fever have been uncom-
on since the 1970s. However, starting in 1987, an increase
n cases has been observed. The enhanced understanding of
he causative organism, group A beta hemolytic streptococ-
us, has resulted in the development of kits that allow rapid
etection of group A streptococci with specificity greater
han 95% and more rapid identification of their presence in
pper respiratory infection. Because the test has a low
ensitivity, a negative test requires throat culture confirma-
ion. Rheumatic fever prevention and treatment guidelines
ave been established previously by the AHA (12). Prompt
ecognition and treatment comprise primary rheumatic
ever prevention.
Patients who have had an episode of rheumatic fever are
t high risk of developing recurrent episodes of acute
heumatic fever. Patients who develop carditis are especially
rone to similar episodes with subsequent attacks. Second-
ry prevention of rheumatic fever recurrence is thus of great
mportance. Continuous antimicrobial prophylaxis has been
hown to be effective. Anyone who has had rheumatic fever
ith or without carditis, including patients with mitral
tenosis (MS) should receive prophylaxis for recurrent
heumatic fever (12).
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. Aortic Stenosis
he most common cause of AS in adults is calcification of
normal trileaflet or congenital bicuspid valve (13,14).
alcific AS is an active disease process characterized by lipid
ccumulation, inflammation, and calcification, with many
imilarities to atherosclerosis (15–19). Rheumatic AS due to
usion of the commissures with scarring and eventual
alcification of the cusps is less common and is invariably
ccompanied by MV disease.
. Grading the Degree of Stenosis
or these guidelines, we graded AS severity on the basis of
variety of hemodynamic and natural history data (Table 1)
7,20), using definitions of aortic jet velocity, mean pressure
radient, and valve area as follows:
Mild (area 1.5 cm2, mean gradient less than 25 mm
Hg, or jet velocity less than 3.0 m per second)
Moderate (area 1.0 to 1.5 cm2, mean gradient 25–40
mm Hg, or jet velocity 3.0–4.0 m per second)
Severe (area less than 1.0 cm2, mean gradient greater
than 40 mm Hg or jet velocity greater than 4.0 m per
second).
hen stenosis is severe and cardiac output is normal, the
ean transvalvular pressure gradient is generally greater
han 40 mm Hg. However, when cardiac output is low,
evere stenosis may be present with a lower transvalvular
radient and velocity, as discussed below. Some patients
ith severe AS remain asymptomatic, whereas others with
nly moderate stenosis develop symptoms. Therapeutic
ecisions, particularly those related to corrective surgery, are
ased largely on the presence or absence of symptoms.
hus, the absolute valve area (or transvalvular pressure
radient) is not the primary determinant of the need for
ortic valve replacement (AVR).
. Natural History
he natural history of AS in the adult consists of a
rolonged latent period during which morbidity and mor-
ality are very low. The rate of progression of the stenotic
esion has been estimated in a variety of invasive and
oninvasive studies (21). Once even moderate stenosis is
resent (jet velocity greater than 3.0 m per second; Table 1),
he average rate of progression is an increase in jet velocity
f 0.3 m per second per year, an increase in mean pressure
radient of 7 mm Hg per year, and a decrease in valve area
f 0.1 cm2 per year (22–27); however, there is marked
ndividual variability in the rate of hemodynamic progres-
ion. Although it appears that the progression of AS can be
ore rapid in patients with degenerative calcific disease
han in those with congenital or rheumatic disease (27–29),
t is not possible to predict the rate of progression in an
ndividual patient. For this reason, regular clinical follow-ups mandatory in all patients with asymptomatic mild to
oderate AS. In addition, progression to AS may occur in
atients with aortic sclerosis, defined as valve thickening
ithout obstruction to LV outflow (30).
Aortic sclerosis is present in approximately 25% of adults
ver 65 years of age and is associated with clinical factors
uch as age, sex, hypertension, smoking, serum low-density
ipoprotein and lipoprotein(a) levels, and diabetes mellitus
31). Aortic sclerosis on echocardiography in subjects with-
ut known coronary disease is also associated with adverse
linical outcome, with an approximately 50% increased risk
f myocardial infarction and cardiovascular death compared
ith subjects with a normal aortic valve (32–34). The
echanism of this association is unclear and is likely related
o subclinical atherosclerosis, endothelial dysfunction, or
ystemic inflammation rather than valve hemodynamics.
Eventually, symptoms of angina, syncope, or heart failure
evelop after a long latent period, and the outlook changes
ramatically. After the onset of symptoms, average survival
s 2 to 3 years (35–39), with a high risk of sudden death.
hus, the development of symptoms identifies a critical
oint in the natural history of AS. It is important to
mphasize that symptoms may be subtle and often are not
licited by the physician in taking a routine clinical history.
Sudden death is known to occur in patients with severe
S and, in older retrospective studies, has been reported to
ccur without prior symptoms (35,40–42). However, in
rospective echocardiographic studies, sudden death in
reviously asymptomatic patients is rare (20,27,38,43–45),
stimated at less than 1% per year when patients with
nown AS are followed up prospectively.
. Management of the Asymptomatic Patient
symptomatic patients with AS have outcomes similar to
ge-matched normal adults; however, disease progression
ith symptom onset is common (20,27,38,43–47). Patients
ith asymptomatic AS require frequent monitoring for
evelopment of symptoms and progressive disease.
. Echocardiography (Imaging, Spectral, and Color Dopp-
er) in Aortic Stenosis
lass I
. Echocardiography is recommended for the diagnosis
and assessment of AS severity. (Level of Evidence: B)
. Echocardiography is recommended in patients with
AS for the assessment of LV wall thickness, size, and
function. (Level of Evidence: B)
. Echocardiography is recommended for re-evaluation
of patients with known AS and changing symptoms
or signs. (Level of Evidence: B)
. Echocardiography is recommended for the assess-
ment of changes in hemodynamic severity and LV
function in patients with known AS during preg-
nancy. (Level of Evidence: B)
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re-evaluation of asymptomatic patients: every year for
severe AS; every 1–2 years for moderate AS; and every
3–5 years for mild AS. (Level of Evidence: B)
chocardiography is indicated when there is a systolic
urmur that is grade 3/6 or greater, when there is a single
2, or if there are symptoms that might be due to AS. The
-dimensional (2D) echocardiogram is valuable for evalua-
ion of valve anatomy and function and to determine the LV
esponse to pressure overload. In nearly all patients, the
everity of the stenotic lesion can be defined with Doppler
chocardiographic measurements of maximum jet velocity,
ean transvalvular pressure gradient, and continuity equa-
ion valve area, as discussed in the “ACC/AHA/ASE 2004
uidelines for the Clinical Application of Echocardiogra-
hy” (1). Doppler evaluation of AS severity requires atten-
ion to technical details, with the most common error being
nderestimation of disease severity due to a nonparallel
ntercept angle between the ultrasound beam and high-
elocity jet through the narrowed valve. When measurement
f LV outflow tract diameter is problematic, the ratio of
utflow tract velocity to aortic jet velocity can be substituted
or valve area, because this ratio is, in effect, indexed for
ody size. A ratio of 0.9 to 1.0 is normal, with a ratio less
han 0.25 indicating severe stenosis. Echocardiography is
lso used to assess LV size and function, degree of hyper-
rophy, and presence of other associated valvular disease.
. Exercise Testing
lass IIb
Exercise testing in asymptomatic patients with AS
may be considered to elicit exercise-induced symp-
toms and abnormal blood pressure responses. (Level
of Evidence: B)
lass III
Exercise testing should not be performed in symp-
tomatic patients with AS. (Level of Evidence: B)
xercise testing in adults with AS has poor diagnostic
ccuracy for evaluation of concurrent CAD. Presumably,
his is due to the presence of an abnormal baseline ECG,
V hypertrophy, and limited coronary flow reserve. Elec-
rocardiographic ST depression during exercise occurs in
0% of adults with asymptomatic AS and has no known
rognostic significance.
Exercise testing should not be performed in symptomatic
atients because of the high risk of complications; however,
n asymptomatic patients, exercise testing is relatively safe
nd may provide information that is not uncovered during
he initial clinical evaluation (20,46–52). When the medical
istory is unclear, exercise testing can identify a limited
xercise capacity, abnormal blood pressure responses, or
ven exercise-induced symptoms (46,47,52). An abnormal
emodynamic response (e.g., hypotension or failure to oncrease blood pressure with exercise) in a patient with
evere AS is considered a poor prognostic finding (46,53).
inally, in selected patients, the observations made during
xercise may provide a basis for advice about physical activity.
xercise testing in asymptomatic patients should be performed
nly under the supervision of an experienced physician, with
lose monitoring of blood pressure and the ECG.
. Serial Evaluations
he frequency of follow-up visits to the physician de-
ends on the severity of AS and on the presence of
omorbid conditions. An essential component of each
isit is patient education about the expected disease
ourse and symptoms of AS. Patients should be advised
o promptly report the development of any change in
xercise tolerance, exertional chest discomfort, dyspnea,
ightheadedness, or syncope.
Serial echocardiography is an important part of an
ntegrated approach that includes a detailed history,
hysical examination, and, in some patients, a carefully
onitored exercise test. Because the rate of progression
aries considerably, clinicians often perform an annual
chocardiogram on patients known to have moderate to
evere AS. Serial echocardiograms are helpful to assess
hanges in stenosis severity, LV hypertrophy, and LV
unction. Therefore, in patients with severe AS, an
chocardiogram every year may be appropriate. In pa-
ients with moderate AS, serial studies performed every 1
o 2 years are satisfactory, and in patients with mild AS,
erial studies can be performed every 3 to 5 years.
chocardiograms should be performed more frequently if
here is a change in signs or symptoms.
. Medical Therapy
ntibiotic prophylaxis is indicated in all patients with AS
or prevention of infective endocarditis and, in those with
heumatic AS, for prevention of recurrent rheumatic
ever. Patients with associated systemic arterial hyperten-
ion should be treated cautiously with appropriate anti-
ypertensive agents. With these exceptions, there is no
pecific medical therapy for patients who have not yet
eveloped symptoms. Patients who develop symptoms
equire surgery, not medical therapy.
There are no medical treatments proven to prevent or
elay the disease process in the aortic valve leaflets;
owever, the association of AS with clinical factors
imilar to those associated with atherosclerosis and the
echanisms of disease at the tissue level (15–19,30 –
4,54 –58) and small retrospective studies of the effect of
ipid-lowering therapy (59 – 64) have led to the hypoth-
sis that intervention may be possible to slow or prevent
isease progression in the valve leaflet (56,65). Yet, a
rospective, randomized, placebo-controlled trial in pa-
ients with calcific aortic valve disease failed to demon-
trate a benefit of atorvastatin in reducing the progression
f aortic valve stenosis over a 3-year period (66). It is
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesoteworthy that the patients in this study had high levels
f aortic valve calcification by computed tomography and
vidence of moderate to severe AS at baseline. Thus,
urther trials in patients with less severe aortic valve
alcification, with longer follow-up periods, are needed.
n the meanwhile, evaluation and modification of cardiac
isk factors is important in patients with aortic valve
isease to prevent concurrent CAD.
. Physical Activity and Exercise
ecommendations for physical activity are based on the
linical examination, with special emphasis on the hemody-
amic severity of the stenotic lesion. Recommendations on
articipation in competitive sports have been published by
he Task Force on Acquired Valvular Heart Disease of the
6th Bethesda Conference (67). Physical activity is not
estricted in asymptomatic patients with mild AS; these
atients can participate in competitive sports. Patients with
oderate to severe AS should avoid competitive sports that
nvolve high dynamic and static muscular demands. Other
orms of exercise can be performed safely, but it is advisable
o evaluate such patients with an exercise test before they
egin an exercise or athletic program.
. Indications for Cardiac Catheterization
lass I
. Coronary angiography is recommended before AVR
in patients with AS at risk for CAD (see Section
X-B). (Level of Evidence: B)
. Cardiac catheterization for hemodynamic measure-
ments is recommended for assessment of severity of
AS in symptomatic patients when noninvasive tests
are inconclusive or when there is a discrepancy
between noninvasive tests and clinical findings re-
garding severity of AS. (Level of Evidence: C)
. Coronary angiography is recommended before AVR
in patients with AS for whom a pulmonary autograft
(Ross procedure) is contemplated and if the origin of
the coronary arteries was not identified by noninva-
sive technique. (Level of Evidence: C)
lass III
. Cardiac catheterization for hemodynamic measure-
ments is not recommended for the assessment of
severity of AS before AVR when noninvasive tests are
adequate and concordant with clinical findings.
(Level of Evidence: C)
. Cardiac catheterization for hemodynamic measure-
ments is not recommended for the assessment of LV
function and severity of AS in asymptomatic patients.
(Level of Evidence: C)
n preparation for AVR, coronary angiography is indicated
n patients suspected of having CAD, as discussed in
ection X-B. If the clinical and echocardiographic data are
ypical of severe isolated AS, coronary angiography may be 0ll that is needed before AVR. A complete left- and
ight-heart catheterization may be necessary to assess the
emodynamic severity of the AS if there is a discrepancy
etween clinical and echocardiographic data.
The pressure gradient across a stenotic valve is related to
he valve orifice area and the transvalvular flow (68). Thus,
n the presence of depressed cardiac output, relatively low
ressure gradients may be obtained in patients with severe
S. On the other hand, during exercise or other high-flow
tates, significant pressure gradients can be measured in
inimally stenotic valves. For these reasons, complete
ssessment of AS requires measurement of transvalvular
ow, determination of the mean transvalvular pressure
radient, and calculation of the effective valve area. Atten-
ion to detail with accurate measurements of pressure and
ow is important, especially in patients with low cardiac
utput or a low transvalvular pressure gradient.
. Low-Flow/Low-Gradient Aortic Stenosis
lass IIa
. Dobutamine stress echocardiography is reasonable to
evaluate patients with low-flow/low-gradient AS and
LV dysfunction. (Level of Evidence: B)
. Cardiac catheterization for hemodynamic measure-
ments with infusion of dobutamine can be useful for
evaluation of patients with low-flow/low-gradient AS
and LV dysfunction. (Level of Evidence: C)
atients with severe AS and low cardiac output often
resent with a relatively low transvalvular pressure gradient
i.e., mean gradient less than 30 mm Hg). Such patients can
e difficult to distinguish from those with low cardiac output
nd only mild to moderate AS. In the latter group, primary
ontractile dysfunction is responsible for the decreased
jection fraction and low stroke volume; the problem is
urther complicated by reduced valve opening forces that
ontribute to limited valve mobility and apparent stenosis.
n both situations, the low-flow state and low-pressure
radient contribute to a calculated effective valve area that
an meet criteria for severe AS. Alternate measures of AS
everity have been proposed as being less flow dependent
han gradients or valve area. These include valve resistance
nd stroke work loss. However, all of these measures are
ow dependent, have not been shown to predict clinical
utcome, and have not gained widespread clinical use (69).
In selected patients with low-flow/low-gradient AS and
V dysfunction, it may be useful to determine the transval-
ular pressure gradient and to calculate valve area during a
aseline state and again during exercise or low-dose phar-
acological (i.e., dobutamine infusion) stress, with the goal
f determining whether stenosis is severe or only moderate
n severity (51,70–76). Such studies can be performed in
ither the echocardiography or the cardiac catheterization
aboratory. If a dobutamine infusion produces an increment
n stroke volume and an increase in valve area greater than
.2 cm2 and little change in gradient, it is likely that the
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ACC/AHA Practice Guidelines August 1, 2006:598–675aseline evaluation overestimated the severity of stenosis. In
ontrast, patients with severe AS will have a fixed valve area
ith an increase in stroke volume and an increase in
radient. These patients are likely to respond favorably to
urgery. Patients in whom stroke volume fails to increase
ith dobutamine (less than 20% increase) appear to have a
ery poor prognosis with either medical or surgical therapy
1,77).
Dobutamine stress testing in patients with AS should be
erformed only in centers with experience in pharmacolog-
cal stress testing and with a cardiologist in attendance.
. Indications for Aortic Valve Replacement
lass I
. AVR is indicated for symptomatic patients with
severe AS.* (Level of Evidence: B)
. AVR is indicated for patients with severe AS* under-
going coronary artery bypass graft surgery (CABG).
(Level of Evidence: C)
. AVR is indicated for patients with severe AS* under-
going surgery on the aorta or other heart valves.
(Level of Evidence: C)
. AVR is recommended for patients with severe AS*
and LV systolic dysfunction (ejection fraction less
than 0.50). (Level of Evidence: C)
lass IIa
AVR is reasonable for patients with moderate AS*
undergoing CABG or surgery on the aorta or other
heart valves (see Section X-D). (Level of Evidence: B)
lass IIb
. AVR may be considered for asymptomatic patients
with severe AS* and abnormal response to exercise
(e.g., development of symptoms or asymptomatic
hypotension). (Level of Evidence: C)
. AVRmay be considered for adults with severe asymp-
tomatic AS* if there is a high likelihood of rapid
progression (age, calcification, and CAD) or if sur-
gery might be delayed at the time of symptom onset.
(Level of Evidence: C)
. AVR may be considered in patients undergoing
CABG who have mild AS* when there is evidence,
such as moderate to severe valve calcification, that
progression may be rapid. (Level of Evidence: C)
. AVR may be considered for asymptomatic patients
with extremely severe AS (aortic valve area less than
0.6 cm2, mean gradient greater than 60 mm Hg, and
jet velocity greater than 5.0 m per second) when the
patient’s expected operative mortality is 1.0% or less.
(Level of Evidence: C)
lass III
AVR is not useful for the prevention of sudden death
in asymptomatic patients with AS who have none of pthe findings listed under the Class IIa/IIb recom-
mendations. (Level of Evidence: B)
See Table 1 (7).
n adults with severe, symptomatic, calcific AS, AVR is the
nly effective treatment. Younger patients with congenital
r rheumatic AS may be candidates for valvotomy (see
ection VI-A-2). Although there is some lack of agreement
bout the optimal timing of surgery in asymptomatic pa-
ients, it is possible to develop rational guidelines for most
atients. A proposed management strategy for patients with
evere AS is shown in Figure 2 (78). Particular consider-
tion should be given to the natural history of asymptomatic
atients and to operative risks and outcomes after surgery.
ee also Section VII-A.
. Symptomatic Patients
n symptomatic patients with AS, AVR improves symptoms
nd improves survival (36,79–83). These salutary results of
urgery are partly dependent on LV function. The depressed
jection fraction in many patients in this latter group is
aused by excessive afterload (afterload mismatch) (84), and
V function improves after AVR in such patients. If LV
ysfunction is not caused by afterload mismatch, survival is
till improved, but improvement in LV function and reso-
ution of symptoms might not be complete after AVR
79,82,85–87). Therefore, in the absence of serious comor-
id conditions, AVR is indicated in virtually all symptom-
tic patients with severe AS. Because of the risk of sudden
eath, AVR should be performed promptly after the onset
f symptoms. Age is not a contraindication to surgery, with
everal series showing outcomes similar to age-matched
ormal subjects in the very elderly. The operative risks can
e estimated with readily available and well-validated online
isk calculators from the Society of Thoracic Surgeons
www.sts.org), the European System for Cardiac Operative
isk Evaluation (www.euroscore.org) (88–90), and Ambler
t al (91).
. Asymptomatic Patients
lthough AVR is associated with low perioperative mor-
idity and mortality in many centers, the average perioper-
tive mortality in the Society of Thoracic Surgeons (STS)
atabase is 3.0% to 4.0% for isolated AVR and 5.5% to 6.8%
or AVR plus CABG (92,93). These rates are 33% higher in
enters with low volume than in centers with the highest
urgical volume (94). A review of Medicare data (95),
nvolving 684 US hospitals and more than 142 000 patients,
ndicates that the average in-hospital mortality for AVR in
atients over the age of 65 years is 8.8% (13.0% in
ow-volume centers and 6.0% in high-volume centers). In
ddition, despite improved longevity of current-generation
ioprosthetic valves (96,97), AVR in young patients subjects
hem to the risks of structural valve deterioration of bio-
rostheses (96,98–102) and the appreciable morbidity and
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesortality of mechanical valves (100,102–106). Thus, the
ombined risk of surgery in older patients and the late
omplications of a prosthesis in younger patients needs to be
alanced against the possibility of preventing sudden death,
hich, as noted above, occurs at a rate of less than 1.0% per
ear.
Despite these considerations, some difference of opinion
ersists among clinicians regarding the indications for AVR
n asymptomatic patients with severe AS, because the
robability of remaining free of cardiac symptoms without
urgery is less than 50% at 5 years (20,27,45). Studies
uggest that patients at risk of rapid disease progression and
mpending symptom onset can be identified on the basis of
linical and echocardiographic parameters. The rate of
emodynamic progression is faster in patients with asymp-
omatic severe (27) or mild to moderate (29) AS when
atient age is over 50 years and severe valve calcification or
oncurrent CAD is present. Adverse clinical outcomes are
ore likely in patients with a more rapid rate of hemody-
amic progression, defined as an annual increase in aortic jet
elocity greater than 0.3 m per second per year or a decrease
n valve area greater than 0.1 cm2 per year (20,27). The
resence of LV hypertrophy by ECG and smaller aortic
igure 2. Management strategy for patients with severe aortic stenosis. Pr
y age, symptoms, and coronary risk factors. Cardiac catheterization and ang
nd echocardiography. Modified from CM Otto. Valvular aortic stenosis: d
78). AVA indicates aortic valve area; BP, blood pressure; CABG, coronary
aximal velocity across aortic valve by Doppler echocardiography.alve area by Doppler echocardiography predict the devel- Cpment of symptoms (20,45). In addition, serum levels of
-type natriuretic peptide may provide important prognos-
ic information (107). In situations in which there is delay
etween symptom onset and surgical intervention, patients
re at high risk of adverse outcomes during the waiting
eriod. These higher-risk patients might warrant more
requent echocardiography or earlier consideration of valve
eplacement.
. Patients Undergoing Coronary Artery Bypass or Other
ardiac Surgery
atients with severe AS, with or without symptoms, who
re undergoing CABG should undergo AVR at the time
f the revascularization procedure. Similarly, patients
ith severe AS undergoing surgery on other valves (such
s MV repair) or the aortic root should also undergo
VR as part of the surgical procedure. In patients with
oderate AS, it is generally accepted practice to perform
VR at the time of CABG (108 –112). However, there
re no data to support a policy of AVR for mild AS at the
ime of CABG, with the exception of those patients with
oderate to severe valvular calcification (29,108,109,
12–114). Recommendations for AVR at the time of
ative coronary angiography should be performed routinely as determined
phy may also be helpful when there is discordance between clinical findings
severity and timing of intervention. J Am Coll Cardiol 2006;47:2141–51
y bypass graft surgery; echo, echocardiography; LV, left ventricular; Vmax,eoper
iogra
iseaseABG are discussed in Section X-D.
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lass IIb
. Aortic balloon valvotomy might be reasonable as a
bridge to surgery in hemodynamically unstable adult
patients with AS who are at high risk for AVR. (Level
of Evidence: C)
. Aortic balloon valvotomy might be reasonable for
palliation in adult patients with AS in whom AVR
cannot be performed because of serious comorbid
conditions. (Level of Evidence: C)
lass III
Aortic balloon valvotomy is not recommended as an
alternative to AVR in adult patients with AS; certain
younger adults without valve calcification may be an
exception (see Section VI-A-2). (Level of Evidence: B)
ercutaneous balloon aortic valvotomy has an important
ole in treating adolescents and young adults with AS (see
ection VI-A-2) but a very limited role in older adults.
mmediate hemodynamic results include a moderate reduc-
ion in the transvalvular pressure gradient, but the postval-
otomy valve area rarely exceeds 1.0 cm2. Although early
ymptomatic improvement often occurs, serious acute com-
lications develop with a frequency greater than 10% (115–
18), and restenosis and clinical deterioration occur within
to 12 months in most patients (116,119–122). Therefore,
n adults with AS, balloon valvotomy is not a substitute for
VR (122–125).
The indications for palliative valvotomy in patients in
hom AVR cannot be recommended because of serious
omorbid conditions are even less well established. Most
symptomatic patients with severe AS who require urgent
oncardiac surgery can undergo surgery at a reasonably low
isk with monitoring of anesthesia and attention to fluid
alance (126–130). Balloon aortic valvotomy is not recom-
ended for these patients. If preoperative correction of AS
s needed, they should be considered for AVR.
. Medical Therapy for the Inoperable Patient
omorbid conditions (e.g., malignancy) or, on occasion,
atient preferences might preclude AVR for severe AS.
nder such circumstances, there is no therapy that prolongs
ife, and only limited medical therapies are available to
lleviate symptoms. Patients with evidence of pulmonary
ongestion can benefit from cautious treatment with digi-
alis, diuretics, and angiotensin-converting enzyme (ACE)
nhibitors. In patients with acute pulmonary edema due to
S, nitroprusside infusion may be used to reduce congestion
nd improve LV performance. Such therapy should be
erformed in an intensive care unit under the guidance of
nvasive hemodynamic monitoring (131). Atrial fibrillation
as an adverse effect on atrial pump function and ventricular
ate; if prompt cardioversion is unsuccessful, pharmacolog-
cal control of the ventricular rate is essential. a. Special Considerations in the Elderly
ecause there is no effective medical therapy and balloon
alvotomy is not an acceptable alternative to surgery, AVR
ust be considered in all elderly patients who have symp-
oms caused by AS. AVR is technically possible at any age
132), but the decision to proceed with such surgery
epends on many factors, including the patient’s wishes and
xpectations. Older patients with symptoms due to severe
S, normal coronary arteries, and preserved LV function
an expect a better outcome than those with CAD or LV
ysfunction (133). Deconditioned and debilitated patients
ften do not return to an active existence, and the presence
f the other comorbid disorders could have a major impact
n outcome.
In addition to the confounding effects of CAD and the
otential for stroke, other considerations are peculiar to
lder patients. For example, a narrow LV outflow tract and
small aortic annulus sometimes present in elderly women
ould require enlargement of the annulus. Heavy calcifica-
ion of the valve, annulus, and aortic root may require
ebridement. Likewise, excessive or inappropriate hypertro-
hy associated with AS can increase the risk of perioperative
orbidity and mortality, and preoperative recognition of
lderly patients with marked LV hypertrophy followed by
ppropriate perioperative management can reduce this risk
ubstantially. There is no perfect method for weighing all of
he relevant factors and identifying specifically high- and
ow-risk elderly patients, but this risk can be estimated well
n individual patients (88–91,134).
. Aortic Regurgitation
. Acute Aortic Regurgitation
n acute severe AR, the sudden large regurgitant volume is
mposed on a left ventricle of normal size that has not had
ime to accommodate to the volume overload. With an
brupt increase in end-diastolic volume, the ventricle oper-
tes on the steep portion of a normal diastolic pressure-
olume relationship, and LV end-diastolic and left atrial
ressures may increase rapidly and dramatically. The Frank-
tarling mechanism is used, but the inability of the ventricle
o develop compensatory chamber dilatation acutely results
n a decrease in forward stroke volume. Although tachycar-
ia develops as a compensatory mechanism to maintain
ardiac output, this is often insufficient. Hence, patients
requently present with pulmonary edema and/or cardio-
enic shock. Patients may also present with signs and
ymptoms of myocardial ischemia.
. Diagnosis
any of the characteristic physical findings of chronic AR
re modified or absent when valvular regurgitation is acute,
hich can lead to underestimation of its severity. Echocar-
iography is indispensable in confirming the presence and
everity of the valvular regurgitation, determining its cause,
nd determining whether there is rapid equilibration of
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesortic and LV diastolic pressure. Evidence for rapid pressure
quilibration includes a short AR diastolic half-time (less
han 300 ms), a short mitral deceleration time (less than 150
s), or premature closure of the MV.
Acute AR caused by aortic root dissection is a surgical
mergency that requires particularly prompt identification
nd management. TEE is indicated when aortic dissection
s suspected (135–137). In some settings, computed tomo-
raphic imaging or magnetic resonance imaging should be
erformed if this will lead to a more rapid diagnosis than
an be achieved by TEE (135,136,138). Cardiac catheter-
zation, aortography, and coronary angiography are rarely
equired, are associated with increased risk, and might delay
rgent surgery unnecessarily (136,139–142). Angiography
hould be considered only when the diagnosis cannot be
etermined by noninvasive imaging and when patients have
nown CAD, especially those with previous CABG (see
ection X-B).
. Treatment
eath due to pulmonary edema, ventricular arrhythmias,
lectromechanical dissociation, or circulatory collapse is com-
on in acute severe AR, even with intensive medical manage-
ent. Urgent surgical intervention is recommended. Nitro-
russide, and possibly inotropic agents such as dopamine or
obutamine to augment forward flow and reduce LV end-
iastolic pressure, may be helpful to manage the patient
emporarily before operation. Intra-aortic balloon counterpul-
ation is contraindicated. Although beta blockers are often
sed in treating aortic dissection, these agents should be used
ery cautiously, if at all, in the setting of acute AR because they
ill block the compensatory tachycardia. In patients with acute
evere AR resulting from infective endocarditis, surgery should
ot be delayed, especially if there is hypotension, pulmonary
dema, or evidence of low output.
. Chronic Aortic Regurgitation
R represents a condition of combined volume overload and
ressure overload (143). As the disease progresses, recruitment
f preload reserve and compensatory hypertrophy permit the
entricle to maintain normal ejection performance despite the
levated afterload. The majority of patients remain asymptom-
tic throughout this compensated phase, which may last for
ecades. In many patients, however, the balance between
fterload excess, preload reserve, and hypertrophy cannot be
aintained indefinitely, and afterload mismatch (144) or
epressed contractility ultimately results in a reduction in
jection fraction, first into the low-normal range and then
elow normal. Patients often develop dyspnea at this point in
he natural history, and diminished coronary flow reserve may
esult in exertional angina. However, this transition may be
uch more insidious, and it is possible for patients to remain
symptomatic until severe LV dysfunction has developed.
For purposes of the subsequent discussion, patients with
ormal LV systolic function will be defined as those with
ormal LV ejection fraction at rest. It is recognized that other indices of LV function may not be “normal” in chronic severe
R and that the hemodynamic abnormalities noted above may
e considerable. It is also recognized that the transition to LV
ystolic dysfunction represents a continuum and that there is
o single hemodynamic measurement that represents the
bsolute boundary between normal LV systolic function and
V systolic dysfunction.
LV systolic dysfunction (defined as an ejection fraction
elow normal at rest) is initially a reversible phenomenon
elated predominantly to afterload excess, and full recovery
f LV size and function is possible with AVR (145–152).
ith time, depressed myocardial contractility predominates
ver excessive loading as the cause of progressive systolic
ysfunction. This can progress to the extent that the full
enefit of surgical correction of AR, in terms of recovery of
V function and improved survival, can no longer be
chieved (150,153–159).
. Natural History
symptomatic Patients With Normal Left Ventricular Function
The current recommendations are derived from 9 pub-
ished series (160–169) involving a total of 593 asymptom-
tic patients with initially normal LV systolic function with
mean follow-up period of 6.6 years. The rate of progres-
ion to symptoms or LV systolic dysfunction averaged 4.3%
er year. Sudden death occurred in 7 of the 593 patients, an
verage mortality rate of less than 0.2% per year. Seven of
he 9 studies reported the rate of development of asymp-
omatic LV dysfunction, defined as an ejection fraction at
est below normal (161–165,167,168); 37 of a total of 535
atients developed depressed systolic function at rest with-
ut symptoms during a mean 5.9-year follow-up period, a
ate of 1.2% per year.
Despite the low likelihood of patients developing asymp-
omatic LV dysfunction, it should also be emphasized that
ore than one fourth of patients who die or develop systolic
ysfunction do so before the onset of warning symptoms
161–163,167). Thus, thorough questioning of patients
egarding symptomatic status is not sufficient in the serial
valuation of asymptomatic patients, and quantitative eval-
ation of LV function is also indispensable.
symptomatic Patients With Depressed Systolic Function
he limited data in asymptomatic patients with depressed
V ejection fraction indicate that the majority develop
ymptoms that warrant AVR within 2 to 3 years (170–172).
he average rate of symptom onset in such patients is
reater than 25% per year.
ymptomatic Patients
here are no contemporary large-scale studies of the natural
istory of symptomatic patients with chronic AR because
he onset of angina or significant dyspnea is usually an
ndication for valve replacement. Data emanating from the
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ACC/AHA Practice Guidelines August 1, 2006:598–675resurgical era indicate that patients with dyspnea, angina, or
vert heart failure have a poor outcome with mortality rates of
reater than 10% per year in patients with angina pectoris and
reater than 20% per year in those with heart failure (173–
75). Similar poor outcomes have been reported in the
urrent era in symptomatic patients who do not undergo
VR, even among those with preserved LV systolic func-
ion (166,176,177).
. Diagnosis and Initial Evaluation
lass I
. Echocardiography is indicated to confirm the pres-
ence and severity of acute or chronic AR. (Level of
Evidence: B)
. Echocardiography is indicated for diagnosis and assess-
ment of the cause of chronic AR (including valve
morphology and aortic root size and morphology) and
for assessment of LV hypertrophy, dimension (or vol-
ume), and systolic function. (Level of Evidence: B)
. Echocardiography is indicated in patients with an
enlarged aortic root to assess regurgitation and the
severity of aortic dilatation. (Level of Evidence: B)
. Echocardiography is indicated for the periodic re-
evaluation of LV size and function in asymptomatic
patients with severe AR. (Level of Evidence: B)
. Radionuclide angiography or magnetic resonance
imaging is indicated for the initial and serial assess-
ment of LV volume and function at rest in patients
with AR and suboptimal echocardiograms. (Level of
Evidence: B)
. Echocardiography is indicated to re-evaluate mild,
moderate, or severe AR in patients with new or
changing symptoms. (Level of Evidence: B)
lass IIa
. Exercise stress testing for chronic AR is reasonable
for assessment of functional capacity and symptom-
atic response in patients with a history of equivocal
symptoms. (Level of Evidence: B)
. Exercise stress testing for patients with chronic AR is
reasonable for the evaluation of symptoms and func-
tional capacity before participation in athletic activ-
ities. (Level of Evidence: C)
. Magnetic resonance imaging is reasonable for the
estimation of AR severity in patients with unsatisfac-
tory echocardiograms. (Level of Evidence: B)
lass IIb
Exercise stress testing in patients with radionuclide
angiography may be considered for assessment of LV
function in asymptomatic or symptomatic patients
with chronic AR. (Level of Evidence: B)
chocardiography is indicated 1) to confirm the diagno-
is of AR if there is an equivocal diagnosis based on
hysical examination; 2) to assess the cause of AR and tossess valve morphology; 3) to provide a semiquantitative
stimate of the severity of AR; 4) to assess LV dimension,
ass, and systolic function; and 5) to assess aortic root
ize. In asymptomatic patients with preserved systolic
unction, these initial measurements represent the base-
ine information with which future serial measurements
an be compared. In addition to semiquantitative assess-
ent of the severity of AR by color flow jet area and
idth by Doppler echocardiography, quantitative mea-
urement of regurgitant volume, regurgitant fraction, and
egurgitant orifice area can be performed in experienced
aboratories (Table 1). Indirect measures of severity of
R are helpful, using the rate of decline in regurgitant
radient measured by the slope of diastolic flow velocity,
he degree of reversal in pulse wave velocity in the
escending aorta, and the magnitude of LV outflow tract
elocity (1,178,179).
For purposes of the subsequent discussion of management
f patients with AR, severe AR is defined as clinical and
oppler evidence of severe regurgitation (Table 1) in addition
o LV cavity dilatation. If the patient is asymptomatic and
eads an active lifestyle, and the echocardiogram is of good
uality, no other testing is necessary. If the patient has severe
R and is sedentary or has equivocal symptoms, exercise
esting is helpful to assess functional capacity, symptomatic
esponses, and hemodynamic effects of exercise (Fig. 3). If the
chocardiogram is of insufficient quality to assess LV function,
adionuclide angiography or cardiac magnetic resonance
hould be used in asymptomatic patients to measure LV
jection fraction at rest and to estimate LV volumes. In
atients who are symptomatic on initial evaluation, it is
easonable to proceed directly to TEE or cardiac catheteriza-
ion and angiography if the echocardiogram is of insufficient
uality to assess LV function or severity of AR.
The exercise ejection fraction and the change in ejection
raction from rest to exercise are often abnormal, even in
symptomatic patients (160,162–164,67,172,180–186). How-
ver, the predictive nature of this response in asymptomatic
atients with normal LV systolic function and without severe
V dilatation has not been fully demonstrated.
. Medical Therapy
lass I
Vasodilator therapy is indicated for chronic therapy
in patients with severe AR who have symptoms or LV
dysfunction when surgery is not recommended be-
cause of additional cardiac or noncardiac factors.
(Level of Evidence: B)
lass IIa
Vasodilator therapy is reasonable for short-term ther-
apy to improve the hemodynamic profile of patients
with severe heart failure symptoms and severe LV
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesdysfunction before proceeding with AVR. (Level of
Evidence: C)
lass IIb
Vasodilator therapy may be considered for long-term
therapy in asymptomatic patients with severe AR
who have LV dilatation but normal systolic function.
(Level of Evidence: B)
lass III
. Vasodilator therapy is not indicated for long-term
therapy in asymptomatic patients with mild to mod-
erate AR and normal LV systolic function. (Level of
Evidence: B)
. Vasodilator therapy is not indicated for long-term
therapy in asymptomatic patients with LV systolic
dysfunction who are otherwise candidates for AVR.
igure 3. Management strategy for patients with chronic severe aortic regu
etermined by age, symptoms, and coronary risk factors. Cardiac catheteri
linical findings and echocardiography. “Stable” refers to stable echocardiog
adionuclide ventriculography (RVG) or magnetic resonance imaging (MR
nd systolic function. AVR indicates aortic valve replacement; DD, end
imension.(Level of Evidence: C) r. Vasodilator therapy is not indicated for long-term
therapy in symptomatic patients with either normal
LV function or mild to moderate LV systolic dys-
function who are otherwise candidates for AVR.
(Level of Evidence: C)
herapy with vasodilating agents is designed to improve
orward stroke volume and reduce regurgitant volume.
hese effects should translate into reductions in LV end-
iastolic volume, wall stress, and afterload, resulting in
reservation of LV systolic function and reduction in LV
ass. Reduced end-diastolic volume and increased ejection
raction have been observed in small numbers of patients
eceiving long-term oral therapy with hydralazine and
ifedipine for periods of 1 to 2 years (187,188); with
ifedipine, these effects are associated with a reduction in
V mass (164,188). Less consistent results have been
tion. Preoperative coronary angiography should be performed routinely as
and angiography may also be helpful when there is discordance between
c measurements. In some centers, serial follow-up may be performed with
ther than echocardiography (Echo) to assess left ventricular (LV) volume
olic dimension; EF, ejection fraction; eval, evaluation; SD, end-systolicrgita
zation
raphi
I) raeported with ACE inhibitors, depending on the degree of
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ACC/AHA Practice Guidelines August 1, 2006:598–675eduction in arterial pressure and end-diastolic volume
189–191). Reduced blood pressure with enalapril and
uinapril has been associated with decreases in end-diastolic
olume and mass but no change in ejection fraction
190,191).
Whether vasodilator therapy can prolong the compensated
hase of asymptomatic patients who have volume-loaded left
entricles but normal systolic function has been investigated in
nly 2 studies. The first compared long-acting nifedipine
ersus digoxin in a prospective randomized trial (164). Over a
-year period, fewer patients randomized to nifedipine re-
uired AVR because of symptoms or development of LV
ysfunction (ejection fraction less than 0.50). This study
nrolled a relatively small number of patients (143 patients);
here were relatively few end points (20 patients in the digoxin
roup and 6 in the nifedipine group underwent AVR); and
here was no placebo control group. A second study compared
lacebo, long-acting nifedipine, and enalapril in 95 consecutive
atients, who were followed for 7 years (169). Neither nifed-
pine nor enalapril reduced the development of symptoms or
V dysfunction warranting AVR compared with placebo.
oreover, neither drug significantly altered LV dimension,
jection fraction, or mass over the course of time compared
ith placebo. Thus, definitive recommendations regarding the
ndications for long-acting nifedipine or ACE inhibitors can-
ot be made at this time.
Vasodilator therapy is not recommended for asymptom-
tic patients with mild or moderate AR and normal LV
unction in the absence of systemic hypertension, because
hese patients have an excellent outcome with no therapy. In
atients with severe AR, vasodilator therapy is not an
lternative to surgery in asymptomatic patients with LV
ystolic dysfunction. Symptomatic patients should be con-
idered surgical candidates rather than candidates for long-
erm medical therapy unless AVR is not recommended
ecause of additional cardiac or noncardiac factors.
. Physical Activity and Exercise
symptomatic patients with normal LV systolic function
ay participate in all forms of normal daily physical activity,
ncluding mild forms of exercise and in some cases compet-
tive athletics. Isometric exercise should be avoided. Rec-
mmendations regarding participation in competitive ath-
etics were published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
67). Before participation in athletics, exercise testing to at
east the level of exercise required by the proposed activity is
ecommended so that the patient’s tolerance for this degree
f exercise can be evaluated. This does not necessarily
valuate the long-term effects of strenuous exercise, which
re unknown.
. Serial Testing
n general, the stability and chronicity of the regurgitant
esion and the LV response to volume load need to be
stablished when the patient first presents to the physician, especially if AR is moderate to severe. If the chronic nature
f the lesion is uncertain and the patient does not present
nitially with one of the indications for surgery, repeat
hysical examination and echocardiography should be per-
ormed within 2 to 3 months after the initial evaluation to
nsure that a subacute process with rapid progression is not
nder way. Once the chronicity and stability of the process
ave been established, the frequency of clinical re-evaluation
nd repeat noninvasive testing depends on the severity of
he valvular regurgitation, the degree of LV dilatation, the
evel of systolic function, and whether previous serial studies
ave revealed progressive changes in LV size or function
Fig. 3).
Asymptomatic patients with mild AR, little or no LV
ilatation, and normal LV systolic function can be seen on
yearly basis with instructions to alert the physician if
ymptoms develop in the interim. Yearly echocardiography
s not necessary unless there is clinical evidence that regur-
itation has worsened. Routine echocardiography can be
erformed every 2 to 3 years in such patients.
Asymptomatic patients with normal systolic function but
evere AR and significant LV dilatation (end-diastolic
imension greater than 60 mm) require more frequent and
areful re-evaluation, with a history and physical examina-
ion every 6 months and echocardiography every 6 to 12
onths, depending on the severity of dilatation and stability
f measurements. If patients are stable, echocardiographic
easurements are not required more frequently than every
2 months. In patients with more advanced LV dilatation
end-diastolic dimension greater than 70 mm or end-
ystolic dimension greater than 50 mm), for whom the risk
f developing symptoms or LV dysfunction ranges between
0% and 20% per year (163,164), it is reasonable to perform
erial echocardiograms as frequently as every 4 to 6 months.
erial chest X-rays and ECGs have less value but are helpful
n selected patients.
Chronic AR may develop from disease processes that
nvolve the proximal ascending aorta. In patients with aortic
oot dilatation, serial echocardiograms are indicated to
valuate aortic root size, as well as LV size and function.
his is discussed in Section III-B-3.
Repeat echocardiograms are also recommended when the
atient has onset of symptoms, there is an equivocal history
f changing symptoms or exercise tolerance, or there are
linical findings that suggest worsening regurgitation or
rogressive LV dilatation. Patients with echocardiographic
vidence of progressive LV dilatation or declining systolic
unction have a greater likelihood of developing symptoms
r LV dysfunction (163) and should have more frequent
ollow-up examinations (every 6 months) than those with
table LV function.
Serial exercise testing is also not recommended routinely
n asymptomatic patients with preserved systolic function;
owever, exercise testing may be invaluable to assess func-
ional capacity and symptomatic responses in patients with
quivocal changes in symptomatic status. Serial exercise
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ymptoms develop.
. Indications for Cardiac Catheterization
lass I
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is indicated for
assessment of severity of regurgitation, LV function,
or aortic root size when noninvasive tests are incon-
clusive or discordant with clinical findings in patients
with AR. (Level of Evidence: B)
. Coronary angiography is indicated before AVR in
patients at risk for CAD. (Level of Evidence: C)
lass III
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is not indicated for
assessment of LV function, aortic root size, or sever-
ity of regurgitation before AVR when noninvasive
tests are adequate and concordant with clinical find-
ings and coronary angiography is not needed. (Level
of Evidence: C)
. Cardiac catheterization with aortic root angiography
and measurement of LV pressure is not indicated for
assessment of LV function and severity of regurgita-
tion in asymptomatic patients when noninvasive tests
are adequate. (Level of Evidence: C)
ardiac catheterization is not required in patients with
hronic AR unless there are questions about the severity of
R, hemodynamic abnormalities, or LV systolic dysfunc-
ion that persist despite physical examination and noninva-
ive testing, or unless AVR is contemplated and there is a
eed to assess coronary anatomy. The indications for
oronary arteriography are discussed in Section X-B.
Hemodynamic and angiographic assessment of the sever-
ty of AR and LV function may be necessary in some
atients being considered for surgery when there are con-
icting data between clinical assessment and noninvasive
ests. Hemodynamic measurements during exercise are oc-
asionally helpful for determining the effect of AR on LV
unction or making decisions regarding medical or surgical
herapy.
. Indications for Aortic Valve Replacement or Repair
he majority of patients with severe AR requiring surgery
ndergo valve replacement (see Section VII-A). However,
n several surgical centers, there is increasing experience in
erforming aortic valve repair in selected patients. In the
iscussion that follows, the term “AVR” applies to both
ortic valve replacement and aortic valve repair, with the
nderstanding that aortic valve repair should be considered
nly in those surgical centers that have developed the
ppropriate technical expertise, gained experience in patient
election, and demonstrated outcomes equivalent to those of oalve replacement. The indications for valve replacement
nd repair do not differ.
In patients with pure, chronic AR, AVR should be
onsidered only if AR is severe (Table 1). Patients with only
ild AR are not candidates for AVR, and if such patients
ave symptoms or LV dysfunction, other causes should be
onsidered, such as CAD, hypertension, or cardiomyopathic
rocesses. The following discussion applies only to patients
ith pure, severe AR.
lass I
. AVR is indicated for symptomatic patients with
severe AR irrespective of LV systolic function. (Level
of Evidence: B)
. AVR is indicated for asymptomatic patients with
chronic severe AR and LV systolic dysfunction (ejection
fraction 0.50 or less) at rest. (Level of Evidence: B)
. AVR is indicated for patients with chronic severe AR
while undergoing CABG or surgery on the aorta or
other heart valves. (Level of Evidence: C)
lass IIa
AVR is reasonable for asymptomatic patients with
severe AR with normal LV systolic function (ejection
fraction greater than 0.50) but with severe LV dila-
tation (end-diastolic dimension greater than 75 mm
or end-systolic dimension greater than 55 mm).*
(Level of Evidence: B)
lass IIb
. AVR may be considered in patients with moderate
AR while undergoing surgery on the ascending aorta.
(Level of Evidence: C)
. AVR may be considered in patients with moderate
AR while undergoing CABG. (Level of Evidence: C)
. AVRmay be considered for asymptomatic patients with
severe AR and normal LV systolic function at rest
(ejection fraction greater than 0.50) when the degree of
LV dilatation exceeds an end-diastolic dimension of 70
mm or end-systolic dimension of 50 mm, when there is
evidence of progressive LV dilatation, declining exercise
tolerance, or abnormal hemodynamic responses to ex-
ercise.* (Level of Evidence: C)
lass III
AVR is not indicated for asymptomatic patients with
mild, moderate, or severe AR and normal LV systolic
function at rest (ejection fraction greater than 0.50)
when the degree of dilatation is not moderate or
severe (end-diastolic dimension less than 70 mm,
end-systolic dimension less than 50 mm).* (Level of
Evidence: B)
Consider lower threshold values for patients of small stature
f either gender.
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unction
VR is indicated in patients with normal LV systolic
unction (ejection fraction greater than 0.50 at rest) who
ave symptoms. In selected patients, exercise testing may be
aluable in determining symptomatic status. If the cause of
hese mild symptoms is uncertain and they are not severe
nough to interfere with the patient’s lifestyle, a period of
bservation may be reasonable. However, new onset of mild
yspnea has different implications in severe AR, especially if
here is increasing LV chamber size or declining LV systolic
unction. Thus, even if patients have not achieved the
hreshold values of LV size and function recommended for
urgery in asymptomatic patients, development of mild
ymptoms is an indication for AVR in a patient who is
earing these values.
ymptomatic Patients With Left Ventricular Dysfunction
ymptomatic patients with mild to moderate LV systolic
ysfunction (ejection fraction 0.25 to 0.50) should undergo
VR. Patients with New York Heart Association (NYHA)
unctional class IV symptoms have worse postoperative survival
ates and lower likelihood of recovery of systolic function than
atients with less severe symptoms (151,153,155,157), but
VR will improve ventricular loading conditions and expedite
ubsequent management of LV dysfunction (192).
symptomatic Patients
VR in asymptomatic patients remains a controversial
opic, but it is generally agreed (144,193–199) that AVR is
ndicated in patients with LV systolic dysfunction. The
ommittee recognizes that there may be variability in any
iven measurement of LV dimension or ejection fraction.
herefore, the committee recommends that 2 consecutive
easurements be obtained before one proceeds with a
ecision to recommend surgery in the asymptomatic pa-
ient. These consecutive measurements could be obtained
ith the same test repeated in a short time period (such as
second echocardiogram after an initial echocardiogram) or
ith a separate, independent test (e.g., radionuclide ven-
riculography, magnetic resonance imaging, or contrast left
entriculography after an initial echocardiogram).
AVR is also recommended in patients with severe LV
ilatation (end-diastolic dimension greater than 75 mm or
nd-systolic dimension greater than 55 mm), even if ejec-
ion fraction is normal. The relatively small number of
symptomatic patients with preserved ejection fraction de-
pite severe increases in end-systolic and end-diastolic
hamber size should be considered for surgery, because they
ppear to represent a high-risk group with an increased
ncidence of sudden death (163,200), and the results of valve
eplacement in such patients have thus far been excellent
201). In contrast, postoperative mortality is considerable
nce patients with severe LV dilatation develop symptoms cr LV systolic dysfunction (201). These data do not strongly
upport the use of extreme LV enlargement as an indication
or AVR, unless cardiac symptoms or systolic dysfunction is
resent (202). However, the committee recommends sur-
ery before the left ventricle achieves an extreme degree of
ilatation and recommends AVR for patients with LV
nd-diastolic dimension greater than 75 mm.
Patients with severe AR in whom the degree of LV
ilatation has not reached but is approaching these thresh-
ld values (e.g., LV end-diastolic dimension of 70 to 75 mm
r end-systolic dimension of 50 to 55 mm) should be
ollowed with frequent echocardiograms every 4 to 6
onths, as noted previously (Fig. 3). In addition, AVR may
e considered in such patients if there is evidence of
eclining exercise tolerance or abnormal hemodynamic
esponses to exercise, for example, an increase in pulmonary
rtery wedge pressure greater than 25 mm Hg with exercise.
Anthropometric normalization of LV end-diastolic
imension (or volume) should be considered, but unfor-
unately, there is lack of agreement as to whether or not
ormalization based on body surface area or body mass
ndex is predictive of outcome (177,203). Normalization
f end-diastolic dimension for body surface area tends to
ask the diagnosis of LV enlargement, especially in
atients who are overweight (204). The use of height and
consideration of gender are likely to be more appropri-
te than body surface area (205). LV dimensions alone
ay be misleading in small patients of either gender, and
he threshold values of end-diastolic and end-systolic
imension recommended above for AVR in asymptom-
tic patients (75 and 55 mm, respectively) may need to be
educed in such patients. In such patients, it is particu-
arly important that LV ejection fraction and not merely
ystolic dimension be monitored.
. Concomitant Aortic Root Disease
n addition to causing acute AR, diseases of the proximal
orta may also contribute to chronic AR (206). In such
atients, the valvular regurgitation may be less important
n decision making than the primary disease of the aorta,
uch as Marfan syndrome, dissection, or chronic dilata-
ion of the aortic root related to hypertension or a
icuspid aortic valve (see Section III-C). In general, AVR
nd aortic root reconstruction are indicated in patients
ith disease of the aortic root or proximal aorta and AR
f any severity when the degree of dilatation of the aorta
r aortic root reaches or exceeds 5.0 cm by echocardiog-
aphy (207). However, some have recommended surgery
t a lower level of dilatation (4.5 cm) or based on a rate
f increase of 0.5 cm per year or greater in surgical centers
ith established expertise in repair of the aortic root and
scending aorta (208). Aortic root and ascending aorta
ilation in patients with bicuspid aortic valves is dis-
ussed in greater detail in Section III-C.
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fter AVR, close follow-up is necessary during the early
nd long-term postoperative course to evaluate prosthetic
alve function and assess LV function (see Section IX-B).
n echocardiogram should be performed soon after surgery
o assess the results of surgery on LV size and function and
o serve as a baseline against which subsequent echocardio-
rams may be compared. Within the first few weeks of
urgery, there is little change in LV systolic function, and
jection fraction may even deteriorate compared with pre-
perative values because of the reduced preload (209), even
hough ejection fraction may increase over the subsequent
everal months. Thus, persistent or more severe systolic
ysfunction early after AVR is a poor predictor of subse-
uent improvement in LV function in patients with preop-
rative LV dysfunction. A better predictor of subsequent
V systolic function is the reduction in LV end-diastolic
imension, which declines significantly within the first week
r 2 after AVR (151,210,211). This is an excellent marker
f the functional success of valve replacement, because 80%
f the overall reduction in end-diastolic dimension observed
uring the long-term postoperative course occurs within the
rst 10 to 14 days after AVR (151,210,211), and the
agnitude of reduction in end-diastolic dimension after
urgery correlates with the magnitude of increase in ejection
raction (151).
Patients with persistent LV dilatation on the initial
ostoperative echocardiogram should be treated as would
ny other patient with symptomatic or asymptomatic LV
ysfunction, including treatment with ACE inhibitors and
eta-adrenergic blocking agents. In such patients, repeat
chocardiography to assess LV size and systolic function is
arranted at the 6- and 12-month re-evaluations. If LV
ysfunction persists beyond this time frame, repeat echo-
ardiograms should be performed as clinically indicated.
. Special Considerations in the Elderly
he vast majority of elderly patients with aortic valve disease
ave AS or combined AS and AR, and pure AR is
ncommon (212). Patients older than 75 years are more
ikely to develop symptoms or LV dysfunction at earlier
tages of LV dilatation, have more persistent LV dysfunc-
ion and heart failure symptoms after surgery, and have
orse postoperative survival rates than their younger coun-
erparts. Many such patients have concomitant CAD,
hich must be considered in the evaluation of symptoms,
V dysfunction, and indications for surgery.
. Bicuspid Aortic Valve With Dilated Ascending Aorta
lass I
. Patients with known bicuspid aortic valves should
undergo an initial transthoracic echocardiogram to
assess the diameters of the aortic root and ascending
aorta. (Level of Evidence: B) w. Cardiac magnetic resonance imaging or cardiac com-
puted tomography is indicated in patients with bicus-
pid aortic valves when morphology of the aortic root
or ascending aorta cannot be assessed accurately by
echocardiography. (Level of Evidence: C)
. Patients with bicuspid aortic valves and dilatation of
the aortic root or ascending aorta (diameter greater
than 4.0 cm*) should undergo serial evaluation of
aortic root/ascending aorta size and morphology by
echocardiography, cardiac magnetic resonance, or
computed tomography on a yearly basis. (Level of
Evidence: C)
. Surgery to repair the aortic root or replace the
ascending aorta is indicated in patients with bicuspid
aortic valves if the diameter of the aortic root or
ascending aorta is greater than 5.0 cm* or if the rate
of increase in diameter is 0.5 cm per year or more.
(Level of Evidence: C)
. In patients with bicuspid valves undergoing AVR
because of severe AS or AR (see Sections III-A-6 and
III-B-2-g), repair of the aortic root or replacement of
the ascending aorta is indicated if the diameter of the
aortic root or ascending aorta is greater than 4.5 cm.*
(Level of Evidence: C)
lass IIa
. It is reasonable to give beta-adrenergic blocking
agents to patients with bicuspid valves and dilated
aortic roots (diameter greater than 4.0 cm*) who are
not candidates for surgical correction and who do not
have moderate to severe AR. (Level of Evidence: C)
. Cardiac magnetic resonance imaging or cardiac com-
puted tomography is reasonable in patients with bicus-
pid aortic valves when aortic root dilatation is detected
by echocardiography to further quantify severity of
dilatation and involvement of the ascending aorta.
(Level of Evidence: B)
Consider lower threshold values for patients of small stature
f either gender.
Many patients with bicuspid aortic valves have disorders
f vascular connective tissue that involve loss of elastic tissue
213,214), which may result in dilatation of the aortic root
r ascending aorta even in the absence of hemodynamically
ignificant AS or AR (215–218). Aortic root or ascending
ortic dilatation can progress with time in this condition,
nd the risk of aortic dissection is related to the severity of
ilatation (214,219–221). Recommendations for athletic
articipation in patients with bicuspid valve disease and
ssociated dilatation of the aortic root or ascending aorta
rom the 36th Bethesda Conference (67) are based on
imited data but with the understanding that aortic dissec-
ion can occur in some patients with aortic root or ascending
orta diameters less than 50 mm (208,220,222). Therapy
ith beta-adrenergic blocking agents might be effective in
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ata have been developed in patients with Marfan syndrome
223) and not in patients with bicuspid aortic valves.
The dimensions of the aortic root and ascending aorta
how considerable variability in normal populations. Re-
ression formulas and nomograms have been developed for
dolescents and adults that account for age and body surface
rea (224). An upper limit of 2.1 cm per m2 has been
stablished at the level of the aortic sinuses. Dilatation is
onsidered an increase in diameter above the norm for age
nd body surface area, and an aneurysm has been defined as
50% increase over the normal diameter (225).
In recommending elective surgery for this condition, a
umber of factors must be considered, including the pa-
ient’s age, the relative size of the aorta and aortic root, the
tructure and function of the aortic valve, and the experience
f the surgical team (208,214,221,222). Aortic valve–
paring operations are feasible in most patients with dilata-
ion of the aortic root or ascending aorta who do not have
ignificant AR or aortic valve calcification (226–228). Pa-
ients with bicuspid valves should undergo elective repair of
he aortic root or replacement of the ascending aorta if the
iameter of these structures exceeds 5.0 cm. Such surgery
hould be performed by a surgical team with established
xpertise in these procedures. Others have recommended a
alue of 2.5 cm per m2 or greater as the indication for
urgery (229). If patients with bicuspid valves and associated
ortic root enlargement undergo AVR because of severe AS
r AR (Sections III-A-6 and III-B-2-g), it is recommended
hat repair of the aortic root or replacement of the ascending
orta be performed if the diameter of these structures is
reater than 4.5 cm (230).
. Mitral Stenosis
n patients with MS from rheumatic fever, the pathological
rocess causes leaflet thickening and calcification, commis-
ural fusion, chordal fusion, or a combination of these
rocesses (231,232). The normal MV area is 4.0 to 5.0 cm2.
arrowing of the valve area to less than 2.5 cm2 typically
ccurs before the development of symptoms (68). With a
eduction in valve area by the rheumatic process, blood can
ow from the left atrium to the left ventricle only if
ropelled by a pressure gradient, and the transmitral gradi-
nt is the fundamental expression of MS (233). The
esulting elevation of left atrial pressure is reflected back into
he pulmonary venous circulation. Decreased pulmonary
enous compliance that results in part from an increased
ulmonary endothelin-1 spillover rate may also contribute
o increased pulmonary venous pressure (234). Increased
ressure and distension of the pulmonary veins and capil-
aries can lead to pulmonary edema as pulmonary venous
ressure exceeds that of plasma oncotic pressure. In patients
ith chronic MV obstruction, however, even when it is
evere and pulmonary venous pressure is very high, pulmo-
ary edema may not occur owing to a marked decrease in
ulmonary microvascular permeability. The pulmonary ar- gerioles may react with vasoconstriction, intimal hyperplasia,
nd medial hypertrophy, which lead to pulmonary arterial
ypertension.
. Natural History
n MV area greater than 1.5 cm2 usually does not produce
ymptoms at rest; however, if there is an increase in
ransmitral flow or a decrease in the diastolic filling period,
here will be a rise in left atrial pressure and development of
ymptoms. From hydraulic considerations, at any given
rifice size, the transmitral gradient is a function of the
quare of the transvalvular flow rate and is dependent on the
iastolic filling period (68). Thus, the first symptoms of
yspnea in patients with mild MS are usually precipitated by
xercise, emotional stress, infection, pregnancy, or atrial
brillation with a rapid ventricular response. As the obstruc-
ion across the MV increases, decreasing effort tolerance
ccurs. As the severity of stenosis increases, cardiac output
ecomes subnormal at rest and fails to increase during
xercise.
The natural history of patients with untreated MS has
een defined from studies in the 1950s and 1960s (235–
37). MS is a continuous, progressive, lifelong disease,
sually consisting of a slow, stable course in the early years
ollowed by a progressive acceleration later in life (235–238).
nce symptoms develop, there is another period of almost
decade before symptoms become disabling (235). In the
symptomatic or minimally symptomatic patient, survival is
reater than 80% at 10 years, with 60% of patients having no
rogression of symptoms, but once significant limiting
ymptoms occur, there is a dismal 0% to 15% 10-year
urvival rate (235–239). When severe pulmonary hyperten-
ion develops, mean survival drops to less than 3 years (240).
he mortality rate of untreated patients with MS is due to
rogressive pulmonary and systemic congestion in 60% to
0%, systemic embolism in 20% to 30%, pulmonary embo-
ism in 10%, and infection in 1% to 5% (231,237). In North
merica and Europe, this classic history of MS has been
eplaced by an even milder, delayed course with the decline
n incidence of rheumatic fever (238,241). The mean age of
resentation is now in the fifth to sixth decade (238,241);
ore than one third of patients undergoing valvotomy are
lder than 65 years (242). In some geographic areas, MS
rogresses more rapidly, presumably owing to either a more
evere rheumatic insult or repeated episodes of rheumatic
arditis due to new streptococcal infections, which results in
evere symptomatic MS in the late teens and early 20s (238).
Although MS is best described as a disease continuum,
nd there is no single value that defines severity, for these
uidelines, MS severity is based on a variety of hemody-
amic and natural history data (Table 1) using mean
radient, pulmonary artery systolic pressure, and valve area
s follows: mild (area greater than 1.5 cm2, mean gradient
ess than 5 mm Hg, or pulmonary artery systolic pressure
ess than 30 mm Hg), moderate (area 1.0 to 1.5 cm2, mean
radient 5 to 10 mm Hg, or pulmonary artery systolic
p
c
a
2
C
1
2
3
4
5
C
C
T
w
o
M
i
a
c
a
a
v
T
t
m
l
c
s
i
g
l
c
r
s
(
D
h
(
e
v
M
d
t
p
p
(
a
h
(
m
w
I
s
v
o
a
b
i
s
s
s
s
m
p
t
n
n
r
i
m
m
M
h
621JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:598–675 ACC/AHA Practice Guidelinesressure 30 to 50 mm Hg), and severe (area less than 1.0
m2, mean gradient greater than 10 mm Hg, or pulmonary
rtery systolic pressure greater than 50 mm Hg).
. Indications for Echocardiography in Mitral Stenosis
lass I
. Echocardiography should be performed in patients
for the diagnosis of MS, assessment of hemodynamic
severity (mean gradient, MV area, and pulmonary
artery pressure), assessment of concomitant valvular
lesions, and assessment of valve morphology (to
determine suitability for percutaneous mitral balloon
valvotomy). (Level of Evidence: B)
. Echocardiography should be performed for re-
evaluation in patients with known MS and changing
symptoms or signs. (Level of Evidence: B)
. Echocardiography should be performed for assess-
ment of the hemodynamic response of the mean
gradient and pulmonary artery pressure by exercise
Doppler echocardiography in patients with MS when
there is a discrepancy between resting Doppler echo-
cardiographic findings, clinical findings, symptoms,
and signs. (Level of Evidence: C)
. TEE in MS should be performed to assess the
presence or absence of left atrial thrombus and to
further evaluate the severity of MR in patients con-
sidered for percutaneous mitral balloon valvotomy.
(Level of Evidence: C)
. TEE in MS should be performed to evaluate MV
morphology and hemodynamics in patients when trans-
thoracic echocardiography provides suboptimal data.
(Level of Evidence: C)
lass IIa
Echocardiography is reasonable in the re-evaluation
of asymptomatic patients with MS and stable clinical
findings to assess pulmonary artery pressure (for
those with severe MS, every year; moderate MS,
every 1 to 2 years; and mild MS, every 3 to 5 years).
(Level of Evidence: C)
lass III
TEE in the patient with MS is not indicated for
routine evaluation of MV morphology and hemody-
namics when complete transthoracic echocardio-
graphic data are satisfactory. (Level of Evidence: C)
he diagnostic tool of choice in the evaluation of a patient
ith MS is 2D and Doppler echocardiography. Echocardi-
graphy is able to identify restricted diastolic opening of the
V leaflets due to “doming” of the anterior leaflet and
mmobility of the posterior leaflet. Planimetry of the orifice
rea may be possible from the short-axis view. 2-D echo-
ardiography can be used to assess the morphological
ppearance of the MV apparatus, including leaflet mobility
nd flexibility, leaflet thickness, leaflet calcification, subval- 7ular fusion, and the appearance of commissures (243–245).
hese features may be important when one considers the
iming and type of intervention to be performed. Patients with
obile noncalcified leaflets, no commissural calcification, and
ittle subvalvular fusion may be candidates for either balloon
atheter or surgical commissurotomy/valvotomy. There are
everal methods used to assess suitability for valvotomy,
ncluding a Wilkins score (246), an echocardiographic
rouping (based on valve flexibility, subvalvular fusion, and
eaflet calcification) (244), and the absence or presence of
ommisural calcium (245).
The mean transmitral gradient can be accurately and
eproducibly measured from the continuous-wave Doppler
ignal across the MV with the modified Bernoulli equation
247,248). The MV area can be noninvasively derived from
oppler echocardiography with either the diastolic pressure
alf-time method (248–251) or the continuity equation
249). Doppler echocardiography may also be used to
stimate pulmonary artery systolic pressure from the TR
elocity signal (252) and to assess severity of concomitant
R or AR. Formal hemodynamic exercise testing can be
one noninvasively with either a supine bicycle or upright
readmill with Doppler recordings of transmitral and tricus-
id velocities to assess both the transmitral gradient and
ulmonary artery systolic pressure at rest and with exercise
253–257). The criteria for assessment of the severity of MS
re summarized in Table 1 and are applicable when the
eart rate is between 60 and 90 bpm.
In the asymptomatic patient who has documented mild MS
valve area greater than 1.5 cm2 and mean gradient less than 5
m Hg), no further investigations are needed on the initial
orkup (Fig. 4). These patients usually remain stable for years.
f there is more significant MS, a decision to proceed further
hould be based on the suitability of the patient for mitral
alvotomy. In patients with pliable, noncalcified valves with no
r little subvalvular fusion, no calcification in the commissures,
nd no left atrial thrombus, percutaneous mitral valvotomy can
e performed with a low complication rate and may be
ndicated if symptoms develop. Because of the slowly progres-
ive course of MS, patients may remain “asymptomatic” with
evere stenosis merely by readjusting their lifestyles to a more
edentary level. Patients with moderate pulmonary hyperten-
ion at rest (pulmonary artery systolic pressure greater than 50
m Hg) and pliable MV leaflets may be considered for
ercutaneous mitral valvotomy even if they deny having symp-
oms. In patients who lead a sedentary lifestyle, a hemody-
amic exercise test with Doppler echocardiography is useful, as
oted above. Objective limitation of exercise tolerance with a
ise in transmitral gradient greater than 15 mm Hg and a rise
n pulmonary artery systolic pressure greater than 60 mm Hg
ay be an indication for percutaneous valvotomy if the MV
orphology is suitable. In asymptomatic patients with severe
S (valve area less than 1.0 cm2) and severe pulmonary
ypertension (pulmonary artery systolic pressure greater than
5% of systemic pressure either at rest or with exercise) who do
n
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alloon valvotomy or surgical valve repair, it is controversial
hether MV replacement should be performed to prevent
ight ventricular (RV) failure, but surgery is generally recom-
ended in such patients.
. Medical Therapy
. Medical Therapy: General
ecause rheumatic fever is the primary cause of MS, prophy-
axis against rheumatic fever is recommended. Infective endo-
igure 4. Management strategy for patients with mitral stenosis. *The wri
itral valve area (MVA) and that the mean transmitral gradients, pulmonar
hould also be taken into consideration. †There is controversy as to whe
ulmonary hypertension (pulmonary artery pressure greater than 60 mm H
alve replacement to prevent right ventricular failure. ‡Assuming no other c
hest X-ray; ECG, electrocardiogram; echo, echocardiography; LA, left aarditis is uncommon but does occur in isolated MS, and pppropriate endocarditis prophylaxis is also recommended. In
atients with more than a mild degree of MS, counseling on
voidance of unusual physical stresses is advised. Agents with
egative chronotropic properties, such as beta blockers or heart
ate-regulating calcium channel blockers, may be of benefit in
atients in sinus rhythm who have exertional symptoms if
hese symptoms occur with high heart rates. Salt restriction
nd intermittent administration of a diuretic are useful if there
s evidence of pulmonary vascular congestion.
Although MS is a slowly progressive condition, acute
ommittee recognizes that there may be variability in the measurement of
ry wedge pressure (PAWP), and pulmonary artery systolic pressure (PASP)
atients with severe mitral stenosis (MVA less than 1.0 cm2) and severe
hould undergo percutaneous mitral balloon valvotomy (PMBV) or mitral
or pulmonary hypertension is present. AF indicates atrial fibrillation; CXR,
R, mitral regurgitation; 2D, 2-dimensional.ting c
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesatients with severe MS, especially with the onset of rapid
trial fibrillation, and this can be rapidly fatal. Thus,
atients should be counseled to seek medical attention
mmediately if they experience a sudden marked increase in
hortness of breath.
. Medical Therapy: Atrial Fibrillation
hirty to forty percent of patients with symptomatic MS
evelop atrial fibrillation (235,236). There may be signifi-
ant hemodynamic consequences that result from the acute
evelopment of atrial fibrillation, primarily from the rapid
entricular rate, which shortens the diastolic filling period
nd causes elevation of left atrial pressure. Atrial fibrillation
ccurs more commonly in older patients (235) and is
ssociated with a poorer prognosis, with a 10-year survival
ate of 25% compared with 46% in patients who remain in
inus rhythm (237). The risk of arterial embolization,
specially stroke, is significantly increased in patients with
trial fibrillation.
Treatment of an acute episode of rapid atrial fibrillation
onsists of anticoagulation with heparin and control of the
eart rate response. Intravenous digoxin, heart rate-regulating
alcium channel blockers, or beta blockers should be used to
ontrol ventricular response. Intravenous or oral amiodarone
an also be used when beta blockers or heart rate-regulating
alcium channel blockers cannot be used. If there is hemody-
amic instability, electrical cardioversion should be undertaken
rgently, with intravenous heparin before, during, and after the
rocedure. In selected patients, chemical cardioversion may
lso be attempted. Patients who have been in atrial fibrillation
onger than 24 to 48 hours without anticoagulation are at an
ncreased risk for embolic events after cardioversion, but
mbolization may occur with less than 24 hours of atrial
brillation. The decision to proceed with elective cardioversion
s dependent on multiple factors, including duration of atrial
brillation, hemodynamic response to the onset of atrial
brillation, a documented history of prior episodes of atrial
brillation, and a history of prior embolic events. If the
ecision has been made to proceed with elective cardioversion
n a patient who has had documented atrial fibrillation for
onger than 24 to 48 hours and who has not been undergoing
ong-term anticoagulation, 1 of 2 approaches is recommended,
ased on data from patients with nonrheumatic atrial fibrilla-
ion. The first is anticoagulation with warfarin for more than 3
eeks, followed by elective cardioversion (258). The second is
nticoagulation with heparin and TEE to look for left atrial
hrombus. In the absence of left atrial thrombus, cardioversion
s performed with intravenous heparin before, during, and after
he procedure (259). It is important to continue long-term
nticoagulation after cardioversion.
Recurrent paroxysmal atrial fibrillation may be treated
n selected patients with class IC antiarrhythmic drugs (in
onjunction with a negative dromotropic agent) or class
II antiarrhythmic drugs for maintenance of sinus
hythm. However, eventually, atrial fibrillation becomes
esistant to prevention or cardioversion, and control of tentricular response becomes the mainstay of therapy.
atients with either paroxysmal or sustained atrial fibril-
ation should be treated with long-term anticoagulation
ith warfarin to prevent embolic events. It is controver-
ial whether percutaneous mitral valvotomy should be
erformed in patients with new-onset atrial fibrillation
nd moderate to severe MS who are otherwise
symptomatic.
. Medical Therapy: Prevention of Systemic Embolization
lass I
. Anticoagulation is indicated in patients with MS and
atrial fibrillation (paroxysmal, persistent, or perma-
nent). (Level of Evidence: B)
. Anticoagulation is indicated in patients with MS and
a prior embolic event, even in sinus rhythm. (Level of
Evidence: B)
. Anticoagulation is indicated in patients with MS
with left atrial thrombus. (Level of Evidence: B)
lass IIb
. Anticoagulation may be considered for asymptomatic
patients with severe MS and left atrial dimension
greater than or equal to 55 mm by echocardiography.*
(Level of Evidence: B)
. Anticoagulation may be considered for patients with
severe MS, an enlarged left atrium, and spontaneous
contrast on echocardiography. (Level of Evidence: C)
This recommendation is based on a grade C level of evidence
iven by the American College of Chest Physicians Fourth
onsensus Conference on Antithrombotic Therapy (260).
Systemic embolization may occur in 10% to 20% of
atients with MS (235,236), with increasing risk related to
ge and atrial fibrillation (235,236,261). One third of
mbolic events occur within 1 month of the onset of atrial
brillation, and two thirds occur within 1 year. An embolic
vent may thus be the initial manifestation of MS.
There are no randomized trials examining the efficacy
f anticoagulation in preventing embolic events specifi-
ally in patients with MS, but retrospective studies have
hown a 4- to 15-fold decrease in the incidence of
mbolic events with anticoagulation in these patients
262,263). Most studies involved patients who had 1
mbolus before the onset of anticoagulation therapy.
owever, large randomized trials have demonstrated a
ignificant reduction in embolic events by treatment with
nticoagulation in patients with atrial fibrillation not
ssociated with MS (264,265), and the subset of patients
ho benefited most from anticoagulation were those with
he highest risk of embolic events. Patients with MS at
he highest risk for future embolic events are those with
rior embolic events and those with paroxysmal or
ersistent atrial fibrillation. There are no data to support
he concept that oral anticoagulation is beneficial in
p
a
w
b
s
e
4
E
I
a
3
t
C
a
c
5
I
m
h
b
u
s
r
i
6
P
w
e
d
F
m
p
s
(
M
624 Bonow et al. JACC Vol. 48, No. 3, 2006
ACC/AHA Practice Guidelines August 1, 2006:598–675atients with MS who have not had atrial fibrillation or
n embolic event. It is controversial whether patients
ithout atrial fibrillation or an embolic event who might
e at higher risk for future embolic events (i.e., those with
evere MS or an enlarged left atrium) should be consid-
red for long-term warfarin therapy.
. Recommendations Regarding Physical Activity and
xercise
n the majority of patients with MS, exertional symptoms
re the limiting factor in terms of exercise tolerance. The
6th Bethesda Conference on Recommendations for De-
ermining Eligibility for Competition in Athletes with
ardiovascular Abnormalities published guidelines for
symptomatic patients with MS who wish to engage in
ompetitive athletics (67).
igure 5. Management strategy for patients with mitral stenosis and mi
easurement of mitral valve area (MVA) and that the mean transmitral gra
ressure (PASP) should also be taken into consideration. †There is controve
evere pulmonary hypertension (PH; PASP greater than 60 mm Hg) should u
MVR) to prevent right ventricular failure. CXR indicates chest X-ray; ECG, electro
VG, mean mitral valve pressure gradient; NYHA, New York Heart Association. Serial Testing
n the asymptomatic patient, yearly re-evaluation is recom-
ended (Fig. 4). At the time of the yearly evaluation, a
istory, physical examination, chest X-ray, and ECG should
e obtained. An echocardiogram is not recommended yearly
nless there is a change in clinical status or the patient has
evere MS. Ambulatory ECG monitoring (Holter or event
ecorder) to detect paroxysmal atrial fibrillation is indicated
n patients with palpitations.
. Evaluation of the Symptomatic Patient
atients who develop symptoms should undergo evaluation
ith a history, physical examination, ECG, chest X-ray, and
chocardiogram (Figs. 5 and 6). 2-D and Doppler echocar-
iography is indicated to evaluate MV morphology, MV
ptoms. *The committee recognizes that there may be variability in the
, pulmonary artery wedge pressure (PAWP), and pulmonary artery systolic
to whether patients with severe mitral stenosis (MVA less than 1.0 cm2) and
percutaneous mitral balloon valvotomy (PMBV) or mitral valve replacementld sym
dient
rsy as
ndergo
cardiogram; echo, echocardiography; LA, left atrial; MR, mitral regurgitation;
; PAP, pulmonary artery pressure; 2D, 2-dimensional.
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesemodynamics, and pulmonary artery pressure. Patients
ith NYHA functional class II symptoms and moderate or
evere MS (MV area less than or equal to 1.5 cm2 or mean
radient greater than 5 mm Hg) may be considered for mitral
alloon valvotomy if they have suitable MV morphology and
o left atrial thrombi. Patients who have NYHA functional
lass III or IV symptoms and evidence of severe MS have a
oor prognosis if left untreated and should be considered for
ntervention with either balloon valvotomy or surgery.
Formal exercise testing or dobutamine stress testing may
igure 6. Management strategy for patients with mitral stenosis and mode
ariability in the measurement of mitral valve area (MVA) and that the
ulmonary artery systolic pressure (PASP) should also be taken into con
orphology should undergo percutaneous mitral balloon valvotomy (PM
lectrocardiogram; echo, echocardiography; LA, left atrial; MR, mitral r
eplacement; NYHA, New York Heart Association; 2D, 2-dimensional.e useful to differentiate symptoms due to MS from other wauses. Exercise tolerance, heart rate and blood pressure
esponse, transmitral gradient, and pulmonary artery pres-
ure can be obtained at rest and during exercise. This can
sually be accomplished with either supine bicycle or up-
ight exercise with Doppler recording of TR and transmitral
elocities. Right- and left-heart catheterization with exer-
ise may be helpful and occasionally necessary. Patients who
re symptomatic with a significant elevation of pulmonary
rtery pressure (greater than 60 mm Hg), mean transmitral
radient (greater than 15 mm Hg), or pulmonary artery
o severe symptoms. *The writing committee recognizes that there may be
n transmitral gradient, pulmonary artery wedge pressure (PAWP), and
ation. †It is controversial as to which patients with less favorable valve
rather than mitral valve surgery (see text). CXR, chest X-ray; ECG,
itation; MVG, mean mitral valve pressure gradient; MVR, mitral valverate t
mea
sider
BV)
egurgedge pressure (greater than 25 mm Hg) during exercise
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idered for further intervention.
. Indications for Invasive Hemodynamic Evaluation
lass I
. Cardiac catheterization for hemodynamic evaluation
should be performed for assessment of severity of MS
when noninvasive tests are inconclusive or when
there is discrepancy between noninvasive tests and
clinical findings regarding severity of MS. (Level of
Evidence: C)
. Catheterization for hemodynamic evaluation includ-
ing left ventriculography (to evaluate severity of MR)
for patients with MS is indicated when there is a
discrepancy between the Doppler-derived mean gra-
dient and valve area. (Level of Evidence: C)
lass IIa
. Cardiac catheterization is reasonable to assess the he-
modynamic response of pulmonary artery and left atrial
pressures to exercise when clinical symptoms and rest-
ing hemodynamics are discordant. (Level of Evidence: C)
. Cardiac catheterization is reasonable in patients with
MS to assess the cause of severe pulmonary arterial
hypertension when out of proportion to severity of
MS as determined by noninvasive testing. (Level of
Evidence: C)
lass III
Diagnostic cardiac catheterization is not recommended
to assess theMV hemodynamics when 2D and Doppler
echocardiographic data are concordant with clinical
findings. (Level of Evidence: C)
ith the advent of Doppler echocardiography, cardiac
atheterization is no longer required for assessment of
emodynamics in the majority of patients with isolated MS.
here is often overestimation of the transmitral gradient
hen catheterization is performed with pulmonary artery
edge pressure as a substitute for left atrial pressure, even
fter correction for phase delay. Thus, the transmitral
radient derived by Doppler echocardiography may be more
ccurate than that obtained by cardiac catheterization with
ulmonary artery wedge pressure (266).
In most instances, Doppler measurements of transmitral
radient, valve area, and pulmonary pressure will correlate
ell with each other. Catheterization is indicated to assess
emodynamics when there is a discrepancy between
oppler-derived hemodynamics and the clinical status of a
ymptomatic patient. Absolute left- and right-side pressure
easurements should be obtained by catheterization when
here is elevation of pulmonary artery pressure out of
roportion to mean gradient and valve area. Catheterization
ncluding left ventriculography (to evaluate the severity of
R) is indicated when there is a discrepancy between the
oppler-derived mean gradient and valve area. If symptomsppear to be out of proportion to noninvasive assessment of
esting hemodynamics, right- and left-heart catheterization
ith exercise may be useful. Coronary angiography may be
equired in selected patients who may need intervention (see
ection X-B).
. Indications for Percutaneous Mitral Balloon Valvotomy
lass I
. Percutaneous mitral balloon valvotomy is effective for
symptomatic patients (NYHA functional class II, III,
or IV), with moderate or severe MS* and valve mor-
phology favorable for percutaneous mitral balloon val-
votomy in the absence of left atrial thrombus or mod-
erate to severe MR. (Level of Evidence: A)
. Percutaneous mitral balloon valvotomy is effective for
asymptomatic patients with moderate or severe MS*
and valve morphology that is favorable for percutaneous
mitral balloon valvotomy who have pulmonary hyper-
tension (pulmonary artery systolic pressure greater
than 50 mm Hg at rest or greater than 60 mm Hg
with exercise) in the absence of left atrial thrombus or
moderate to severe MR. (Level of Evidence: C)
lass IIa
Percutaneous mitral balloon valvotomy is reasonable
for patients with moderate or severe MS* who have a
nonpliable calcified valve, are in NYHA functional
class III–IV, and are either not candidates for surgery
or are at high risk for surgery. (Level of Evidence: C)
lass IIb
. Percutaneous mitral balloon valvotomy may be con-
sidered for asymptomatic patients with moderate or
severe MS* and valve morphology favorable for percu-
taneous mitral balloon valvotomy who have new onset
of atrial fibrillation in the absence of left atrial throm-
bus or moderate to severe MR. (Level of Evidence: C)
. Percutaneous mitral balloon valvotomy may be con-
sidered for symptomatic patients (NYHA functional
class II, III, or IV) with MV area greater than 1.5 cm2
if there is evidence of hemodynamically significant
MS based on pulmonary artery systolic pressure
greater than 60 mm Hg, pulmonary artery wedge
pressure of 25 mmHg or more, or mean MV gradient
greater than 15 mm Hg during exercise. (Level of
Evidence: C)
. Percutaneous mitral balloon valvotomy may be con-
sidered as an alternative to surgery for patients with
moderate or severe MS who have a nonpliable calci-
fied valve and are in NYHA class III–IV. (Level of
Evidence: C)
lass III
. Percutaneous mitral balloon valvotomy is not indicated
for patients with mild MS. (Level of Evidence: C)
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performed in patients with moderate to severe MR or
left atrial thrombus. (Level of Evidence: C)
See Table 1 (7).
The immediate results of percutaneous mitral valvotomy are
imilar to those of mitral commissurotomy (267–276). The
ean valve area usually doubles (from 1.0 to 2.0 cm2), with a
0% to 60% reduction in transmitral gradient. Overall, 80% to
5% of patients may have a successful procedure, which is
efined as an MV area greater than 1.5 cm2 and a decrease in
eft atrial pressure to less than 18 mm Hg in the absence of
omplications. The most common acute complications re-
orted in large series include severe MR, which occurs in 2% to
0%, and a residual atrial septal defect.
Event-free survival after percutaneous balloon valvotomy
freedom from death, repeat valvotomy, or MV replace-
ent) overall is 50% to 65% over 3 to 7 years, with an
vent-free survival of 80% to 90% in patients with favorable
V morphology (245,269,271–278). More than 90% of
atients free of events remain in NYHA functional class I or
I after percutaneous mitral valvotomy. Randomized trials
ave compared percutaneous balloon valvotomy with both
losed and open surgical commissurotomy (279–284).
here was no significant difference in acute hemodynamic
esults or complication rate between percutaneous mitral
alvotomy and surgery, and early follow-up data indicate no
ifference in hemodynamics, clinical improvement, or exer-
ise time. However, longer-term follow-up studies at 3 to 7
ears (282,283) indicate more favorable hemodynamic and
ymptomatic results with percutaneous balloon valvotomy
han with closed commissurotomy.
The immediate results, acute complications, and follow-up
esults of percutaneous balloon valvotomy are dependent on
ultiple factors. It is of utmost importance that this procedure
e performed in centers with skilled and experienced operators.
ther factors include age, NYHA functional class, stenosis
everity, LV end-diastolic pressure, cardiac output, and pul-
onary artery wedge pressure (269,271,272,276). The under-
ying MV morphology is the factor of greatest importance in
etermining outcome (243–246,269,272,273,276,277,285–
88), and immediate postvalvotomy hemodynamics are pre-
ictive of long-term clinical outcome (271,273,276). Patients
ith valvular calcification, thickened fibrotic leaflets with
ecreased mobility, and subvalvular fusion have a higher
ncidence of acute complications and a higher rate of recurrent
tenosis on follow-up.
Patients who are being considered for an intervention
hould undergo evaluation with a history, physical examina-
ion, and 2D and Doppler echocardiographic examination.
he appearance and mobility of the MV apparatus and
ommissures should be evaluated by 2D echocardiography, and
he transmitral gradient, MV area, and pulmonary artery
ressure should be obtained from the Doppler examination. If
here is a discrepancy between symptoms and hemodynamics,
formal hemodynamic exercise test may be performed.Relative contraindications to percutaneous balloon val-
otomy include the presence of a left atrial thrombus and
ignificant (3 to 4) MR. Patients thought to be candi-
ates for percutaneous mitral valvotomy should undergo
EE to rule out left atrial thrombus and to examine the
everity of MR. Percutaneous mitral balloon valvotomy
hould be performed only by skilled operators at institutions
ith extensive experience in performing the technique
267,270). Thus, the decision to proceed with percutaneous
alloon valvotomy or surgical commissurotomy is depen-
ent on the experience of the operator and institution.
ecause of the less invasive nature of percutaneous balloon
alvotomy compared with surgical intervention, appropriate
atients without symptoms or those with NYHA functional
lass II symptoms may be considered for catheter-based
herapy (Figs. 4 and 5).
. Indications for Surgery for Mitral Stenosis
lass I
. MV surgery (repair if possible) is indicated in pa-
tients with symptomatic (NYHA functional class
III–IV) moderate or severe MS* when 1) percutane-
ous mitral balloon valvotomy is unavailable, 2) per-
cutaneous mitral balloon valvotomy is contraindi-
cated because of left atrial thrombus despite
anticoagulation or because concomitant moderate to
severe MR is present, or 3) the valve morphology is
not favorable for percutaneous mitral balloon valvot-
omy in a patient with acceptable operative risk. (Level
of Evidence: B)
. Symptomatic patients with moderate to severe MS*
who also have moderate to severe MR should receive
MV replacement, unless valve repair is possible at the
time of surgery. (Level of Evidence: C)
lass IIa
MV replacement is reasonable for patients with se-
vere MS* and severe pulmonary hypertension (pul-
monary artery systolic pressure greater than 60 mm
Hg) with NYHA functional class I–II symptoms who
are not considered candidates for percutaneous mitral
balloon valvotomy or surgical MV repair. (Level of
Evidence: C)
lass IIb
MV repair may be considered for asymptomatic pa-
tients with moderate or severe MS* who have had
recurrent embolic events while receiving adequate
anticoagulation and who have valve morphology fa-
vorable for repair. (Level of Evidence: C)
lass III
. MV repair for MS is not indicated for patients with
mild MS. (Level of Evidence: C)
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patients undergoing MV repair; open commissurot-
omy is the preferred approach. (Level of Evidence: C)
See Table 1 (7).
f there is significant calcification, fibrosis, and subvalvular
usion of the MV apparatus, commissurotomy or percuta-
eous balloon valvotomy is less likely to be successful, and
V replacement will be necessary. Given the risk of MV
eplacement and the potential long-term complications of a
rosthetic valve, there are stricter indications for MV
peration in these patients with calcified fibrotic valves. In
he patient with NYHA functional class III symptoms due
o severe MS or combined MS/MR, MV replacement
esults in excellent symptomatic improvement. Postpone-
ent of surgery until the patient reaches the functional class
V symptomatic state should be avoided, because operative
ortality is high and the long-term outcome is suboptimal.
owever, if the patient presents in NYHA functional class
V heart failure, surgery should not be denied, because the
utlook without surgical intervention is grave. It is contro-
ersial whether asymptomatic or mildly symptomatic pa-
ients with severe MS (valve area less than 1 cm2) and severe
ulmonary hypertension (pulmonary artery systolic pressure
reater than 60 to 80 mm Hg) should undergo MV
eplacement to prevent RV failure, but surgery is generally
ecommended in such patients. It is recognized that patients
ith such severe pulmonary hypertension are rarely asymp-
omatic.
0. Management of Patients After Valvotomy or Com-
issurotomy
baseline echocardiogram should be performed after the
rocedure to obtain a baseline measurement of postopera-
ive hemodynamics and to exclude significant complications
uch as MR, LV dysfunction, or atrial septal defect (in the
ase of percutaneous valvotomy). This echocardiogram
hould be performed at least 72 h after the procedure,
ecause acute changes in atrial and ventricular compliance
mmediately after the procedure affect the reliability of the
alf-time in calculation of valve area (249,250). Patients
ith severe MR or a large atrial septal defect should be
onsidered for early surgery; however, the majority of small
eft-to-right shunts at the atrial level will close spontane-
usly over the course of 6 months.
Repeat percutaneous balloon valvotomy can be performed
n the patient in whom there is restenosis after either a prior
urgical commissurotomy or balloon valvotomy (289,290).
he results of these procedures are adequate in many
atients but may be less satisfactory than the overall results
f initial valvotomy because there is usually more valve
eformity, calcification, and fibrosis than with the initial
rocedure (286,290,291).. Mitral Valve Prolapse
tilizing current echocardiographic criteria for diagnosing
VP (valve prolapse of 2 mm or more above the mitral
nnulus in the long-axis parasternal view and other views
292), the prevalence of this entity is 1% to 2.5% of the
opulation (293). MVP occurs as a clinical entity with or
ithout thickening (5 mm or greater, measured during
iastasis) and with or without MR.
The basic microscopic feature of primary MVP is marked
roliferation of the spongiosa, the delicate myxomatous
onnective tissue between the atrialis (a thick layer of
ollagen and elastic tissue that forms the atrial aspect of the
eaflet) and the fibrosa or ventricularis (dense layer of
ollagen that forms the basic support of the leaflet). Myx-
matous proliferation of the acid mucopolysaccharide–
ontaining spongiosa tissue causes focal interruption of the
brosa. Secondary effects of the primary MVP syndrome
nclude fibrosis of the surface of the MV leaflets, thinning
nd/or elongation of the chordae tendineae, and ventricular
riction lesions.
. Natural History
he natural history of asymptomatic MVP is heterogeneous
nd can vary from benign with normal life expectancy to
dverse with significant morbidity or mortality. The most
requent predictor of cardiovascular mortality is moderate to
evere MR and, less frequently, an LV ejection fraction less
han 0.50 (294). Echocardiographic evidence of thickened
V leaflets (5 mm or greater) is also a predictor of
omplications related to MVP (295–299). In most patients,
VP is associated with a benign prognosis (300,301), with
n age-adjusted survival rate for both men and women
imilar to that of individuals without this entity (302).
In some patients, after an initially prolonged asymptomatic
nterval, the entire process may enter an accelerated phase as a
esult of left atrial and ventricular dysfunction and atrial
brillation. In some instances, spontaneous rupture of MV
hordae will occur. Infective endocarditis is a serious compli-
ation of MVP, which is the leading predisposing cardiovas-
ular diagnosis in most series of patients reported with endo-
arditis. Several studies have indicated an increased likelihood
f cerebrovascular accidents in patients under 45 years of age
ho have MVP beyond what would have been expected in a
imilar population without MVP (303).
Sudden death is a rare complication of MVP, occurring in
ewer than 2% of known cases during long-term follow-up
296,303–309). Annual mortality rates are less than 1% per year.
. Evaluation and Management of the Asymptomatic
atient
lass I
Echocardiography is indicated for the diagnosis of
MVP and assessment of MR, leaflet morphology, and
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesventricular compensation in asymptomatic patients
with physical signs of MVP. (Level of Evidence: B)
lass IIa
. Echocardiography can effectively exclude MVP in
asymptomatic patients who have been diagnosed
without clinical evidence to support the diagnosis.
(Level of Evidence: C)
. Echocardiography can be effective for risk stratifica-
tion in asymptomatic patients with physical signs of
MVP or known MVP. (Level of Evidence: C)
lass III
. Echocardiography is not indicated to exclude MVP in
asymptomatic patients with ill-defined symptoms in
the absence of a constellation of clinical symptoms or
physical findings suggestive of MVP or a positive
family history. (Level of Evidence: B)
. Routine repetition of echocardiography is not indi-
cated for the asymptomatic patient who has MVP
and no MR or MVP and mild MR with no changes
in clinical signs or symptoms. (Level of Evidence: C)
The primary diagnostic evaluation of the patient with
VP is the physical examination (307,310). However,
VP can be present in the absence of the classic ausculta-
ory findings, and systolic clicks may be intermittent and
ariable.
2D and Doppler echocardiography is the most useful
oninvasive tests for defining MVP. Valve prolapse of 2
m or more above the mitral annulus in the long-axis
arasternal view and other views, especially when the
eaflet coaptation occurs on the atrial side of the annular
lane, indicates a high likelihood of MVP. There is
isagreement concerning the reliability of the echocar-
iographic appearance of anterior leaflet billowing when
bserved only in the apical 4-chamber view (297,311).
eaflet thickness of 5 mm or more indicates abnormal
eaflet thickness, and its added presence makes MVP
ven more certain. Leaflet redundancy is often associated
ith an enlarged mitral annulus and elongated chordae
endineae (307). The absence or presence of MR is an
mportant consideration, and MVP is more likely when
R is detected as a high-velocity eccentric jet in late
ystole (312).
Antibiotic prophylaxis, for the prevention of endocarditis
uring procedures associated with bacteremia, is recom-
ended for most patients with a definite diagnosis of MVP,
articularly if there is associated MR (313). The committee
ecommends that patients without MR who have leaflet
hickening, elongated chordae, left atrial enlargement, or LV
ilatation receive endocarditis prophylaxis (295–299,314)
see Section II-C-1). m. Evaluation and Management of the Symptomatic
atient
lass I
. Aspirin therapy (75 to 325 mg per day) is recom-
mended for symptomatic patients with MVP who
experience cerebral transient ischemic attacks. (Level
of Evidence: C)
. In patients with MVP and atrial fibrillation, warfarin
therapy is recommended for patients aged greater
than 65 or those with hypertension, MR murmur, or
a history of heart failure. (Level of Evidence: C)
. Aspirin therapy (75 to 325 mg per day) is recom-
mended for patients with MVP and atrial fibrillation
who are less than 65 years old and have no history of
MR, hypertension, or heart failure. (Level of Evi-
dence: C)
. In patients with MVP and a history of stroke,
warfarin therapy is recommended for patients with
MR, atrial fibrillation or left atrial thrombus. (Level
of Evidence: C)
lass IIa
. In patients with MVP and a history of stroke, who do
not have MR, atrial fibrillation or left atrial throm-
bus, warfarin therapy is reasonable for patients with
echocardiographic evidence of thickening (5 mm or
greater) and/or redundancy of the valve leaflets.
(Level of Evidence: C)
. In patients with MVP and a history of stroke, aspirin
therapy is reasonable for patients who do not have MR,
atrial fibrillation, left atrial thrombus, or echocardio-
graphic evidence of thickening (5mm or greater) or
redundancy of the valve leaflets. (Level of Evidence: C)
. Warfarin therapy is reasonable for patients with
MVP with transient ischemic attacks despite aspirin
therapy. (Level of Evidence: C)
. Aspirin therapy (75 to 325 mg per day) can be
beneficial for patients with MVP and a history of
stroke who have contraindications to anticoagulants.
(Level of Evidence: B)
lass IIb
Aspirin therapy (75 to 325 mg per day) may be
considered for patients in sinus rhythm with echo-
cardiographic evidence of high-risk MVP. (Level of
Evidence: C)
atients with MVP and palpitations associated with mild
achyarrhythmias or increased adrenergic symptoms and
hose with chest pain, anxiety, or fatigue often respond to
herapy with beta blockers (315). In many cases, however,
he cessation of stimulants such as caffeine, alcohol, and
igarettes may be sufficient to control symptoms.
Daily aspirin therapy (75 to 325 mg per day) is recom-
ended for MVP patients with documented transient focal
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ACC/AHA Practice Guidelines August 1, 2006:598–675eurological events who are in sinus rhythm with no atrial
hrombi. Such patients also should avoid cigarettes and oral
ontraceptives. The American Stroke Association guidelines
315a) recommend aspirin for patients with MVP who have
xperienced an ischemic stroke (class IIa, level of evidence C),
ased on the evidence of efficacy of antiplatelet agents for
eneral stroke patients. No randomized trials have addressed
he efficacy of selected antithrombotic therapies for the specific
ubgroup of stroke patients with MVP. In the current guide-
ines, the committee recommends aspirin for those post-stroke
atients with MVP who have no evidence of MR, atrial
brillation, left artrial thrombus, or echocardiographic evidence
f thickening (5mm or greater) or redundancy of the valve
eaflets. However, long-term anticoagulation therapy with
arfarin is recommended (class I) for post-stroke patients with
VP who have MR, atrial fibrillation, or left atrial thrombus.
n the absence of these indications, warfarin is also recom-
ended (class IIa) in post-stroke patients with MVP who have
chocardiographic evidence of thickening (5 mm or greater) or
edundancy of the valve leaflets and in MVP patients who
xperience recurrent transient ischemic attacks while taking
spirin. In each of these situations, the international normal-
zed ratio (INR) should be maintained between 2.0
o 3.0).
In MVP patients with atrial fibrillation, warfarin therapy is
ndicated in patients aged greater than 65 years and in those
ith MR, hypertension, or a history of heart failure (INR 2.0
o 3.0). Aspirin therapy is satisfactory in patients with atrial
brillation who are younger than 65 years old, have no MR,
nd have no history of hypertension or heart failure (316,317).
aily aspirin therapy is often recommended for patients with
igh-risk echocardiographic characteristics.
A normal lifestyle and regular exercise are encouraged for
ost patients with MVP, especially those who are asymp-
omatic (309,317). Restriction from competitive sports is
ecommended when moderate LV enlargement, LV dys-
unction, uncontrolled tachyarrhythmias, long-QT interval,
nexplained syncope, prior resuscitation from cardiac arrest,
r aortic root enlargement is present individually or in
ombination (307).
Asymptomatic patients with MVP and no significant
R can be evaluated clinically every 3 to 5 years. Serial
chocardiography is not necessary in most patients and is
ecommended only in patients who have high-risk charac-
eristics on the initial echocardiogram and in those who
evelop symptoms consistent with cardiovascular disease or
ho have a change in physical findings that suggests
evelopment of significant MR. Patients who have high-
isk characteristics, including those with moderate to severe
R, should be followed up once a year.
Patients with severe MR with symptoms or impaired LV
ystolic function require cardiac catheterization and evalua-
ion for MV surgery (see Section III-F-3-b). The thick-
ned, redundant MV can often be repaired rather than
eplaced, with a low operative mortality and excellent short-
nd long-term results (318,319). i. Surgical Considerations
anagement of MVP may require surgery, particularly in
hose patients who develop a flail leaflet due to rupture of
hordae tendineae or their marked elongation. Most such
alves can be repaired successfully by surgeons experienced
n MV repair, especially when the posterior leaflet of the
V is predominantly affected. MV repair for MR due to
VP is associated with excellent long-term survival and
emains superior to MV replacement beyond 10 years and
p to 20 years after surgery (318,319). Anterior leaflet repair
s associated with a higher risk for reoperation than poste-
ior leaflet repair. As noted in Section III-F-3-b, cardiolo-
ists are strongly encouraged to refer patients who are
andidates for complex MV repair to surgical centers expe-
ienced in performing MV repair. Residual MR is associ-
ted with a higher risk for reoperation (319). Recommen-
ations for surgery in patients with MVP and MR are the
ame as for those with other forms of nonischemic severe
R (see Section VII-B-1-c).
. Mitral Regurgitation
. Acute Severe Mitral Regurgitation
. Diagnosis
he patient with acute severe MR is almost always severely
ymptomatic. Physical examination of the precordium may
e misleading, because a normal-sized left ventricle does not
roduce a hyperdynamic apical impulse. The systolic mur-
ur of MR may not be holosystolic and may even be absent.
ransthoracic echocardiography may demonstrate the dis-
uption of the MV and provide semiquantitative informa-
ion on lesion severity; however, transthoracic echocardiog-
aphy may underestimate lesion severity by inadequate
maging of the color flow jet, and TEE should be performed
f MV morphology and regurgitant severity are still in
uestion after transthoracic echocardiography. TEE is also
elpful in demonstrating the anatomic cause of acute severe
R and directing successful surgical repair.
. Medical Therapy
n acute severe MR, medical therapy has a limited role and
s aimed primarily to stabilize hemodynamics in preparation
or surgery. In the normotensive patient, nitroprusside may
ffectively diminish the amount of MR, which in turn
ncreases forward output and reduces pulmonary congestion.
n the hypotensive patient, nitroprusside should not be
dministered alone, but combination therapy with an ino-
ropic agent (such as dobutamine) and nitroprusside is of
enefit in some patients. In such patients, aortic balloon
ounterpulsation increases forward output and mean arterial
ressure while diminishing regurgitant volume and LV
lling pressure and can be used to stabilize the patient while
hey are prepared for surgery. If infective endocarditis is the
ause of acute MR, identification and treatment of the
nfectious organism are essential.
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. Natural History
atients with mild to moderate MR may remain asymp-
omatic with little or no hemodynamic compromise for
any years; however, MR from a primary MV abnormality
ends to progress over time with an increase in volume
verload due to an increase in the effective orifice area.
rogression of the MR is variable and is determined by
rogression of lesions or mitral annulus size (320).
The compensated phase of MR is variable but may last
or many years, but the prolonged burden of volume
verload may eventually result in LV dysfunction. In this
hase, contractile dysfunction impairs ejection, and end-
ystolic volume increases. There may be further LV dilata-
ion and increased LV filling pressure. These hemodynamic
vents result in reduced forward output and pulmonary
ongestion. However, the still favorable loading conditions
ften maintain ejection fraction in the low-normal range
0.50 to 0.60) despite the presence of significant muscle
ysfunction (321–323). Correction of MR should be per-
ormed before the advanced phases of LV decompensation.
Numerous studies indicate that patients with chronic
evere MR have a high likelihood of developing symptoms
r LV dysfunction over the course of 6 to 10 years
313,317,324,325). However, the incidence of sudden death
n asymptomatic patients with normal LV function varies
idely among these studies.
The natural history of severe MR due to a flail posterior
eaflet has been documented (313). At 10 years, 90% of
atients are dead or require MV operation. The mortality
ate in patients with severe MR caused by flail leaflets is 6%
o 7% per year. However, patients at risk of death are
redominantly those with LV ejection fractions less than
.60 or with NYHA functional class III–IV symptoms, and
ess so those who are asymptomatic and have normal LV
unction (313,326). Severe symptoms also predict a poor
utcome after MV repair or replacement (326).
. Indications for Transthoracic Echocardiography
lass I
. Transthoracic echocardiography is indicated for
baseline evaluation of LV size and function, RV and
left atrial size, pulmonary artery pressure, and sever-
ity of MR (Table 1) in any patient suspected of
having MR. (Level of Evidence: C)
. Transthoracic echocardiography is indicated for de-
lineation of the mechanism of MR. (Level of Evi-
dence: B)
. Transthoracic echocardiography is indicated for an-
nual or semiannual surveillance of LV function (es-
timated by ejection fraction and end-systolic dimen-
sion) in asymptomatic patients with moderate to
severe MR. (Level of Evidence: C) e. Transthoracic echocardiography is indicated in pa-
tients with MR to evaluate the MV apparatus and LV
function after a change in signs or symptoms. (Level
of Evidence: C)
. Transthoracic echocardiography is indicated to eval-
uate LV size and function and MV hemodynamics in
the initial evaluation after MV replacement or MV
repair. (Level of Evidence: C)
lass IIa
Exercise Doppler echocardiography is reasonable in
asymptomatic patients with severe MR to assess
exercise tolerance and the effects of exercise on
pulmonary artery pressure and MR severity. (Level of
Evidence: C)
lass III
Transthoracic echocardiography is not indicated for
routine follow-up evaluation of asymptomatic pa-
tients with mild MR and normal LV size and systolic
function. (Level of Evidence: C)
n initial comprehensive 2D Doppler echocardiogram pro-
ides a baseline estimation of LV and left atrial size, an
stimation of LV ejection fraction, and approximation of
he severity of MR (1). Quantification of the severity of MR
Table 1) is strongly recommended (7,324,327,328). In the
ajority of patients, an estimate of pulmonary artery pres-
ure can be obtained from the TR peak velocity. Changes
rom these baseline values are used subsequently to guide
he timing of MV surgery.
The initial transthoracic echocardiogram should disclose the
natomic cause of the MR. A central color flow jet of MR with
structurally normal MV apparatus suggests the presence of
unctional MR, which may be due to annular dilatation from
V dilatation or tethering of the posterior leaflet because of
egional LV dysfunction in patients with ischemic heart
isease. An eccentric color flow jet of MR with abnormalities
f the MV apparatus indicates organic MR. In patients with
rganic MR, the echocardiogram should assess the presence of
alcium in the annulus or leaflets, the redundancy of the valve
eaflets, and the MV leaflet involved (anterior leaflet, posterior
eaflet, or bileaflet). These factors will help determine the
easibility of valve repair if surgery is contemplated. The system
roposed by Carpentier (329) identifies the anatomic and
hysiologic characteristics of the valve that aid the surgeon in
lanning MV repair. The valve dysfunction is described on the
asis of the motion of the free edge of the leaflet relative to the
lane of the annulus: type I, normal; type II, increased, as in
VP; type IIIA, restricted during systole and diastole, and
ype IIIB, restricted during systole.
Multiple parameters from the Doppler examination should
e used to diagnose severe MR (Table 1), including the color
ow jet width and area, the intensity of the continuous-wave
oppler signal, the pulmonary venous flow contour, the peakarly mitral inflow velocity, and quantitative measures of
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here should be enlargement of the left ventricle and left atrium
n chronic severe MR. Abnormalities of the MV apparatus are
ften present if there is severe MR, but ischemic LV dysfunc-
ion may also result in severe MR. If a discrepancy is present,
r if the patient has poor windows on transthoracic echocar-
iography, then further evaluation of the severity of MR is
equired, including cardiac catheterization, magnetic resonance
maging, or TEE.
. Indications for Transesophageal Echocardiography
lass I
. Preoperative or intraoperative TEE is indicated to
establish the anatomic basis for severe MR in pa-
tients in whom surgery is recommended to assess
feasibility of repair and to guide repair. (Level of
Evidence: B)
. TEE is indicated for evaluation of MR patients in
whom transthoracic echocardiography provides nondi-
agnostic information regarding severity of MR, mech-
anism of MR, and/or status of LV function. (Level of
Evidence: B)
lass IIa
Preoperative TEE is reasonable in asymptomatic
patients with severe MR who are considered for
surgery to assess feasibility of repair. (Level of Evi-
dence: C)
lass III
TEE is not indicated for routine follow-up or surveil-
lance of asymptomatic patients with native valve MR.
(Level of Evidence: C)
. Serial Testing
symptomatic patients with mild MR and no evidence of
V enlargement, LV dysfunction, or pulmonary hyperten-
ion can be followed on a yearly basis with instructions to
lert the physician if symptoms develop in the interim.
early echocardiography is not necessary unless there is
linical evidence that MR has worsened. In patients with
oderate MR, clinical evaluation including echocardiogra-
hy should be performed annually and sooner if symptoms
ccur.
In asymptomatic patients with severe MR, clinical eval-
ation and echocardiography should be performed every 6
o 12 months to assess symptoms or transition to asymp-
omatic LV dysfunction. Exercise stress testing may be used
o add objective evidence regarding symptoms and changes
n exercise tolerance. Exercise testing is especially important
f a good history of the patient’s exercise capacity cannot be
btained. Measurement of pulmonary artery pressure and
ssessment of severity of MR during exercise may be
elpful. wAlthough interpretation of LV ejection fraction in pa-
ients with severe MR is difficult because the loading
onditions facilitate ejection, several studies indicate that
he preoperative ejection fraction is an important predictor
f postoperative survival in patients with chronic MR
321,330–333). Ejection fraction in a patient with MR with
ormal LV function is usually greater than or equal to 0.60.
onsistent with this concept, postoperative ventricular
unction is lower and survival is reduced in patients with a
reoperative ejection fraction less than 0.60 compared with
atients with higher ejection fractions (332,333).
Alternatively or in concert, LV end-systolic dimension
or volume), which may be less load dependent than ejection
raction, can be used in timing of MV surgery. End-systolic
imension should be less than 40 mm preoperatively to
nsure normal postoperative LV function (333–336).
If patients become symptomatic, they should undergo
V surgery even if LV function appears to be normal.
. Guidelines for Physical Activity and Exercise
ecommendations regarding participation in competitive
thletics were published by the Task Force on Acquired
alvular Heart Disease of the 36th Bethesda Conference
67). Asymptomatic patients with MR of any severity who
re in sinus rhythm and who have normal LV and left atrial
imensions and normal pulmonary artery pressure may
xercise without restriction (67). However, those with
efinite LV enlargement (greater than or equal to 60 mm),
ulmonary hypertension, or any degree of LV systolic
ysfunction at rest should not participate in any competitive
ports.
. Medical Therapy
n asymptomatic patients with chronic MR, there is no
enerally accepted medical therapy. Although the use of
asodilators may appear to be logical for the same reasons
hat they are effective in acute MR, there are no large
ong-term studies to indicate that they are beneficial. Thus,
n the absence of systemic hypertension, there is no known
ndication for the use of vasodilating drugs or ACE inhib-
tors in asymptomatic patients with MR and preserved LV
unction.
However, in patients with functional or ischemic MR
resulting from dilated or ischemic cardiomyopathy), there
s reason to believe that preload reduction may be beneficial
337). If LV systolic dysfunction is present, primary treat-
ent of the LV systolic dysfunction with drugs such as
CE inhibitors or beta blockers (particularly carvedilol) and
iventricular pacing have all been shown to reduce the
everity of functional MR (338–341).
In patients with MR who develop symptoms but have
reserved LV function, surgery is the most appropriate
herapy. If atrial fibrillation develops, heart rate should be
ontrolled with rate-lowering calcium channel blockers,
eta blockers, digoxin, or, rarely, amiodarone. In patients
ith severe MR and chronic atrial fibrillation, a Maze
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesrocedure may be added to an MV repair (see Atrial
ibrillation in Section III-F-3-b), because this will reduce
he risk of postoperative stroke. Patients with MR and atrial
brillation should receive chronic anticoagulation, with the
NR maintained at 2.0 to 3.0.
. Indications for Cardiac Catheterization
lass I
. Left ventriculography and hemodynamic measurements
are indicated when noninvasive tests are inconclusive
regarding severity of MR, LV function, or the need for
surgery. (Level of Evidence: C)
. Hemodynamic measurements are indicated when
pulmonary artery pressure is out of proportion to the
severity of MR as assessed by noninvasive testing.
(Level of Evidence: C)
. Left ventriculography and hemodynamic measure-
ments are indicated when there is a discrepancy
between clinical and noninvasive findings regarding
severity of MR. (Level of Evidence: C)
. Coronary angiography is indicated before MV repair
or MV replacement in patients at risk for CAD.
(Level of Evidence: C)
lass III
Left ventriculography and hemodynamic measure-
ments are not indicated in patients with MR in
whom valve surgery is not contemplated. (Level of
Evidence: C)
Cardiac catheterization, with or without exercise, is
ecessary when there is a discrepancy between clinical and
oninvasive findings. Although the standard semiquantita-
ive approach to determining the severity of MR from
entriculography has its own limitations (342), ventriculog-
aphy does provide an additional method to assess LV
ilatation and function and gauge the severity of MR.
xercise hemodynamics may provide additional information
hat is helpful in decision making. In patients who have risk
actors for CAD (e.g., advanced age, hypercholesterolemia,
r hypertension), or when there is a suspicion that MR is
schemic in origin (either because of known myocardial
nfarction or suspected ischemia), coronary angiography
hould be performed before surgery.
. Indications for Surgery
. Types of Surgery
n most cases, MV repair is the operation of choice when
he valve is suitable for repair and appropriate surgical
kill and expertise are available. This procedure preserves
he patient’s native valve without a prosthesis and there-
ore avoids the risk of chronic anticoagulation (except in
atients in atrial fibrillation) or prosthetic valve failure
ate after surgery. Additionally, preservation of the mitral
pparatus leads to better postoperative LV function andurvival than in cases in which the apparatus is disrupted
327,343–348). Valve morphology and surgical expertise
re of critical importance for the success of MV repair
see below).
The reoperation rate after MV repair is similar to that
fter MV replacement (319). There is a 7% to 10%
eoperation rate at 10 years in patients undergoing MV
epair, usually for severe recurrent MR (319,349–352).
pproximately 70% of the recurrent MR is thought to be
ue to the initial procedure and 30% to progressive valve
isease (349).
If MV replacement is required, MV replacement with
reservation of the chordal apparatus enhances postop-
rative mitral competence, preserves LV function, and
ncreases postoperative survival compared with MV re-
lacement in which the apparatus is disrupted (345,353–
56). This latter form of MV replacement is never
ecommended and should only be performed in those
ircumstances in which the native valve and apparatus are
o distorted by the preoperative pathology (rheumatic
isease, for example) that the mitral apparatus cannot be
pared. Artificial chordal reconstruction does extend the
pportunities for repair in some such patients (357,358).
The advantages of MV repair make it applicable across
he full spectrum of MR, including the 2 extremes of the
pectrum. Valve repair might be possible in patients with
ar-advanced symptomatic MR and depressed LV func-
ion, because it preserves LV function at the preoperative
evel (347). At the other extreme, in the relatively
symptomatic patient with well-preserved LV function,
epair of a severely regurgitant valve might be contem-
lated to avoid the onset of LV dysfunction from
ong-standing volume overload. However, failed MV
epair that results in the need for a prosthetic valve in an
symptomatic patient would represent a clear complica-
ion of surgery. Hence, “prophylactic” surgery in an
symptomatic patient with MR and normal LV function
equires a very high likelihood of successful repair.
. Indications for Mitral Valve Operation
lass I
. MV surgery is recommended for the symptomatic
patient with acute severe MR.* (Level of Evidence: B)
. MV surgery is beneficial for patients with chronic
severe MR* and NYHA functional class II, III, or IV
symptoms in the absence of severe LV dysfunction
(severe LV dysfunction is defined as ejection fraction
less than 0.30) and/or end-systolic dimension greater
than 55 mm. (Level of Evidence: B)
. MV surgery is beneficial for asymptomatic patients
with chronic severe MR* and mild to moderate LV
dysfunction, ejection fraction 0.30 to 0.60, and/or
end-systolic dimension greater than or equal to 40
mm. (Level of Evidence: B)
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in the majority of patients with severe chronic MR*
who require surgery, and patients should be re-
ferred to surgical centers experienced in MV repair.
(Level of Evidence: C)
lass IIa
. MV repair is reasonable in experienced surgical cen-
ters for asymptomatic patients with chronic severe
MR* with preserved LV function (ejection fraction
greater than 0.60 and end-systolic dimension less
than 40 mm) in whom the likelihood of successful
repair without residual MR is greater than 90%.
(Level of Evidence: B)
. MV surgery is reasonable for asymptomatic pa-
tients with chronic severe MR,* preserved LV
function, and new onset of atrial fibrillation. (Level
of Evidence: C)
. MV surgery is reasonable for asymptomatic pa-
tients with chronic severe MR,* preserved LV
function, and pulmonary hypertension (pulmonary
artery systolic pressure greater than 50 mm Hg at
rest or greater than 60 mm Hg with exercise).
(Level of Evidence: C)
. MV surgery is reasonable for patients with chronic
severe MR* due to a primary abnormality of the
mitral apparatus and NYHA functional class III–IV
symptoms and severe LV dysfunction (ejection frac-
tion less than 0.30 and/or end-systolic dimension
greater than 55 mm) in whom MV repair is highly
likely. (Level of Evidence: C)
lass IIb
MV repair may be considered for patients with
chronic severe secondary MR* due to severe LV
dysfunction (ejection fraction less than 0.30) who
have persistent NYHA functional class III–IV symp-
toms despite optimal therapy for heart failure, in-
cluding biventricular pacing. (Level of Evidence: C)
lass III
. MV surgery is not indicated for asymptomatic pa-
tients with MR and preserved LV function (ejection
fraction greater than 0.60 and end-systolic dimension
less than 40 mm) in whom significant doubt about
the feasibility of repair exists. (Level of Evidence: C)
. Isolated MV surgery is not indicated for patients with
mild or moderate MR. (Level of Evidence: C)
See Table 1 (7).
The prediction of successful MV repair is important in
iming surgery. This prediction is based on the skill and
xperience of the surgeon in performing repair, on the
ause of the MR, and on MV morphology. The skill and wxperience of the surgeon are probably the most impor-
ant determinants of the eventual success of MV repair.
The number of patients undergoing MV repair for MR
as increased steadily over the past decade in the United
tates and Canada in relation to the number undergoing
V replacement. However, among isolated MV procedures
eported in the STS National Cardiac Database from 1999
o 2000 (359), the frequency of repair was only 35.7% (3027
f a total of 8486 procedures), which suggests that MV
epair is underutilized. Current data indicate that the
requency of MV repair is increasing yearly (93). The STS
ational database also indicates an operative mortality rate of
ess than 2% in patients undergoing isolated MV repair in
004, which compares favorably to the more than 6% operative
ortality rate for patients undergoing isolated MV replace-
ent (93). In light of the beneficial effect of MV repair on
urvival and LV function, cardiologists are strongly encouraged
o refer patients who are candidates for MV repair to surgical
enters experienced in performing MV repair.
ymptomatic Patients With Normal Left Ventricular Function
atients with symptoms of congestive heart failure despite
ormal LV systolic function (ejection fraction greater than
.60 and end-systolic dimension less than 40 mm) require
urgery. Surgery should be performed in patients with even
ild symptoms and severe MR (Fig. 7), especially if it
ppears that MV repair rather than replacement can be
erformed.
symptomatic and Symptomatic Patients with Left Ventricular
ysfunction
he timing of surgery for asymptomatic patients is contro-
ersial, but most would now agree that MV surgery is
ndicated with the appearance of echocardiographic indica-
ors of LV dysfunction. These include LV ejection fraction
ess than or equal to 0.60 and/or LV end-systolic dimension
reater than or equal to 40 mm (Fig. 7). MV surgery should
lso be recommended for symptomatic patients with evi-
ence of LV systolic dysfunction (ejection fraction less than
r equal to 0.60 and/or end-systolic dimension greater than
r equal to 40 mm).
Determining the surgical candidacy of the symptomatic
atient with MR and far-advanced LV dysfunction is a
ommon clinical dilemma. The question that often arises is
hether the patient with MR with advanced LV dysfunc-
ion is no longer a candidate for surgery. Although it is
ifficult, one must distinguish primary cardiomyopathy with
econdary “functional” MR from primary MR with second-
ry myocardial dysfunction. In the latter case, surgery
hould still be contemplated if MV repair appears likely
Fig. 7). In patients with severe LV dysfunction and
ignificant functional MR, the modification of MV geom-
try by an “undersized” annular ring may be beneficial
360–365), although the impact on outcomes compared
ith aggressive medical therapy, including beta blockers and
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesardiac resynchronization therapy (338–341), has not been
tudied in a prospective randomized trial.
symptomatic Patients With Normal Left Ventricular Function
s noted previously, repair of a severely regurgitant valve
ay be contemplated in an asymptomatic patient with
evere MR and normal LV function to preserve LV size and
unction and prevent the sequelae of chronic severe MR
324). Although there are no randomized data with which
o recommend this approach to all patients, the committee
ecognizes that some experienced centers are moving in this
irection for patients for whom the likelihood of successful
igure 7. Management strategy for patients with chronic severe mitral regu
ith normal left ventricular (LV) function if performed by an experienced
F indicates atrial fibrillation; Echo, echocardiography; EF, ejection fract
itral valve replacement.epair is high. Natural history studies indicate uniformly that asymptomatic patients with severe MR and normal LV
unction have a high likelihood of developing symptoms
nd/or LV dysfunction that warrants surgery over the course
f 6 to 10 years (313,317,324,325). Two recent studies have
lso addressed the risk of sudden death in asymptomatic
atients with severe MR and normal LV function (324,325).
n a long-term retrospective study in which severity of MR was
uantified by Doppler echocardiography (324), 198 patients
ith an effective orifice area greater than 40 mm2 had a 4%
er year risk of cardiac death during a mean follow-up
eriod of 2.7 years. However, in the second study of 132
atients followed up prospectively for 5 years, during which
ion. *Mitral valve (MV) repair may be performed in asymptomatic patients
al team and if the likelihood of successful MV repair is greater than 90%.
SD, end-systolic dimension; eval, evaluation; HT, hypertension; MVR,rgitat
surgic
ion; Ehe indications for surgery were symptoms, development of
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ACC/AHA Practice Guidelines August 1, 2006:598–675V dysfunction (ejection fraction less than 0.60), LV
ilatation (LV end-systolic dimension greater than 45 mm),
trial fibrillation, or pulmonary hypertension, there was only
cardiac death in an asymptomatic patient, but this patient
ad refused surgery which was indicated by development of
V dilatation (325).
MV repair is often recommended in hemodynamically
table patients with newly acquired severe MR, such as
ight occur with ruptured chordae. Surgery is also recom-
ended in asymptomatic patients with chronic MR with
ecent onset of atrial fibrillation in whom there is a high
ikelihood of successful valve repair (see below).
Surgery for asymptomatic patients with severe MR and
ormal LV function should only be considered if there is a
reater than 90% likelihood of successful valve repair in a
enter experienced in this procedure. As noted above, cardiol-
gists are strongly encouraged to refer patients who are
andidates for MV repair to surgical centers experienced in
erforming MV repair.
trial Fibrillation
he development of atrial fibrillation is independently
ssociated with a high risk of cardiac death or heart failure
366), and preoperative atrial fibrillation is an independent
redictor of reduced long-term survival after MV surgery for
hronic MR (333,366–368). Hence, many clinicians con-
ider the recent onset of atrial fibrillation to be an indication
n and of itself for surgery, if there is a high likelihood of
alve repair (Fig. 7) (356,369). In patients presenting for
V operation with chronic atrial fibrillation, a concomitant
aze procedure may prevent future thromboembolic events
y restoring normal sinus rhythm (370–376). The decision
o proceed with a Maze procedure should be based on the
ge and health of the patient, as well as the surgical
xpertise, because this procedure may add to the morbidity
f the operation.
. Ischemic Mitral Regurgitation
he outlook for the patient with ischemic MR is substan-
ially worse than that for regurgitation from other causes
377,378). A worse prognosis accrues from the fact that
schemic MR is usually caused by LV dysfunction resulting
rom myocardial infarction. Furthermore, the MV itself is
sually anatomically normal, and MR is secondary to papillary
uscle displacement and tethering of the mitral leaflet(s).
he mechanism of MR in chronic ischemic disease is local
V remodeling (apical and posterior displacement of pap-
llary muscles), which leads to excess valvular tenting and
oss of systolic annular contraction (379–386). The indica-
ion for MV operation in the patient who undergoes CABG
ith mild to moderate MR is still unclear, but there are data
o indicate benefit of MV repair in such patients (387–390).
atients with ischemic heart disease who have MR have a
orse prognosis than those without MR (391–394). CABGlone may improve LV function and reduce ischemic MR in relected patients (392,395), especially those with transient
evere MR due to ischemia, in whom myocardial revascu-
arization can eliminate episodes of severe MR. However,
ABG alone is usually insufficient and leaves many patients
ith significant residual MR, and these patients would
enefit from concomitant MV repair at the time of the
ABG (386–390,396–405). Mitral annuloplasty alone
ith a downsized annuloplasty ring is often effective at
elieving MR (400,401,404).
In severe MR secondary to acute myocardial infarction,
ypotension and pulmonary edema often occur. Severe MR
ccurs in 6% to 7% of patients with cardiogenic shock (406).
he cause of the MR should be established, because the
R may be due to a ruptured papillary muscle, papillary
uscle displacement with leaflet tethering, or annular dila-
ation from severe LV dilatation. Those patients with an
cute rupture of the papillary muscle should undergo surgery
n an emergency basis, with either valve repair or MV
eplacement (407). In those patients with papillary muscle
ysfunction, treatment should initially consist of hemody-
amic stabilization, usually with insertion of an intra-aortic
alloon pump. Surgery should be considered for those
atients who do not improve with aggressive medical
herapy. Correction of acute severe ischemic MR usually
equires valve surgery in addition to revascularization. The
est operation for ischemic MR is controversial (408,409),
ut MV repair with an annuloplasty ring is the best
pproach in most instances (387,390,396–405).
. Evaluation of Patients After Mitral Valve Replace-
ent or Repair
fter MV surgery, follow-up is necessary to detect late
urgical failure and assess LV function, as discussed in
ection IX-B. For patients in whom a bioprosthesis has
een inserted, the specter of eventual deterioration is always
resent and must be anticipated. If a mechanical valve has
een inserted, anticoagulation is required, and chronic
urveillance of prothrombin time and INR is necessary.
fter valve repair, follow-up to assess the effectiveness of the
epair is indicated early, especially because most repair
ailures are detected soon after surgery.
. Special Considerations in the Elderly
perative mortality increases and survival is reduced in
atients with MR older than 75 years of age, especially if
V replacement must be performed or if the patient has
oncomitant CAD or other valve lesions (92,95,327,410–
13). Operative mortality in the elderly is low in experi-
nced centers (414), but the overall operative mortality for
V replacement in this age group in the United States
xceeds 14% (95,412,413) and is particularly high (greater
han 20%) in low-volume centers (95). Although the risks
re reduced if MV repair is performed rather than MV
eplacement, the majority of patients in this age group
equire concomitant CABG (413). The average operative
isk for combined MV repair plus CABG in the United
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August 1, 2006:598–675 ACC/AHA Practice Guidelinestates is 8% (93), which will undoubtedly be higher in the
lder population. These risks are worth taking in patients
ith significant symptoms. However, under most circum-
tances, asymptomatic patients or patients with mild symp-
oms should be treated medically.
. Multiple Valve Disease
emarkably few data exist to objectively guide the manage-
ent of mixed valve disease. The large number of combined
emodynamic disturbances (and their varied severity) yields
large number of potential combinations to consider, and
ew data exist for any specific category. Hence, each case
ust be considered individually, and management must be
ased on understanding the potential derangements in
emodynamics and LV function and the probable benefit of
edical versus surgical therapy. The committee has devel-
ped no specific recommendations in this section. Specific
ombined valve lesions are discussed in the full text of these
uidelines.
. Tricuspid Valve Disease
. Diagnosis
he physical examination is the initial key to diagnosis of
ricuspid valve disease. Echocardiography is valuable in
ssessing tricuspid valve structure and motion, measuring
nnular size, and identifying other cardiac abnormalities
hat might influence tricuspid valve function. Doppler
chocardiography provides estimation of the severity of TR
415), RV systolic pressure, and the tricuspid valve diastolic
radient. Because clinically insignificant TR is detected by
olor Doppler imaging in many normal persons, clinical
orrelation and judgment must accompany the echocardio-
raphic results. Systolic pulmonary artery pressures greater
han 55 mm Hg are likely to cause TR with anatomically
ormal tricuspid valves, whereas TR occurring with systolic
ulmonary artery pressures less than 40 mm Hg is likely to
eflect a structural abnormality of the valve apparatus.
ystolic pulmonary artery pressure estimation combined
ith information about annular circumference will further
mprove the accuracy of clinical assessment.
. Management
lass I
Tricuspid valve repair is beneficial for severe TR in
patients with MV disease requiring MV surgery.
(Level of Evidence: B)
lass IIa
. Tricuspid valve replacement or annuloplasty is rea-
sonable for severe primary TR when symptomatic.
(Level of Evidence: C)
. Tricuspid valve replacement is reasonable for severe TR
secondary to diseased/abnormal tricuspid valve leaflets rnot amenable to annuloplasty or repair. (Level of Evi-
dence: C)
lass IIb
Tricuspid annuloplasty may be considered for less
than severe TR in patients undergoing MV surgery
when there is pulmonary hypertension or tricuspid
annular dilatation. (Level of Evidence: C)
lass III
. Tricuspid valve replacement or annuloplasty is not
indicated in asymptomatic patients with TR whose
pulmonary artery systolic pressure is less than 60
mm Hg in the presence of a normal MV. (Level of
Evidence: C)
. Tricuspid valve replacement or annuloplasty is not
indicated in patients with mild primary TR. (Level of
Evidence: C)
Surgery for TR commonly occurs at the time of MV
urgery. TR associated with dilatation of the tricuspid
nnulus should be repaired (416,417) because tricuspid
ilatation is an ongoing process that may progress to severe
R if left untreated. Patients with severe TR of any cause
ave a poor long-term outcome because of RV dysfunction
nd/or systemic venous congestion (418). Tricuspid valve
nd chordal reconstruction can be attempted in some cases
f TR resulting from endocarditis and trauma (419–421).
n recent years, annuloplasty has become an established
urgical approach to significant TR (416,417,422–424).
When the valve leaflets themselves are diseased, abnor-
al, or destroyed, valve replacement with a low-profile
echanical valve or bioprosthesis is often necessary (425). A
iological prosthesis is preferred because of the high rate of
hromboembolic complications with mechanical prostheses
n the tricuspid position.
. Drug-Related Valvular Heart Disease
n addition to the common causes of the valvular lesions
escribed in the preceding sections, there are a number of
ncommon causes related to systemic diseases (e.g., rheuma-
oid arthritis, systemic lupus erythematosus, anti-phospholipid
ntibody syndrome, and ankylosing spondylitis), drugs (e.g.,
rgotamine, methysergide, anorexiant medications, and per-
olide), and toxins. It is beyond the scope of these guidelines to
iscuss the specific pathology and natural history of valve
isease stemming from each of these many causes. In general,
he evaluation and management strategies for patients with
alve disease related to these disorders are directed both
oward the underlying systemic process when appropriate
nd to the diagnosis and treatment of the associated valvular
isease according to the guidelines developed for each of the
alve lesions, as described in Section III.
The sympathomimetic appetite-suppressant drug fen-
uramine and its pure d-enantiomer, dexfenfluramine, were
emoved from the market in September 1997 after several
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ACC/AHA Practice Guidelines August 1, 2006:598–675eports of unusual left-sided valvular heart disease (AR and
R) linked to these agents (426–430). To date, an excess
revalence of valvular heart disease has not been reported for
ibutramine, a serotonin and norepinephrine reuptake in-
ibitor, or for phentermine when used as monotherapy for
besity (431,432). There are now several reports of a
arcinoid-like valvulopathy in Parkinson’s disease patients
reated with pergolide, a dopamine-receptor agonist (433–
35).
. Radiation Heart Disease
ediastinal radiation may produce cardiac valve abnormal-
ties that usually become evident at least 5 years after the
adiation injury. The assessment and treatment of these
atients can be difficult, in part because these valve lesions
ccur within a context of multiple cardiac and noncardiac
bnormalities produced by radiation. Radiation-induced
alvular lesions stem from calcification of valve leaflets and
he fibrous skeleton of the heart. Mixed aortic valve disease
ith AS and AR is the most common lesion, but MR and
R may also occur.
Valve dysfunction is often part of a presenting picture of
ongestive heart failure and dyspnea, but the relative con-
ributions of valve dysfunction and restrictive cardiomyop-
thy may be difficult to separate. In addition, recurrent
leural effusions are often prominent, and radiation-induced
ulmonary dysfunction can occur. Thus, dyspnea is usually
multifactorial problem in these patients. For patients with
adiation heart disease, surgery for any cardiac lesion should
e approached with caution (436). Patients with this con-
ition should be evaluated in centers with experience in its
anagement (437).
V. EVALUATION AND MANAGEMENT OF INFECTIVE
NDOCARDITIS
lass I
Patients at risk for infective endocarditis who have
unexplained fever for more than 48 h should have at
least 2 sets of blood cultures obtained from different
sites. (Level of Evidence: B)
lass III
Patients with known valve disease or a valve prosthe-
sis should not receive antibiotics before blood cul-
tures are obtained for unexplained fever. (Level of
Evidence: C)
he diagnosis of infective endocarditis in a patient with a
athological murmur or a valvular prosthesis and unex-
lained fever lasting more than 72 h should include an
ssessment for vascular and immunologic phenomena, 3 to
sets of blood cultures, and a transthoracic echocardiogram.
definitive diagnosis may be made with positive blood
ultures and/or characteristic echocardiographic findings.
he role of echocardiography has emerged with visualiza- tion of vegetation by transthoracic echocardiography in
pproximately 60% to 75% of patients and by TEE in more
han 95% of patients (438). When the echocardiogram is
echnically inadequate, is nondiagnostic, or is negative for
nfective endocarditis, TEE should be obtained. The mod-
fied Duke criteria (439) define major and minor criteria for
nfective endocarditis.
. Antimicrobial Therapy
ntimicrobial therapy in endocarditis is guided by identifi-
ation of the causative organism. The majority (80%) of
ases of endocarditis are due to streptococcal and staphylo-
occal organisms. The latter species is also the most fre-
uent organism in endocarditis resulting from intravenous
rug abuse. Eighty percent of tricuspid valve infection is by
taphylococcus aureus. This organism is also a frequent cause
f infective endocarditis in patients with insulin-dependent
iabetes mellitus. With prosthetic valve endocarditis, a wide
pectrum of organisms can be responsible within the first
ear of operation. However, in “early” prosthetic valve
ndocarditis, usually defined as endocarditis during the first
months after surgery, Staphylococcus epidermidis is the
redominant offending organism. Late-onset prosthetic
alve endocarditis follows the profile of native valve endo-
arditis, that is, streptococci (viridans) and staphylococci. En-
erococcus faecalis and E. faecium account for 90% of entero-
occal endocarditis, which is usually associated with
alignancy or manipulation of the genitourinary or gastro-
ntestinal tract. Gram-positive and Gram-negative bacilli
re relatively uncommon causes of endocarditis. In recent
ears, the HACEK group of organisms (Haemophilus,
ctinobacillus, Cardiobacterium, Eikenella, and Kingella species)
as become an important cause of endocarditis. These organ-
sms cause large vegetations (greater than 1 cm), large-vessel
mbolism, and congestive heart failure. They should be con-
idered along with fungal endocarditis when large vegetations
re noted. Fungi, especially Candida, are important causes of
ndocarditis in patients with prosthetic valves, compromised
mmune systems, and intravenous drug abuse. The AHA
ecommendations for antimicrobial regimens were updated in
005 (440), and complete treatment regimens are provided in
hat document which can be found at http://www.
mericanheart.org/presenter.jhtml?identifier2158.
Culture-negative endocarditis most frequently (62%) re-
ults from prior antibiotic treatment before blood cultures
re drawn. Other reasons for negative blood cultures include
nfections due to Candida; Aspergillus; other fastidious,
low-growing organisms such as Q-fever and Bartonella
rganisms; and noninfective endocarditis such as Libman-
acks endocarditis in patients with systemic lupus erythem-
tosus.
. Indications for Echocardiography in Suspected or
nown Endocarditis
chocardiography is useful for detection and characteriza-
ion of the hemodynamic and pathological consequences
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesf infection, including valvular vegetations; valvular re-
urgitation; ventricular dysfunction; and associated le-
ions such as abscesses, shunts, and ruptured chordae.
he indications for transthoracic and TEE are discussed
n the “ACC/AHA/ASE 2004 Guidelines for the Clin-
cal Application of Echocardiography” (1) and the 2005
HA endocarditis guidelines (440). Transesophageal
maging is more sensitive in detecting vegetations than
ransthoracic imaging (438,440,441), particularly in pa-
ients with prosthetic valves, and in determining the pres-
nce and severity of important complications such as ab-
cesses and perforations. In patients with prosthetic valves,
t is reasonable to proceed directly to TEE as the first-line
iagnostic test when endocarditis is suspected. Echocardi-
graphy can be useful in the case of culture-negative
ndocarditis (442) or the diagnosis of a persistent bactere-
ia the source of which remains unidentified after appro-
riate evaluation (1).
. Transthoracic Echocardiography in Endocarditis
lass I
. Transthoracic echocardiography to detect valvular
vegetations with or without positive blood cultures is
recommended for the diagnosis of infective endocar-
ditis. (Level of Evidence: B)
. Transthoracic echocardiography is recommended to
characterize the hemodynamic severity of valvular
lesions in known infective endocarditis. (Level of
Evidence: B)
. Transthoracic echocardiography is recommended for
assessment of complications of infective endocarditis
(e.g., abscesses, perforation, and shunts). (Level of
Evidence: B)
. Transthoracic echocardiography is recommended for
reassessment of high-risk patients (e.g., those with a
virulent organism, clinical deterioration, persistent
or recurrent fever, new murmur, or persistent bacte-
remia). (Level of Evidence: C)
lass IIa
Transthoracic echocardiography is reasonable to di-
agnose infective endocarditis of a prosthetic valve in
the presence of persistent fever without bacteremia or
a new murmur. (Level of Evidence: C)
lass IIb
Transthoracic echocardiography may be considered
for the re-evaluation of prosthetic valve endocarditis
during antibiotic therapy in the absence of clinical
deterioration. (Level of Evidence: C)
lass III
Transthoracic echocardiography is not indicated to
re-evaluate uncomplicated (including no regurgita-
tion on baseline echocardiogram) native valve endo- pcarditis during antibiotic treatment in the absence of
clinical deterioration, new physical findings, or per-
sistent fever. (Level of Evidence: C)
. Transesophageal Echocardiography in Endocarditis
lass I
. TEE is recommended to assess the severity of valvu-
lar lesions in symptomatic patients with infective
endocarditis, if transthoracic echocardiography is
nondiagnostic. (Level of Evidence: C)
. TEE is recommended to diagnose infective endocar-
ditis in patients with valvular heart disease and
positive blood cultures, if transthoracic echocardiog-
raphy is nondiagnostic. (Level of Evidence: C)
. TEE is recommended to diagnose complications of
infective endocarditis with potential impact on prog-
nosis and management (e.g., abscesses, perforation,
and shunts). (Level of Evidence: C)
. TEE is recommended as first-line diagnostic study to
diagnose prosthetic valve endocarditis and assess for
complications. (Level of Evidence: C)
. TEE is recommended for preoperative evaluation in
patients with known infective endocarditis, unless
the need for surgery is evident on transthoracic
imaging and unless preoperative imaging will delay
surgery in urgent cases. (Level of Evidence: C)
. Intraoperative TEE is recommended for patients
undergoing valve surgery for infective endocarditis.
(Level of Evidence: C)
lass IIa
TEE is reasonable to diagnose possible infective
endocarditis in patients with persistent staphylococ-
cal bacteremia without a known source. (Level of
Evidence: C)
lass IIb
TEE might be considered to detect infective endo-
carditis in patients with nosocomial staphylococcal
bacteremia. (Level of Evidence: C)
. Indications for Surgery in Patients With Acute
nfective Endocarditis
urgery is indicated in patients with life-threatening con-
estive heart failure or cardiogenic shock due to surgically
reatable valvular heart disease with or without proven
nfective endocarditis if the patient has reasonable prospects
f recovery with satisfactory quality of life after the opera-
ion (378,440,443–453). Surgery should not be delayed in
he setting of acute infective endocarditis when congestive
eart failure intervenes. Surgery is not indicated if compli-
ations (severe embolic cerebral damage) or comorbid con-
itions make the prospect of recovery remote.
The indications for surgery for infective endocarditis inatients with stable hemodynamics are less clear. Consulta-
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ACC/AHA Practice Guidelines August 1, 2006:598–675ion with a cardiovascular surgeon is recommended in a
atient with complicated endocarditis so that the surgical
eam is aware of the patient who may suddenly need surgery.
urgery is recommended in patients with annular or aortic
bscesses, heart block, recurrent emboli on appropriate
ntibiotic therapy, infections resistant to antibiotic therapy,
nd fungal endocarditis. Prosthetic valve endocarditis and
ative valve endocarditis caused by S. aureus are almost
lways surgical diseases. Early surgery in MV endocarditis
aused by virulent organisms (such as S. aureus or fungi) may
ake repair possible. Echocardiography, especially with
ransesophageal imaging, identifies vegetations and provides
ize estimation in many instances. Patients with a vegetation
iameter greater than 10 mm have a significantly higher
ncidence of embolization than those with a vegetation
iameter less than or equal to 10 mm (438), and this risk
ppears to be higher in patients with MV endocarditis than
n those with aortic valve endocarditis. However, surgery on
he basis of vegetation size alone is controversial.
Patients with prosthetic valves who receive warfarin
nticoagulation and develop endocarditis should have their
arfarin discontinued and replaced with heparin. This
ecommendation is less related to the possibility of hemor-
hagic complications of endocarditis (454) than to the
ossibility of urgent surgery. Likewise, aspirin, if part of the
edical regimen, should also be discontinued. If neurolog-
cal symptoms develop, anticoagulation should be discon-
inued until an intracranial hemorrhagic event is excluded by
agnetic resonance imaging or computed tomographic
canning.
. Surgery for Native Valve Endocarditis
lass I
. Surgery of the native valve is indicated in patients
with acute infective endocarditis who present with
valve stenosis or regurgitation resulting in heart
failure. (Level of Evidence: B)
. Surgery of the native valve is indicated in patients
with acute infective endocarditis who present with
AR or MR with hemodynamic evidence of elevated
LV end-diastolic or left atrial pressures (e.g., prema-
ture closure of MV with AR, rapid decelerating MR
signal by continuous-wave Doppler [v-wave cutoff
sign], or moderate or severe pulmonary hyperten-
sion). (Level of Evidence: B)
. Surgery of the native valve is indicated in patients
with infective endocarditis caused by fungal or other
highly resistant organisms. (Level of Evidence: B)
. Surgery of the native valve is indicated in patients
with infective endocarditis complicated by heart
block, annular or aortic abscess, or destructive pen-
etrating lesions (e.g., sinus of Valsalva to right
atrium, right ventricle, or left atrium fistula; mitralleaflet perforation with aortic valve endocarditis; or
infection in annulus fibrosa). (Level of Evidence: B)
lass IIa
Surgery of the native valve is reasonable in patients
with infective endocarditis who present with recur-
rent emboli and persistent vegetations despite appro-
priate antibiotic therapy. (Level of Evidence: C)
lass IIb
Surgery of the native valve may be considered in
patients with infective endocarditis who present with
mobile vegetations in excess of 10 mm with or
without emboli. (Level of Evidence: C)
. Surgery for Prosthetic Valve Endocarditis
lass I
. Consultation with a cardiac surgeon is indicated for
patients with infective endocarditis of a prosthetic
valve. (Level of Evidence: C)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with heart
failure. (Level of Evidence: B)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with dehis-
cence evidenced by cine fluoroscopy or echocardiog-
raphy. (Level of Evidence: B)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with evi-
dence of increasing obstruction or worsening regur-
gitation. (Level of Evidence: C)
. Surgery is indicated for patients with infective endo-
carditis of a prosthetic valve who present with com-
plications (e.g., abscess formation). (Level of Evi-
dence: C)
lass IIa
. Surgery is reasonable for patients with infective
endocarditis of a prosthetic valve who present with
evidence of persistent bacteremia or recurrent emboli
despite appropriate antibiotic treatment. (Level of
Evidence: C)
. Surgery is reasonable for patients with infective
endocarditis of a prosthetic valve who present with
relapsing infection. (Level of Evidence: C)
lass III
Routine surgery is not indicated for patients with
uncomplicated infective endocarditis of a prosthetic
valve caused by first infection with a sensitive organ-
ism. (Level of Evidence: C)
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REGNANCY
. Physiological Changes of Pregnancy
he evaluation and management of valvular heart disease in
he pregnant patient requires an understanding of the
ormal physiological changes associated with gestation,
abor, delivery, and the early postpartum period. On aver-
ge, there is a 50% increase in circulating blood volume
uring pregnancy that is accompanied by a commensurate
ncrease in cardiac output that usually peaks between the
idportion of the second and third trimesters. Because of
he effects of uterine circulation and endogenous hormones,
ystemic vascular resistance falls with a disproportionately
reater lowering of diastolic blood pressure and a wide pulse
ressure. Inferior vena caval obstruction from a gravid uterus
n the supine position can result in an abrupt decrease in
ardiac preload, which leads to hypotension.
There is an abrupt increase in cardiac output during labor
nd delivery related in part to the associated anxiety and
ain. Uterine contractions can lead to marked increases in
oth systolic and diastolic blood pressure. After delivery,
here is an initial surge in preload related to the autotrans-
usion of uterine blood into the systemic circulation and to
aval decompression (455).
Pregnancy is also associated with a hypercoagulable state
ue to relative decreases in protein S activity, stasis, and
enous hypertension (456). Estrogens can interfere with
ollagen deposition within the media of the medium and
arge muscular arteries. Circulating elastase can break up the
lastic lamellae and weaken the aortic media during preg-
ancy. Weakening of the vascular wall may in turn predis-
ose to dissection with or without an underlying connective
issue disorder (457). Relaxin, an insulin-like growth factor
ormone, is detectable in serum during pregnancy and
auses a decrease in collagen synthesis and may predispose
o aortic dissection during pregnancy (458).
The increased blood volume and enhanced cardiac output
ssociated with normal pregnancy can accentuate the mur-
urs associated with stenotic heart valve lesions (e.g., MS
nd AS). On the other hand, murmurs of AR, MR, and
entricular septal defect can actually attenuate or become
naudible as systemic vascular resistance is lowered (459).
. Echocardiography
ormal pregnancy is accompanied by echocardiographic
vidence of mild ventricular chamber enlargement. Pul-
onic and tricuspid valvular regurgitation, as assessed by
oppler interrogation, is the rule rather than the exception
460). Most women will demonstrate Doppler evidence of
physiological” MR in the absence of structural valve dis-
ase. Atrioventricular valve regurgitation may result from
he annular dilatation that accompanies ventricular enlarge-
ent. Appreciation of these echocardiographic and Dopplerndings in normal individuals is an important foundation tor the noninvasive evaluation of subjects with suspected
alvular disease. The use of ultrasound during pregnancy
oses no risk to the mother or fetus.
. Management Guidelines
linical experience has identified several cardiac conditions
n which the physiological changes of pregnancy are poorly
olerated. For some conditions, such as cyanotic heart
isease, Eisenmenger syndrome, or severe pulmonary hy-
ertension, pregnancy should be discouraged. Valvular heart
esions associated with high maternal and fetal risk during
regnancy include severe AS with or without symptoms,
R or AR with NYHA functional class III or IV symp-
oms, MS with NYHA functional class II to IV symptoms,
echanical valves that require chronic anticoagulation, AR
ssociated with Marfan syndrome, bicuspid aortic valves
ith aortic root dilatation, and any condition that results in
V systolic dysfunction or pulmonary hypertension (461–
64). Outcomes data are limited for pregnant patients with
alvular heart disease, except for those with MS.
Individual counseling usually requires a multidisciplinary
pproach and should include information regarding contra-
eption, maternal and fetal risks of pregnancy, and expected
ong-term outcomes. However, many patients with valvular
eart disease can be successfully managed throughout preg-
ancy and during labor and delivery with conservative
edical measures designed to optimize intravascular volume
nd systemic loading conditions. Simple interventions such
s bed rest and avoidance of the supine position should not
e overlooked. Whenever possible, symptomatic or severe
alvular lesions should be addressed and rectified before
onception and pregnancy. Contemporaneous management
ith a dedicated obstetric team accustomed to working with
igh-risk patients is encouraged.
. Mitral Stenosis
oung pregnant women with a previous history of acute
heumatic fever and carditis should continue to receive
enicillin prophylaxis as indicated in the nonpregnant state.
atients with mild to moderate MS can almost always be
anaged with judicious use of diuretics and beta blockade.
iuretics are given to relieve pulmonary and excess systemic
enous congestion, but care must be taken to avoid vigorous
olume depletion to protect against uteroplacental hypoper-
usion. Beta blockers are chiefly indicated to treat or prevent
achycardia to optimize diastolic filling. Although the non-
elective beta blocker propranolol has been in use for
ecades, some authorities recommend a cardioselective beta
locker such as metoprolol or atenolol to prevent the
otential deleterious effects of epinephrine blockade on
yometrial activity.
Patients with severe MS who are symptomatic before
onception will not predictably tolerate the hemodynamic
urden of pregnancy and should be considered for percuta-
eous balloon mitral valvotomy before conception, provided
he valve is anatomically suitable. Patients with severe MS
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uring pregnancy should undergo percutaneous balloon
alvotomy (465). Percutaneous mitral balloon valvotomy
hould only be performed in experienced centers and only
fter aggressive medical measures have been exhausted.
. Mitral Regurgitation
VP is the most common cause of MR in pregnant
omen. MR can usually be managed medically, although on
are occasions, MV surgery is required because of ruptured
hordae and acute, severe worsening of MR. Medical
anagement includes diuretics for the rare patient with
ulmonary congestion. Vasodilator therapy is indicated only
n the presence of concomitant systemic hypertension. ACE
nhibitors are considered unsafe and are contraindicated
ecause of their multiple adverse effects on fetal develop-
ent. When MV surgery is required, repair is always
referred.
. Aortic Stenosis
atients with mild AS and normal LV systolic function can
e managed conservatively throughout the entire pregnancy.
atients with moderate to severe obstruction (Table 1) or
ymptoms should be advised to delay conception until relief
f AS can be obtained. Women with severe AS who become
regnant but who remain asymptomatic or have mild
ymptoms may often be managed conservatively during
regnancy with bed rest, oxygen, and beta blockers. In
omen with severe AS who develop symptoms, consider-
tion may have to be given to either percutaneous aortic
alloon valvotomy (466,467) or surgery (depending on the
natomic findings) before labor and delivery. These proce-
ures are fraught with danger to both the mother and fetus,
lthough successful outcomes have been reported. Aortic
oot dilatation in patients with bicuspid aortic valves may
redispose to spontaneous aortic dissection, usually in the
hird trimester.
. Aortic Regurgitation
solated AR, like MR, can usually be managed medically
ith a combination of diuretics and, if necessary, vasodilator
herapy (468). ACE inhibitors are considered unsafe and are
ontraindicated because of their multiple adverse effects on
etal development. Women with symptoms or signs of LV
ailure should be closely monitored throughout labor and
elivery with strict attention to volume status and blood
ressure. Surgery for AR during pregnancy should be
ontemplated only for control of refractory NYHA func-
ional class III or IV symptoms. The recommendations for
VR based on LV size that apply to nonpregnant patients
hould not be used for pregnant patients.
. Pulmonic Stenosis
solated pulmonic stenosis is rarely a significant impediment
o a successful pregnancy. This lesion can be approached oith percutaneous valvotomy under echocardiographic
uidance when necessary.
. Tricuspid Valve Disease
ricuspid valve disease may be congenital (Ebstein’s anom-
ly, tricuspid atresia) or acquired (endocarditis, myxomatous
eplacement/proliferation, carcinoid). The approach to the
atient with tricuspid valve involvement as part of a more
omplex congenital heart disease syndrome is predicated on
he features of the associated lesions. Isolated TR should
ot pose a significant problem during pregnancy, although
are should be taken to prevent diuretic-induced hypoper-
usion.
. Marfan Syndrome
pontaneous aortic dissection or rupture is the most feared
ardiovascular complication associated with pregnancy in
he Marfan syndrome (457,469,470). Dissection can occur
t any point along the aorta but most commonly originates
n the ascending portion. Enlargement of the aortic root to
reater than 4.0 cm identifies a particularly high-risk group,
lthough a normal dimension is by no means a guarantee
gainst this catastrophic complication. Aortic root enlarge-
ent may or may not be accompanied by AR. MVP with
R is also frequently detected.
Any woman with Marfan syndrome should be counseled
gainst pregnancy, because aortic rupture or dissection can
ccur in any root size. All patients with Marfan syndrome
hould have a screening transthoracic echocardiogram with
ssessment of aortic root dimensions. Enlargement greater
han 4.5 cm is generally considered an indication for elective
epair before conception. If any degree of aortic root
nlargement (greater than 4.0 cm) is first detected during
regnancy, some authorities recommend termination of the
regnancy with prompt aortic repair, although this is
ontroversial. Less controversial is the recommendation for
rompt repair if serial imaging studies demonstrate progres-
ive dilatation over time. Dissection and rupture are most
ikely to occur during the third trimester or near the time of
elivery. The use of prophylactic beta blockade throughout
he pregnancy is strongly recommended. Successful surgical
orrection does not confer a normal risk during subsequent
regnancy. Special care must be taken during labor and
elivery to provide adequate analgesia to prevent wide
urges in blood pressure. Obstetric techniques to shorten the
econd stage of labor are appropriate. General anesthesia
nd caesarean section may allow more optimal hemody-
amic control.
. Endocarditis Prophylaxis
he Committee on Rheumatic Fever, Endocarditis, and
awasaki Disease of the AHA does not recommend routine
ntibiotic prophylaxis in patients with valvular heart disease
ndergoing uncomplicated vaginal delivery or caesarean
ection unless infection is suspected (8). Antibiotics are
ptional for high-risk patients with prosthetic heart valves,
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesprevious history of endocarditis, complex congenital heart
isease, or a surgically constructed systemic-pulmonary
onduit. Many practitioners routinely provide antibiotics.
. Cardiac Valve Surgery
ardiac valve surgery is a difficult and complex undertaking
n the pregnant patient. Even under ideal conditions, there
s a high incidence of fetal distress, growth retardation, or
astage (471–475). If possible, it is always preferable to
elay surgery until the time the fetus is viable and a
aesarean section can be performed as part of a concomitant
rocedure (476,477). Surgery should be pursued only in the
etting of medically refractory cardiac symptoms (pulmo-
ary congestion), especially if a low-output syndrome inter-
enes.
For suitable valve lesions, repair is always preferred over
eplacement, and percutaneous mitral balloon valvotomy is
referred over MV replacement in patients with MS. If
alve replacement is necessary, the choice of a heart valve
ubstitute can be problematic.
. Anticoagulation During Pregnancy
. Warfarin
arfarin crosses the placenta and has been associated with
n increased incidence of spontaneous abortion, prematu-
ity, stillbirth, and fetal bleeding. The true incidence of
arfarin embryopathy has been difficult to ascertain. It has
anged from less than 5% to as high as 67% (478–481), and
n estimate of 4% to 10% seems reasonable (482,483).
owever, the risk of clinically important embryopathy may
e lower if the dose of warfarin is less than or equal to 5 mg
er day.
Warfarin is probably safe during the first 6 weeks of
estation, but there is a risk of embryopathy if warfarin is
aken between 6 and 12 weeks of gestation. For women
equiring long-term warfarin therapy who are attempting
regnancy, it is wise to perform frequent pregnancy tests
ith the substitution of unfractionated heparin (UFH) or
ow-molecular-weight heparin (LMWH) for warfarin when
regnancy is achieved. Warfarin is also relatively safe during
he second and third trimesters of pregnancy but must be
iscontinued and switched to a heparin compound several
eeks before delivery.
. Unfractionated Heparin
eparin does not cross the placenta and does not have the
otential to cause fetal bleeding or teratogenicity. Thus,
eparin is generally considered safer than warfarin during
regnancy in terms of the development of embryopathy
482,484). However, bleeding at the uteroplacental junction
s possible, and numerous case series and patient registries
ttest to a high incidence of thromboembolic complications
12% to 24%), including fatal valve thrombosis, in high-risk
regnant women managed with subcutaneous UFH or
MWH (482,485–487). When heparin is used during therst trimester, the risks of maternal thromboembolism and
aternal death are more than doubled.
During pregnancy, the activated partial thromboplastin
ime (aPTT) response to heparin is often attenuated because
f increased levels of factor VIII and fibrinogen. Adjusted-
ose subcutaneous UFH can cause a persistent anticoagu-
ant effect at the time of delivery, which can complicate its
se before labor.
. Low-Molecular-Weight Heparins
MWHs have potential advantages over UFH during
regnancy (488) because they 1) cause less heparin-induced
hrombocytopenia; 2) have a longer plasma half-life and a
ore predictable dose response than UFH; 3) have greater
ase of administration, with lack of need for laboratory
onitoring and the potential for once-daily dosing admin-
stration; 4) are likely associated with a lower risk of
eparin-induced osteoporosis; and 5) appear to have a low
isk of bleeding complications. They do not cross the
lacenta and are likely safe for the fetus.
As the pregnancy progresses (and most women gain
eight), the potential volume of distribution for LMWH
hanges. It is thus necessary to measure plasma anti-Xa
evels 4 to 6 hours after the morning dose and adjust the
ose of LMWH to achieve an anti-Xa level of approxi-
ately 0.7 to 1.2 units per ml.
The use of LMWH during pregnancy remains contro-
ersial because of an early warning by the manufacturer and
he Food and Drug Administration in July 2001 regarding
afety concerns in this situation. In 2004, labeling approved
y the Food and Drug Administration indicated specifically
hat use of LMWH for thromboprophylaxis in pregnant
omen with mechanical prosthetic heart valves has not been
tudied adequately.
. Selection of Anticoagulation Regimen in Pregnant
atients With Mechanical Prosthetic Valves
lass I
. All pregnant patients with mechanical prosthetic
valves must receive continuous therapeutic anticoag-
ulation with frequent monitoring (see Section IX-A).
(Level of Evidence: B)
. For women requiring long-term warfarin therapy
who are attempting pregnancy, pregnancy tests
should be monitored with discussions about subse-
quent anticoagulation therapy, so that anticoagula-
tion can be continued uninterrupted when pregnancy
is achieved. (Level of Evidence: C)
. Pregnant patients with mechanical prosthetic valves
who elect to stop warfarin between weeks 6 and 12 of
gestation should receive continuous intravenous
UFH, dose-adjusted UFH, or dose-adjusted subcu-
taneous LMWH. (Level of Evidence: C)
. For pregnant patients with mechanical prosthetic
valves, up to 36 weeks of gestation, the therapeutic
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cutaneous UFH, dose-adjusted LMWH, or warfarin
should be discussed fully. If continuous intravenous
UFH is used, the fetal risk is lower, but the maternal
risks of prosthetic valve thrombosis, systemic emboli-
zation, infection, osteoporosis, and heparin-induced
thrombocytopenia are relatively higher. (Level of Ev-
idence: C)
. In pregnant patients with mechanical prosthetic
valves who receive dose-adjusted LMWH, the
LMWH should be administered twice daily subcuta-
neously to maintain the anti-Xa level between 0.7
and 1.2 U per ml 4 h after administration. (Level of
Evidence: C)
. In pregnant patients with mechanical prosthetic valves
who receive dose-adjusted UFH, the aPTT should be at
least twice control. (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic
valves who receive warfarin, the INR goal should be
3.0 (range 2.5 to 3.5). (Level of Evidence: C)
. In pregnant patients with mechanical prosthetic
valves, warfarin should be discontinued and contin-
uous intravenous UFH given starting 2 to 3 weeks
before planned delivery. (Level of Evidence: C)
lass IIa
. In patients with mechanical prosthetic valves, it is
reasonable to avoid warfarin between weeks 6 and 12
of gestation owing to the high risk of fetal defects.
(Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is
reasonable to resume UFH 4 to 6 h after delivery and
begin oral warfarin in the absence of significant
bleeding. (Level of Evidence: C)
. In patients with mechanical prosthetic valves, it is
reasonable to give low-dose aspirin (75 to 100 mg per
day) in the second and third trimesters of pregnancy
in addition to anticoagulation with warfarin or hep-
arin. (Level of Evidence: C)
lass III
. LMWH should not be administered to pregnant
patients with mechanical prosthetic valves unless
anti-Xa levels are monitored 4 to 6 h after adminis-
tration. (Level of Evidence: C)
. Dipyridamole should not be used instead of aspirin as
an alternative antiplatelet agent in pregnant patients
with mechanical prosthetic valves because of its
harmful effects on the fetus. (Level of Evidence: B)
n April 2004, labeling approved by the Food and Drug
dministration stated that pregnancy alone conferred an
ncreased risk for thromboembolism and an even higher risk
ith thrombotic disease and certain high-risk pregnancy
onditions. Although not adequately studied, women with
echanical prosthetic heart valves may be at higher risk for ihromboembolism during pregnancy regardless of the anti-
oagulant used, and when pregnant, they have a higher rate
f fetal loss from stillbirth, spontaneous abortion, and
remature delivery.
In patients receiving UFH, therapy requires aggressive
onitoring and appropriate dose adjustment. A minimum
arget aPTT ratio of 1.5 times the control is likely to be
nadequate. A target aPTT ratio of at least twice the control
hould be attained.
There are still insufficient grounds to make definitive
ecommendations about optimal antithrombotic therapy in
regnant patients with mechanical heart valves, because
roperly designed studies have not been performed. Sub-
tantial concern remains about the fetal safety of warfarin,
he efficacy of subcutaneous UFH and of LMWH in
reventing thromboembolic complications, and the risks of
aternal bleeding with various regimens.
The American College of Chest Physicians Conference
n Antithrombotic and Thrombolytic Therapy (489,490)
oncluded that it is reasonable to use one of the following 3
egimens: 1) either LMWH or UFH between 6 and 12
eeks and close to term only, with warfarin used at other
imes; 2) aggressive dose-adjusted UFH throughout preg-
ancy; or 3) aggressive adjusted-dose LMWH throughout
regnancy. Before any of these approaches is used, it is
rucial to explain the risks in detail to the patient. If warfarin
s used, the dose should be adjusted to attain a target INR
f 3.0 (range 2.5 to 3.5). If subcutaneous UFH is used, it
hould be initiated in high doses (17 500 to 20 000 U every
2 h) and adjusted to prolong a 6-h postinjection aPTT of
t least twice the control. Adjusted-dose LMWH appears to
e a reasonable substitute for UFH, but further information
s required about dosing during pregnancy; if LMWH is
sed during pregnancy, it has been recommended that
MWH be administered twice daily and dosed to achieve
nti-Xa levels of 0.7 to 1.2 U per ml 4 to 6 h after injection
489,491).
The addition of aspirin 75 to 100 mg can be considered
n an attempt to further reduce the risk of thrombosis, with
he recognition that it can increase the risk of bleeding
485). Dipyridamole should not be considered as an alter-
ative antiplatelet agent because of its harmful effects on the
etus. Neither warfarin nor heparin is contraindicated in
ostpartum mothers who breast-feed (484).
I. MANAGEMENT OF CONGENITAL VALVULAR HEART
ISEASE IN ADOLESCENTS AND YOUNG ADULTS
he management of valvular abnormalities associated with
omplex congenital heart disease is beyond the scope of
hese guidelines. Rather, this section concerns isolated valve
nvolvement when it is the primary anatomic abnormality.
In evaluating valvular stenosis in children, severity is
sually reported as the peak ventricular-to-peak great artery
ystolic gradient at cardiac catheterization or maximum
nstantaneous or mean gradient by Doppler echocardiogra-
p
D
t
g
v
g
i
p
c
s
g
r
c
m
a
o
A
A
a
r
p
a
a
r
l
w
o
m
g
p
o
g
A
1
A
C
1
2
3
4
5
C
1
2
3
T
s
s
r
E
t
645JACC Vol. 48, No. 3, 2006 Bonow et al.
August 1, 2006:598–675 ACC/AHA Practice Guidelineshy rather than valve area. With the development of
oppler echocardiographic assessment of valvular obstruc-
ion, many pediatric cardiologists have continued to rely on
radients calculated from peak velocity for the semilunar
alves rather than on mean gradient or valve area. The peak
radient measured by Doppler velocity (based on maximum
nstantaneous velocity) is almost always higher than the
eak ventricular–to–peak great vessel gradient measured at
atheterization. The difference between Doppler peak in-
tantaneous and catheterization peak-to-peak gradients is
reater with AS than with pulmonic stenosis and has
esulted in most cardiologists using mean gradients, espe-
ially in patients with AS. Significant valvular regurgitation
ay exacerbate the differences. In contrast to children and
dolescents, valve area is used by many centers in evaluation
f the young adult.
. Aortic Stenosis
dolescents and young adults with isolated AS almost
lways have congenital fusion of 1 or more commissures that
esults in a bicuspid or unicuspid valve. Although the
revalence of bicuspid and unicuspid valves may be as high
s 1% to 2%, only 1 of 50 children born with these
bnormalities will actually have significant obstruction or
egurgitation by adolescence. For purposes of these guide-
ines, adolescents and young adults are defined as patients
ith minimally calcified valves who are less than 30 years
ld. Some adults with minimally calcified valves who are
ore than 30 years old may also benefit under these
uidelines.
As the aortic annulus and aortic valve must grow in
arallel with somatic growth throughout childhood, the rate
f progression of AS during childhood and adolescent
rowth can be different from that in the adult with acquired
S (see Section III-A).
. Evaluation of Asymptomatic Adolescents or Young
dults With Aortic Stenosis
lass I
. An ECG is recommended yearly in the asymptomatic
adolescent or young adult with AS who has a Doppler
mean gradient greater than 30 mm Hg or a peak
velocity greater than 3.5 m per second (peak gradient
greater than 50 mm Hg) and every 2 years if the
echocardiographic Doppler mean gradient is less than
or equal to 30 mm Hg or the peak velocity is less than
or equal to 3.5 m per second (peak gradient less than or
equal to 50 mm Hg). (Level of Evidence C)
. Doppler echocardiography is recommended yearly in
the asymptomatic adolescent or young adult with AS
who has a Doppler mean gradient greater than 30
mm Hg or a peak velocity greater than 3.5 m per
second (peak gradient greater than 50 mm Hg) and
every 2 years if the Doppler gradient is less than or
equal to 30 mm Hg or the peak jet velocity is less athan or equal to 3.5 m per second (peak gradient less
than or equal to 50 mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is an
effective diagnostic tool in the asymptomatic adoles-
cent or young adult when results of Doppler echo-
cardiography are equivocal regarding severity of AS
or when there is a discrepancy between clinical and
noninvasive findings regarding severity of AS. (Level
of Evidence: C)
. Cardiac catheterization is indicated in the adoles-
cent or young adult with AS who has symptoms of
angina, syncope, or dyspnea on exertion if the
Doppler mean gradient is greater than 30 mm Hg
or the peak velocity is greater than 3.5 m per
second (peak gradient greater than 50 mm Hg).
(Level of Evidence C)
. Cardiac catheterization is indicated in the asymp-
tomatic adolescent or young adult with AS who
develops T-wave inversion at rest over the left pre-
cordium if the Doppler mean gradient is greater than
30 mm Hg or the peak velocity is greater than 3.5 m
per second (peak gradient greater than 50 mm Hg).
(Level of Evidence C)
lass IIa
. Graded exercise testing is a reasonable diagnostic
evaluation in the adolescent or young adult with AS
who has a Doppler mean gradient greater than 30
mm Hg or a peak velocity greater than 3.5 m per
second (peak gradient greater than 50 mm Hg) if the
patient is interested in athletic participation, or if the
clinical findings and Doppler findings are disparate.
(Level of Evidence: C)
. Cardiac catheterization for the evaluation of AS is a
reasonable diagnostic tool in the asymptomatic ado-
lescent or young adult who has a Doppler mean
gradient greater than 40 mm Hg or a peak velocity
greater than 4 m per second (peak gradient greater
than 64 mm Hg). (Level of Evidence C)
. Cardiac catheterization for the evaluation of AS is
reasonable in the adolescent or young adult who has a
Doppler mean gradient greater than 30 mm Hg or a
peak velocity greater than 3.5 m per second (peak
gradient greater than 50 mm Hg) if the patient is
interested in athletic participation or becoming preg-
nant, or if the clinical findings and Doppler echocar-
diographic findings are disparate. (Level of Evidence C)
he diagnosis of AS can usually be made clinically, with
everity estimated by ECG and Doppler echocardiographic
tudies. Diagnostic cardiac catheterization is occasionally
equired if there is a discrepancy among clinical evaluation,
CG, and/or Doppler echocardiographic findings. Exercise
esting may be useful, especially in those interested in
thletic participation. Diagnostic cardiac catheterization
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chocardiographic assessment are disparate.
. Indications for Aortic Balloon Valvotomy in Adoles-
ents and Young Adults
lass I
. Aortic balloon valvotomy is indicated in the adoles-
cent or young adult patient with AS who has symptoms
of angina, syncope, or dyspnea on exertion and a
catheterization peak LV-to-peak aortic gradient greater
than or equal to 50 mm Hg without a heavily calcified
valve. (Level of Evidence: C)*
. Aortic balloon valvotomy is indicated for the asymp-
tomatic adolescent or young adult patient with AS who
has a catheterization peak LV-to-peak aortic gradient
greater than 60 mm Hg. (Level of Evidence: C)*
. Aortic balloon valvotomy is indicated in the asymp-
tomatic adolescent or young adult patient with AS
who develops ST or T-wave changes over the left
precordium on ECG at rest or with exercise and who
has a catheterization peak LV-to-aortic gradient
greater than 50 mm Hg. (Level of Evidence: C)*
lass IIa
. Aortic balloon valvotomy is reasonable in the asymp-
tomatic adolescent or young adult patient with AS
when catheterization peak LV-to-peak aortic gradi-
ent is greater than 50 mm Hg and the patient wants
to play competitive sports or desires to become
pregnant. (Level of Evidence: C)*
. In the adolescent or young adult patient with AS, aortic
balloon valvotomy is probably recommended over valve
surgery when balloon valvotomy is possible. Patients
should be referred to a center with expertise in balloon
valvotomy. (Level of Evidence: C)*
lass III
Aortic balloon valvotomy should not be performed
when the asymptomatic adolescent or young adult
patient with AS has a catheterization peak LV-to-
peak aortic gradient less than 40 mm Hg without
symptoms or ECG changes. (Level of Evidence: C)*
Gradients are usually obtained with patients sedated. If
eneral anesthesia is used, the gradients may be somewhat
ower.
Balloon valvotomy is an efficacious treatment in children
nd adolescents with AS due to fusion of commissures,
hereas it is rarely recommended in older adults with
alcific valves, because even short-term palliation is uncom-
on. There are insufficient published data to establish an
ge cutoff. Until more information becomes available, rec-
mmendations for balloon valvotomy should be limited to
dolescents and young adults. Because balloon valvotomy
as resulted in good midterm palliation with little morbiditynd little or no short- or intermediate-term mortality in
hildren, adolescents, and young adults, the indications for
ntervention are considerably more liberal than those in
lder adults, in whom intervention usually involves AVR.
urgical valvotomy is of historical interest and is now rarely
sed except in situations in which interventional cardiolo-
ists are not available.
Children and young adults with peak Doppler gradients
f 64 mm Hg or more or mean gradients greater than 40
m Hg and those with symptoms may be considered for
ardiac catheterization and possible balloon dilation. Pa-
ients with lower gradients (50 mm Hg peak or 30 mm Hg
ean) are sometimes referred for catheterization if they are
nterested in participating in athletics, are contemplating
regnancy, or have developed ST-T-wave changes over the
eft precordium at rest or with exercise. In those children
ho have had a balloon valvuloplasty when younger, a
epeat attempt is usually tried before surgical valve replace-
ent using the above criteria if significant AR is not
resent.
When balloon aortic valvotomy is ineffective or signifi-
ant AR is present, surgical valve repair or replacement may
e necessary. Because degeneration of homograft or bio-
rosthetic valves is usually accelerated in the young (see
ections VII-A and VII-B), AVR is usually performed with
mechanical valve. Recently, there has been a renewed
nterest in valve repair or the Ross operation (81,492–495).
he most common complications of the Ross procedure are
R, usually secondary to neoaortic root dilation, and RV
utflow tract obstruction, with intervention necessary in
oughly 10% of patients within 7 to 10 years. The indica-
ions for surgery with the Ross operation or heterograft
omograft do not differ from those for mechanical valve
eplacement.
. Aortic Regurgitation
lass I
. An adolescent or young adult with chronic severe
AR* with onset of symptoms of angina, syncope, or
dyspnea on exertion should receive aortic valve repair
or replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients
with chronic severe AR* with LV systolic dysfunction
(ejection fraction less than 0.50) on serial studies 1 to
3 months apart should receive aortic valve repair or
replacement. (Level of Evidence: C)
. Asymptomatic adolescent or young adult patients
with chronic severe AR* with progressive LV enlarge-
ment (end-diastolic dimension greater than 4 stan-
dard deviations above normal) should receive aortic
valve repair or replacement. (Level of Evidence: C)
. Coronary angiography is recommended before AVR
in adolescent or young adult patients with AR in
whom a pulmonary autograft (Ross operation) is
contemplated when the origin of the coronary arter-
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(Level of Evidence: C)
lass IIb
. An asymptomatic adolescent with chronic severe AR*
with moderate AS (peak LV–to–peak aortic gradient
greater than 40 mm Hg at cardiac catheterization)
may be considered for aortic valve repair or replace-
ment. (Level of Evidence: C)
. An asymptomatic adolescent with chronic severe AR*
with onset of ST depression or T-wave inversion over
the left precordium on ECG at rest may be consid-
ered for aortic valve repair or replacement. (Level of
Evidence: C)
See Table 1 (7).
AR is an uncommon isolated congenital lesion, al-
hough it may occasionally develop in adolescents and
oung adults with a bicuspid aortic valve, discrete sub-
ortic obstruction, or prolapse of 1 aortic cusp into a
entricular septal defect. It is commonly the consequence
f attempts to relieve stenosis of the valve by either
alloon dilation or surgical valvulotomy, or after the Ross
rocedure. The indications for surgery with severe iso-
ated AR or mixed aortic valve disease are similar to those
or adults, that is, symptoms, LV dysfunction (ejection
raction less than 0.50), or severely increased LV end-
iastolic or end-systolic diameter, taking into account
ariations in body size. As noted above, surgery has
sually involved mechanical or biological valve replace-
ent (see SectionVII-A), but the Ross operation or
ortic valve repair are viable alternatives in some centers.
ndications for surgery in patients with AR and dilated
ortic roots or ascending aortas are the same as those for
lder adult patients (see Sections III-B-3 and III-C).
. Mitral Regurgitation
lass I
. MV surgery is indicated in the symptomatic adoles-
cent or young adult with severe congenital MR* with
NYHA functional class III or IV symptoms. (Level of
Evidence: C)
. MV surgery is indicated in the asymptomatic adoles-
cent or young adult with severe congenital MR* and
LV systolic dysfunction (ejection fraction less than or
equal to 0.60). (Level of Evidence: C)
lass IIa
MV repair is reasonable in experienced surgical cen-
ters in the asymptomatic adolescent or young adult
with severe congenital MR* with preserved LV sys-
tolic function if the likelihood of successful repairwithout residual MR is greater than 90%. (Level of
Evidence: B)
lass IIb
The effectiveness of MV surgery is not well estab-
lished in asymptomatic adolescent or young adult
patients with severe congenital MR* and preserved
LV systolic function in whom valve replacement is
highly likely. (Level of Evidence: C)
See Table 1 (7).
MR caused by myxomatous MV disease and MVP is a
ommon congenital lesion. MR also develops commonly in
hildren with primum atrioventricular septal defects, which
ay involve an isolated ostium primum atrial septal defect;
entricular septal defect in the inlet (posterior) septum; abnor-
alities of the mitral or tricuspid valve, including clefts; or a
ombination of these disorders. Repair of the defects in early
hildhood is now commonplace, with low mortality and
orbidity. The most common long-term sequela of surgery is
R, which can be mild, moderate, or severe.
The pathophysiology, diagnosis, and therapy of residual
R in atrioventricular septal defects, rheumatic fever, or
VP are similar to those discussed for the adult with MR
Section III-F). When patients with MR develop symptoms
r deteriorating LV systolic function, surgery should be
erformed. MV repair is usually possible in MR after
trioventricular septal defect repair or MR secondary to
VP. Rarely, MV replacement with a mechanical or
iological valve is necessary.
. Mitral Stenosis
lass I
MV surgery is indicated in adolescent or young adult
patients with congenital MS who have symptoms
(NYHA functional class III or IV) and mean MV
gradient greater than 10 mm Hg on Doppler echo-
cardiography.* (Level of Evidence: C)
lass IIa
. MV surgery is reasonable in adolescent or young
adult patients with congenital MS who have mild
symptoms (NYHA functional class II) and mean MV
gradient greater than 10 mm Hg on Doppler echo-
cardiography.* (Level of Evidence: C)
. MV surgery is reasonable in the asymptomatic ado-
lescent or young adult with congenital MS with
pulmonary artery systolic pressure 50 mm Hg or
greater and a meanMV gradient greater than or equal
to 10 mm Hg.* (Level of Evidence: C)
lass IIb
The effectiveness of MV surgery is not well estab-
lished in the asymptomatic adolescent or young adult
with congenital MS and new-onset atrial fibrillation
*a
t
C
o
h
m
o
a
M
c
r
i
T
i
p
i
t
m
w
f
a
c
i
m
b
m
m
M
p
t
p
o
e
a
b
S
E
A
a
t
a
v
t
a
n
p
a
w
t
a
E
a
t
e
r
a
fi
s
d
c
6
o
l
o
1
a
C
1
2
3
4
C
1
2
C
648 Bonow et al. JACC Vol. 48, No. 3, 2006
ACC/AHA Practice Guidelines August 1, 2006:598–675or multiple systemic emboli while receiving adequate
anticoagulation.* (Level of Evidence: C)
See Table 1 (7).
In developed countries, MS in adolescents and young
dults is often congenital in origin. In developing areas of
he world, MS is more likely to result from rheumatic fever.
ongenital MS may be associated with a wide variety of
ther congenital cardiac malformations of the left side of the
eart, including bicuspid aortic valve and AS, supravalvar
itral ring, and coarctation of the aorta.
The clinical, electrocardiographic, and radiologic features
f congenital MS are similar to those of acquired MS in
dults. The echocardiogram is essential in evaluating the
V apparatus and papillary muscles and may provide
onsiderable insight into the feasibility of successful valve
epair. The information obtained from transthoracic imag-
ng is usually sufficient in adolescents and young adults, but
EE is sometimes necessary.
Medical management including beta blockers and diuret-
cs may be of some utility with mild MS. It is important to
revent and treat common complications such as pulmonary
nfections, endocarditis, and atrial fibrillation. Surgical in-
ervention may be necessary in severe cases. The surgical
anagement of congenital MS has improved considerably
ith the improved appreciation of the mechanism of MV
unction and the improved ability to visualize the valve
fforded by TEE. In those patients with a parachute MV,
reation of fenestrations among the fused chordae may
ncrease effective orifice area and improve symptoms dra-
atically. MV replacement may occasionally be necessary
ut is especially problematic in those with a hypoplastic
itral annulus, in whom an annulus-enlarging operation
ay be necessary. Recently, balloon dilation of congenital
S has been attempted (496), but its utility is limited in
atients with significant stenosis of the subvalvular appara-
us. This is one of the most difficult and dangerous thera-
eutic catheterization procedures and should be undertaken
nly in centers with operators who have established experi-
nce and skill in this interventional procedure. In adolescent
nd young adult patients with rheumatic MS, the results of
alloon dilation are similar to those in older adults (see
ection III-D-8).
. Tricuspid Valve Disease
cquired disease of the tricuspid valve is very uncommon in
dolescents and young adults and is usually related to
rauma, bacterial endocarditis in intravenous drug abusers,
nd small ventricular septal defects. Most cases of tricuspid
alve disease are congenital, with Ebstein’s anomaly of the
ricuspid valve being the most common.
There is wide variation in the severity of valve leaflet
bnormalities in Ebstein’s anomaly. An interatrial commu-
ication, usually in the form of a patent foramen ovale, is
resent in most cases. If TR elevates right atrial pressurebove left atrial pressure, right-to-left shunting can occur,
ith resulting hypoxemia. One or more accessory conduc-
ion pathways are quite common, with a risk of paroxysmal
trial tachycardia of approximately 25%. Patients with
bstein’s anomaly may be asymptomatic with no cyanosis
nd no atrial arrhythmias, but they often are cyanotic owing
o right-to-left shunting (497), which is associated with
xercise intolerance. RV dysfunction may eventually lead to
ight-sided heart failure, frequently exacerbated by an atrial
rrhythmia such as atrial tachycardia, atrial flutter, or atrial
brillation. Exercise testing may be useful in determining
ymptom status and degree of exercise-induced arterial
esaturation.
Predictors of poor outcome include NYHA functional
lass III or IV symptoms, cardiothoracic ratio greater than
5%, atrial fibrillation, severity of cyanosis, and magnitude
f TR. However, patients with Ebstein’s anomaly who reach
ate adolescence and adulthood often have an excellent
utcome (498).
. Evaluation of Tricuspid Valve Disease in Adolescents
nd Young Adults
lass I
. An ECG is indicated for the initial evaluation of
adolescent and young adult patients with TR, and
serially every 1 to 3 years, depending on severity.
(Level of Evidence: C)
. Chest X-ray is indicated for the initial evaluation of
adolescent and young adult patients with TR, and
serially every 1 to 3 years, depending on severity.
(Level of Evidence: C)
. Doppler echocardiography is indicated for the initial
evaluation of adolescent and young adult patients
with TR, and serially every 1 to 3 years, depending on
severity. (Level of Evidence: C)
. Pulse oximetry at rest and/or during exercise is
indicated for the initial evaluation of adolescent and
young adult patients with TR if an atrial communi-
cation is present, and serially every 1 to 3 years,
depending on severity. (Level of Evidence: C)
lass IIa
. If there is a symptomatic atrial arrhythmia, an elec-
trophysiology study can be useful for the initial
evaluation of adolescent and young adult patients
with TR. (Level of Evidence: C)
. Exercise testing is reasonable for the initial evalua-
tion of adolescent and young adult patients with TR,
and serially every 1 to 3 years. (Level of Evidence: C)
lass IIb
Holter monitoring may be considered for the initial
evaluation of asymptomatic adolescent and young
adult patients with TR, and serially every 1 to 3 years.
(Level of Evidence: C)
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lass I
. Surgery for severe TR is recommended for adolescent
and young adult patients with deteriorating exercise
capacity (NYHA functional class III or IV). (Level of
Evidence: C)
. Surgery for severe TR is recommended for adolescent
and young adult patients with progressive cyanosis
and arterial saturation less than 80% at rest or with
exercise. (Level of Evidence: C)
. Interventional catheterization closure of the atrial
communication is recommended for the adolescent
or young adult with TR who is hypoxemic at rest and
with exercise intolerance due to increasing hypoxemia
with exercise, when the tricuspid valve appears diffi-
cult to repair surgically. (Level of Evidence: C)
lass IIa
. Surgery for severe TR is reasonable in adolescent and
young adult patients with NYHA functional class II
symptoms if the valve appears to be repairable. (Level
of Evidence: C)
. Surgery for severe TR is reasonable in adolescent and
young adult patients with atrial fibrillation. (Level of
Evidence: C)
lass IIb
. Surgery for severe TR may be considered in asymp-
tomatic adolescent and young adult patients with
increasing heart size and a cardiothoracic ratio of
more than 65%. (Level of Evidence: C)
. Surgery for severe TR may be considered in asymp-
tomatic adolescent and young adult patients with
stable heart size and an arterial saturation of less than
85% when the tricuspid valve appears repairable.
(Level of Evidence: C)
. In adolescent and young adult patients with TR who
are mildly cyanotic at rest but who become very
hypoxemic with exercise, closure of the atrial com-
munication by interventional catheterization may be
considered when the valve does not appear amenable
to repair. (Level of Evidence: C)
. If surgery for Ebstein’s anomaly is planned in ado-
lescent and young adult patients (tricuspid valve
repair or replacement), a preoperative electrophysio-
logical study may be considered to identify accessory
pathways. If present, these may be considered for
mapping and ablation either preoperatively or at the
time of surgery. (Level of Evidence: C)
urgical management of Ebstein’s anomaly remains chal-
enging (499). For adolescents and young adults, tricuspid
alve repair may be performed, especially when there is a
obile anterior leaflet free of tethering to the ventriculareptum. If TR is mild and hypoxemia at rest or exercise isroblematic, closure of the atrial septal defect in the
atheterization laboratory has been successful in eliminating
he hypoxemia. Occasionally, the tricuspid valve is not
eparable, and valve replacement with a bioprosthesis or a
echanical valve may be necessary (500).
. Pulmonic Stenosis
ecause the pulmonary valve is the least likely valve to be
ffected by acquired heart disease, virtually all cases of
ulmonary valve stenosis are congenital in origin. Most
atients with stenosis have a conical or dome-shaped
ulmonary valve formed by fusion of the valve leaflets.
ccasionally, the valve may be thickened and dysplastic,
ith the stenosis caused by inability of the valve leaflets to
eparate sufficiently during ventricular systole.
Symptoms are unusual in children or adolescents with
ulmonary valve stenosis even when severe. Adults with
ong-standing severe obstruction may have dyspnea and
atigue secondary to an inability to increase cardiac output
dequately with exercise. Exertional syncope or light-
eadedness may occur in severe pulmonic stenosis with
ystemic or suprasystemic RV pressures, with decreased
reload or dehydration, or with a low systemic vascular
esistance state (such as pregnancy). Eventually, with long-
tanding untreated severe obstruction, TR and RV failure
ay occur. At any age, if the foramen ovale is patent, RV
ompliance may be reduced sufficiently to elevate right atrial
ressure, which allows right-to-left shunting and cyanosis.
. Evaluation of Pulmonic Stenosis in Adolescents and
oung Adults
lass I
. An ECG is recommended for the initial evaluation of
pulmonic stenosis in adolescent and young adult
patients, and serially every 5 to 10 years for follow-up
examinations. (Level of Evidence: C)
. Transthoracic Doppler echocardiography is recom-
mended for the initial evaluation of pulmonic steno-
sis in adolescent and young adult patients, and
serially every 5 to 10 years for follow-up examina-
tions. (Level of Evidence: C)
. Cardiac catheterization is recommended in the ado-
lescent or young adult with pulmonic stenosis for
evaluation of the valvular gradient if the Doppler
peak jet velocity is greater than 3 m per second
(estimated peak gradient greater than 36 mmHg) and
balloon dilation can be performed if indicated. (Level
of Evidence: C)
lass III
Diagnostic cardiac catheterization is not recom-
mended for the initial diagnostic evaluation of pul-
monic stenosis in adolescent and young adult pa-
tients. (Level of Evidence: C)
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lass I
. Balloon valvotomy is recommended in adolescent
and young adult patients with pulmonic stenosis who
have exertional dyspnea, angina, syncope, or presyn-
cope and an RV-to-pulmonary artery peak-to-peak
gradient greater than 30 mm Hg at catheterization.
(Level of Evidence: C)
. Balloon valvotomy is recommended in asymptomatic
adolescent and young adult patients with pulmonic
stenosis and an RV-to-pulmonary artery peak-to-
peak gradient greater than 40 mm Hg at catheteriza-
tion. (Level of Evidence: C)
lass IIb
Balloon valvotomy may be reasonable in asymptom-
atic adolescent and young adult patients with pul-
monic stenosis and an RV-to-pulmonary artery peak-
to-peak gradient 30 to 39 mm Hg at catheterization.
(Level of Evidence: C)
lass III
Balloon valvotomy is not recommended in asymp-
tomatic adolescent and young adult patients with
pulmonic stenosis and an RV-to–pulmonary artery
peak-to-peak gradient less than 30 mm Hg at cath-
eterization. (Level of Evidence: C)
The clinical course of children and young adults with
ulmonary valve stenosis has been well described. The
econd Natural History of Congenital Heart Defects study
501) reported that the probability of 25-year survival was
6%. Fewer than 20% of patients managed medically
equired a valvotomy, and only 4% of the patients who had
ndergone surgery required a second operation. For
atients who had an initial transpulmonary gradient less
han 25 mm Hg, 96% were free of cardiac operation over
25-year period.
Infective endocarditis was uncommon. Only 1 case de-
eloped in the 592 patients followed up for a median of 18
ears, an incidence of 0.94 per 10 000 patient-years.
Surgical relief of severe obstruction by valvotomy with a
ransventricular or transpulmonary artery approach predates
he introduction of cardiopulmonary bypass. Balloon val-
otomy has now become the procedure of choice in the
nited States for the typically domed, thickened valve
502–504). Although long-term follow-up of pulmonary
alloon valvotomy is not yet available, the early and mid-
erm results (up to 10 years) (505) suggest that the long-
erm results will be similar to surgical valvotomy, with little
r no recurrence over a 22- to 30-year period.
In those with severe or long-standing valvular obstruc-
ion, infundibular hypertrophy may cause secondary ob-
truction when the pulmonary valve is successfully dilated.
his frequently regresses over time without treatment. aome have advocated transient pharmacological beta block-
de, but there is insufficient information to determine
hether this is effective or necessary.
. Pulmonary Regurgitation
ulmonic valve regurgitation is unusual as an isolated
ongenital defect, but it is an almost unavoidable result of
ither surgical or balloon valvuloplasty of valvular pulmonic
tenosis or surgical repair of tetralogy of Fallot. Among
atients with pulmonic stenosis who undergo surgical valvot-
my, 87% have pulmonary regurgitation by Doppler echocar-
iography (501), although it was audible in only 58%.
Most physicians would perform pulmonary valve replace-
ent in patients with NYHA class II or III symptoms and
evere pulmonary regurgitation, but the indications in
symptomatic patients on the basis of regurgitant fraction,
V end-diastolic or end-systolic volume, or RV ejection
raction remain unclear.
II. SURGICAL CONSIDERATIONS
. Aortic Valve Surgery
he types of operations available to treat aortic valve
ysfunction include AVR with a mechanical or biopros-
hetic valve, AVR with an allograft (homograft) valve,
ulmonic valve autotransplantation (Ross operation)
81,492,493,495,506), aortic valve repair, and left ventricle
o–descending aorta shunt. Each has specific advantages
nd disadvantages. Cardiopulmonary bypass is used in aortic
alve operations, and these procedures are usually performed
hrough a median sternotomy incision, although partial
ternotomy (minimally invasive incisions) is gaining accep-
ance. See Sections III-A-6 and III-B-2-g for indications
or AVR or repair in patients with AS and AR.
. Antithrombotic Therapy for Patients With Aortic
echanical Heart Valves
fter mechanical AVR, the goal of antithrombotic therapy
s usually to achieve an INR of 2.5 to 3.5 for the first 3
onths after surgery and 2.0 to 3.0 beyond that time (see
ection IX-A). Low-dose aspirin (75 to 100 mg per day) is
lso indicated in addition to warfarin (485), as discussed in
ection IX-A-1. At that level of anticoagulation, the risk of
ignificant hemorrhage appears to be 1% to 2% per year.
. Stented and Nonstented Heterografts
. Aortic Valve Replacement With Stented Heterografts
he first-generation stented heterografts (porcine hetero-
rafts) exhibited a freedom from structural valve deteriora-
ion of approximately 40% by 18 postoperative years. How-
ver, the rate of structural valve deterioration is age-related
96,507–519), being increased for younger patients, and in
atients less than 40 years of age, approximately half of all
orcine valves fail by 10 years. Bovine pericardial valves
ppear to have a lower rate of structural valve deterioration,
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August 1, 2006:598–675 ACC/AHA Practice Guidelinesith 15-year data indicating that 77% of valves in surviving
atients of all ages are functioning without explantation,
nd among patients undergoing primary AVR at an age
reater than 65 years, fewer than 10% underwent valve
xplantation by 15 postoperative years (96,515). The re-
orted rate of structural valve deterioration for second-
eneration porcine valves appears so far to be equivalent to
hat of stented bovine valves.
. Aortic Valve Replacement With Stentless Heterografts
he major goal of stentless heterografts is to achieve
nhanced hemodynamic efficiency relative to stented valves
520–525). The long-term importance of hemodynamic
fficiency of prosthetic heart valves is currently a subject of
nvestigation and disagreement. The argument favoring the
se of stentless valves is that stented valves of any kind are
t least partially stenotic (particularly in small sizes) and that
ven small postoperative gradients may lead to incomplete
V mass regression postoperatively (522,524–526), which
ill, in turn, lead to impaired long-term survival and
ymptom status.
Stentless heterografts have the disadvantages that their
mplantation is more complex than that for stented valves
nd their long-term outcomes are unknown. There is a low
ncidence (7% to 10%) of early mild AR in some series
522,523,525), which may progress with time. Observa-
ional studies with 8- to 10-year follow-up (527) appear to
how a low risk of structural valve deterioration with
tentless heterografts.
. Aortic Valve Homografts
t had been hoped that aortic valve homografts would
utlast heterografts, particularly in young patients, but to
ate, long-term data do not support this view. One possible
dvantage of homografts is in the avoidance of early endo-
arditis and in the treatment of aortic valve endocarditis
528–531), particularly complex aortic root endocarditis.
he risk of thromboembolism is very low after homograft
mplantation, and hemodynamic efficiency is excellent even
n small sizes. The biggest disadvantage of homografts is
hat reoperation after homograft AVR is more difficult than
eoperation after placement of standard prostheses, because
he entire homograft may become severely calcified.
. Pulmonic Valve Autotransplantation
ulmonic valve autotransplantation (Ross operation) has
een performed in small numbers, and long-term follow-up
tudies have been inconsistent, which makes analysis of
ong-term advantages and disadvantages difficult. The
nown advantages of the procedure are that the autograft
ay grow in children, warfarin is not required, there is a low
ncidence of thromboembolism, the autograft is a hemody-
amically efficient valve, and the incidence of endocarditis is
ow (81,492,493,495,506,532). The disadvantage of pul-
onic autotransplantation is that the operation is much
ore complex than standard AVR and in most series haseen associated with at least some increase in in-hospital
ortality. There is also an incidence of early aortic valve
ailure based on technical considerations or dilatation of the
ortic root, and the homograft used to replace the pulmonic
alve is also subject to failure, sometimes early, within a few
ears of operation (506). Deterioration of the pulmonary
omograft often offsets potential advantages of the au-
ograft.
. Aortic Valve Repair
ultiple strategies for aortic valve repair have been ex-
lored, some successfully. In particular, repair of insufficient
icuspid aortic valves in the adult has been increasingly
uccessful at limited numbers of centers (533–535). Among
he advantages of this strategy are the lack of need for
nticoagulation, a low thromboembolic risk, a low endocar-
itis risk, a hemodynamically efficient valve, and a straight-
orward reoperation, if needed. The disadvantages are lack
f uniform applicability, lack of widespread experience with
urgical techniques, and the need for reoperation. Long-
erm data are limited, but the risk of reoperation appears to
e about 15% by 10 postoperative years.
Much progress has been made in the repair of aortic
alves rendered insufficient by aortic root pathology
228,536–541). When an aortic root aneurysm exists, the
peration to restore competence to the aortic valve involves
esecting the aorta and resuspending the valve in association
ith a Dacron graft that is used to replace the aorta.
dvantages of this strategy include avoidance of warfarin, a
ow thromboembolic risk, a very efficient valve, and what
ppears to be a low risk of prosthetic valve endocarditis. The
isadvantages are, again, limited applicability in the setting
f intrinsic leaflet pathology and the high level of surgical
xpertise and experience required.
. Major Criteria for Aortic Valve Selection
lass I
. A mechanical prosthesis is recommended for AVR in
patients with a mechanical valve in the mitral or
tricuspid position. (Level of Evidence: C)
. A bioprosthesis is recommended for AVR in patients
of any age who will not take warfarin or who have
major medical contraindications to warfarin therapy.
(Level of Evidence: C)
lass IIa
. Patient preference is a reasonable consideration in
the selection of aortic valve operation and valve
prosthesis. A mechanical prosthesis is reasonable for
AVR in patients under 65 years of age who do not
have a contraindication to anticoagulation. A bio-
prosthesis is reasonable for AVR in patients under 65
years of age who elect to receive this valve for lifestyle
considerations after detailed discussions of the risks
of anticoagulation versus the likelihood that a second
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dence: C)
. A bioprosthesis is reasonable for AVR in patients
aged 65 years or older without risk factors for throm-
boembolism. (Level of Evidence: C)
. Aortic valve re-replacement with a homograft is
reasonable for patients with active prosthetic valve
endocarditis. (Level of Evidence: C)
lass IIb
A bioprosthesis might be considered for AVR in a
woman of childbearing age (see Sections V–E and V–F).
(Level of Evidence: C)
. Mitral Valve Surgery
. Mitral Valve Repair
. Myxomatous Mitral Valve
lass I
. MV repair is recommended when anatomically pos-
sible for patients with severe degenerative MR who
fulfill clinical indications, and patients should be
referred to surgeons who are expert in repair. (Level of
Evidence: B)
. Patients who have undergone successful MV repair
should continue to receive antibiotics as indicated for
endocarditis prophylaxis. (Level of Evidence: C)
. Patients who have undergone successful MV repair
and have chronic or paroxysmal atrial fibrillation
should continue to receive long-term anticoagulation
with warfarin. (Level of Evidence: B)
. Patients who have undergone successful MV repair
should undergo 2D and Doppler echocardiography
before discharge or at the first postoperative outpa-
tient visit. (Level of Evidence: C)
. Tricuspid valve repair is beneficial for severe TR in
patients with MV disease that requires MV surgery.
(Level of Evidence: B)
lass IIa
. Oral anticoagulation is reasonable for the first 3
months after MV repair. (Level of Evidence: C)
. Long-term treatment with low-dose aspirin (75 to
100 mg per day) is reasonable in patients who have
undergone successful MV repair and remain in sinus
rhythm. (Level of Evidence: C)
. Tricuspid annuloplasty is reasonable for mild TR in
patients undergoing MV repair when there is pulmo-
nary hypertension or tricuspid annular dilatation.
(Level of Evidence: C)
lass IIb
In patients with MR and a history of atrial fibrilla-
tion, a Maze procedure may be considered at the time
of MV repair. (Level of Evidence: B) Iyxomatous MV disease produces MR based on rupture or
longation of chordae tendineae, valve leaflet instability,
nnulus dilatation, or multiple causes that result in excessive
V leaflet motion. In the majority of these conditions,
xperienced surgeons can repair the MV using strategies
hat involve removal of unsupported leaflet structures, trans-
er of chordae (357,358), or the use of artificial chordae to
upport unstable areas of the leaflet, the sliding of supported
reas of the leaflet to cover the MV orifice, and stabilization
f the size and shape of the MV annulus with an artificial
ing (318,319, 27,343–348). MV repair is the treatment of
hoice for degenerative valve disease, because patients in
inus rhythm do not need warfarin, the thromboembolism
ate is low, valve efficiency and hemodynamics are good,
here is little adverse effect on LV function, the risk of
ndocarditis is low, and the long-term survival rate is
avorable compared with MV replacement (see Section
II-F-3). Concomitant tricuspid valve repair should be
erformed when there is severe TR or mild-to-moderate
R and tricuspid annular dilatation (see Section III-H-2).
n patients presenting for MV repair with chronic atrial
brillation, a concomitant surgical procedure to eliminate
trial fibrillation may prevent future embolic events by
estoring normal sinus rhythm (370–376). The decision to
roceed with a surgical procedure to eliminate atrial fibril-
ation should be made based on the age and health of the
atient, as well as the surgical expertise, because this
rocedure may add to the morbidity of the operation (see
ection III-F-3-b).
The likelihood of a successful MV repair is related to the
xtent of the MV dysfunction (with isolated posterior leaflet
ysfunction being the most favorable condition); the pres-
nce and extent of calcification; the amount of pliable,
oncalcified valve tissue; and surgeon experience. Recurrent
R after repair may occur with time, but in favorable
ituations, more than 90% of valves are still functioning well
fter 10 years (318,319).
. Rheumatic Heart Disease
lass I
Percutaneous or surgical MV commissurotomy is
indicated when anatomically possible for treatment of
severe MS, when clinically indicated. (Level of Evi-
dence: C)
heumatic MR is inconsistently reparable, and the long-
erm outcomes after repair are not as good as for valve repair
or degenerative MV disease. Rheumatic pathology often
eads to leaflet and chordal scarring, which restricts the
eaflet motion, and leaflet scarring may be progressive after
epair. Rheumatic MS that is not associated with severe
hordal fusion or shortening or with calcification may be
reated with either percutaneous or open mitral commissur-
tomy with a high degree of long-term success. Clinical
ndications for these procedures are discussed in Sections
II-D-8 and III-D-9.
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y definition, all patients with ischemic MR have signifi-
ant CAD that usually has a significant effect on long-term
urvival. The pathology of ischemic MR has multiple
ubgroups, with the most common situation being func-
ional MR, in which the valve leaflets are structurally
ormal, but LV chamber enlargement and papillary muscle
isplacement tether the MV via the chordal attachments
nd prevent leaflet coaptation (379–386). When functional
R is severe, it may be corrected by placement of an
nnuloplasty ring that decreases the annular circumference,
hortens the intertrigonal distance, reduces the septal-lateral
anterior-posterior) annular diameter, and restores the ge-
metry of the annulus, thereby allowing the MV leaflets to
oapt (387–390,396–405). This strategy acutely decreases
r eliminates MR, but because the fundamental abnormality
s related to LV function, the late survival rate of these
atients is relatively low compared with patients with other
V pathologies, and the recurrence rate of MR is higher.
or patients with moderate functional MR, it is not yet clear
hether MV repair improves outcomes.
Patients with ischemic MV disease who have anatomic
R based on infarction or rupture of the papillary muscles
enefit from either mitral repair or MV replacement.
apillary muscle rupture often produces severe MR and
emodynamic decompensation, which is an indication for
mergency surgery.
. Mitral Valve Endocarditis
ith increased surgical experience in mitral reparative
echniques, MV endocarditis has become more consistently
reatable with repair (542–544). There appears to be a low
isk of recurrent infection, and in experienced hands, it is
ften possible to avoid the need for an MV prosthesis (see
ection IV-C-1). Surgery, however, must not be delayed
ntil extensive valve disruption has occurred.
. Selection of Mitral Valve Prostheses (Mechanical or
ioprostheses)
lass I
A bioprosthesis is indicated for MV replacement in a
patient who will not take warfarin, is incapable of taking
warfarin, or has a clear contraindication to warfarin
therapy. (Level of Evidence: C)
lass IIa
. A mechanical prosthesis is reasonable for MV replace-
ment in patients under 65 years of age with long-
standing atrial fibrillation. (Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in
patients 65 years of age or older. (Level of Evidence: C)
. A bioprosthesis is reasonable for MV replacement in
patients under 65 years of age in sinus rhythm who
elect to receive this valve for lifestyle considerations
after detailed discussions of the risks of anticoagula- vtion versus the likelihood that a second MV replace-
ment may be necessary in the future. (Level of
Evidence: C)
he selection of a valve is a multifactorial decision. The
TS National Cardiac Surgery Database (93) indicates that
he numbers of MV reparative procedures are increasing
elative to MV replacement. Among patients receiving an
V replacement, more patients received mechanical valves
han bioprostheses. Medicare data indicate that the mortal-
ty for isolated MV replacement in patients older than 65
ears is 14.1%, which increases to 20.5% in low-volume
enters (95).When MV pathology is combined with CAD,
he risks of surgery increase.
. Choice of Mitral Valve Operation
V repair should be able to be achieved by experienced
urgeons for the majority of patients with degenerative MV
isease and ischemic valve disease, and patients should be
eferred to surgeons expert in repair. For patients with
heumatic MV disease and endocarditis, repair may be more
ifficult.
For patients undergoing MV replacement, preservation
f the chordal apparatus preserves LV function and en-
ances postoperative survival compared with MV replace-
ent, in which the apparatus is disrupted (345,353–356), as
iscussed in Section III-F-3. In the randomized trials, there
as no difference in survival rate based on valve type.
owever, the failure rate of bioprostheses has been higher
n the mitral than in the aortic position (96,507–509,512–
16,518,545), which adds impetus to the use of mechanical
rostheses in younger patients.
The availability of surgical ablation procedures for atrial
brillation offers the possibility of converting the patient to
inus rhythm and avoiding anticoagulation after MV repair or
eplacement with a bioprosthesis (370–376). If patients can be
aintained in sinus rhythm, the advantage of a bioprosthesis is
nhanced. For patients with a history of atrial fibrillation who
re undergoing MV repair, a Maze-type procedure results in
inus rhythm in 75% to 90% of cases by 6 postoperative
onths, with long-term data indicating sustained results up to
years and reduced risk of stroke (373,376).
. Tricuspid Valve Surgery
lass I
Severe TR in the setting of surgery for multivalvular
disease should be corrected. (Level of Evidence: C)
lass IIa
Tricuspid annuloplasty is reasonable for mild TR in
patients undergoing MV surgery when there is pul-
monary hypertension or tricuspid annular dilatation.
(Level of Evidence: C)
he most common cause of TR is dilatation of the tricuspid
alve annulus caused by pulmonary hypertension. The
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nnuloplasty usually corrects or improves the situation.
evere TR should be treated with annuloplasty during
perations for multivalvular disease (see Section III-H-2).
hen leaflet anatomy is severely abnormal, tricuspid valve
eplacement may be needed, but this situation is not
ommon. There are no data clearly showing the advantage
f one type of tricuspid prosthesis over another.
. Valve Selection for Women of Child-Bearing Age
here is no ideal valve prosthesis for women of childbearing
ge who might wish to become pregnant. Bioprostheses
ay be subject to premature heterograft or homograft
ailure. Because mechanical valves require anticoagulation,
here is an increased risk of fetal abnormalities and mortal-
ty, and there may be an increased risk of maternal compli-
ations, including thromboembolism. Discussion with the
atient concerning the risk of the prosthesis is important.
III. INTRAOPERATIVE ASSESSMENT
lass I
. Intraoperative TEE is recommended for valve repair
surgery. (Level of Evidence: B)
. Intraoperative TEE is recommended for valve re-
placement surgery with a stentless xenograft, ho-
mograft, or autograft valve. (Level of Evidence: B)
. Intraoperative TEE is recommended for valve sur-
gery for infective endocarditis. (Level of Evidence: B)
lass IIa
Intraoperative TEE is reasonable for all patients under-
going cardiac valve surgery. (Level of Evidence: C)
etailed and comprehensive evaluation of valve lesions
uring cardiac surgery has become possible and common
ince the development of TEE. This includes confirmation
f the preoperative diagnosis and associated pathology,
rovision of additional detail and depth about the severity
nd mechanism of valve dysfunction, detection of previously
ndiagnosed conditions, and evaluation of the surgical result
n the operating room, which makes possible the immediate
orrection of detected problems. Studies have documented
he impact of intraoperative TEE on valve surgery, with
hanges in the operative plan based on TEE findings
eported in 11% to 14% of cases and detection of problems
ith surgical procedure and subsequent need to return to
ardiopulmonary bypass reported in 2% to 6% (546–549).
ther important aspects of TEE during valve surgery
nclude assessment of ventricular function and detection of
ntracardiac air and aortic dissection.
Intraoperative TEE is especially important during valve
epair surgery. Examination before cardiopulmonary bypass
rovides insight into the mechanism of valve dysfunction
nd therefore facilitates surgical planning. More impor-
antly, intraoperative TEE allows immediate assessment ofhe repair after cardiopulmonary bypass. Intraoperative
EE during valve replacement surgery with a stented
rosthetic valve is also useful, although there will be a lower
ate of problems detected after cardiopulmonary bypass.
alve replacement with a stentless xenograft, homograft, or
utograft valve will have a higher likelihood of technical
roblems during surgery, and therefore, TEE is virtually
ssential in this setting because it is currently the best way to
ssess valve function intraoperatively.
The committee recommends that institutions performing
alve surgery establish consistent and credible intraoperative
chocardiography programs with knowledgeable echocar-
iographers committed to and capable of providing accurate
natomic and functional information relevant to valve op-
rations.
X. MANAGEMENT OF PATIENTS WITH PROSTHETIC
EART VALVES
he results of valve surgery with regard to survival, func-
ional class, valve function, and complications are dependent
n patient-related factors, cardiac function, type of surgery,
ype of prosthesis, and medical comorbidities (550).
. Antithrombotic Therapy
lass I
. After AVR with bileaflet mechanical or Medtronic Hall
prostheses, in patients with no risk factors,* warfarin is
indicated to achieve an INR of 2.0 to 3.0. If the patient
has risk factors, warfarin is indicated to achieve an INR
of 2.5 to 3.5. (Level of Evidence: B)
. After AVR with Starr-Edwards valves or mechanical
disc valves (other than Medtronic Hall prostheses), in
patients with no risk factors,* warfarin is indicated to
achieve an INR of 2.5 to 3.5. (Level of Evidence: B)
. After MV replacement with any mechanical valve,
warfarin is indicated to achieve an INR of 2.5 to 3.5.
(Level of Evidence: C)
. After AVR or MV replacement with a bioprosthesis
and no risk factors,* aspirin is indicated at 75 to 100
mg per day. (Level of Evidence: C)
. After AVR with a bioprosthesis and risk factors,*
warfarin is indicated to achieve an INR of 2.0 to 3.0.
(Level of Evidence: C)
. After MV replacement with a bioprosthesis and risk
factors,* warfarin is indicated to achieve an INR of
2.5 to 3.5. (Level of Evidence: C)
. For those patients who are unable to take warfarin
after MV replacement or AVR, aspirin is indicated in
a dose of 75 to 325 mg per day. (Level of Evidence: B)
. The addition of aspirin 75 to 100 mg once daily to
therapeutic warfarin is recommended for all patients
with mechanical heart valves and those patients with
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Evidence: B)
lass IIa
. During the first 3 months after AVR with a mechan-
ical prosthesis, it is reasonable to give warfarin to
achieve an INR of 2.5 to 3.5. (Level of Evidence: C)
. During the first 3 months after AVR or MV replace-
ment with a bioprosthesis, in patients with no risk
factors,* it is reasonable to give warfarin to achieve an
INR of 2.0 to 3.0. (Level of Evidence: C)
lass IIb
In high-risk patients with prosthetic heart valves in
whom aspirin cannot be used, it may be reasonable to
give clopidogrel (75 mg per day) or warfarin to
achieve an INR of 3.5 to 4.5. (Level of Evidence: C)
Risk factors include atrial fibrillation, previous thromboem-
olism, LV dysfunction, and hypercoagulable condition.
All patients with mechanical valves require warfarin
herapy, as indicated in Table 2 (568). Aspirin is recom-
ended for all patients with prosthetic heart valves: aspirin
lone in patients with bioprostheses and no risk factors, and
spirin combined with warfarin in patients with mechanical
eart valves and high-risk patients with bioprostheses. In
igh-risk patients who cannot take aspirin, the addition of
lopidogrel to warfarin therapy should be considered. Even
ith the use of warfarin, risk of thromboembolism is 1% to
% per year (99,100,102,551–553), but the risk is consid-
rably higher without treatment with warfarin (554).
Almost all studies have shown that the risk of embolism is
reater with a valve in the mitral position (mechanical or
Table 2. Recommendations for Antithromboti
Heart Valves
Valve Type
Aspirin
(75–100 mg)
Mechanical prosthetic
AVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR—high risk Class I
MVR Class I
Biological prosthetic
AVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
AVR—high risk Class I
MVR—low risk
Less than 3 months Class I
Greater than 3 months Class I
MVR—high risk Class I
Depending on patients’ clinical status, antithrombotic therap
receiving warfarin, aspirin is recommended in virtually all sit
previous thromboembolism, and hypercoagulable condition. I
2.5 and 3.5 for aortic disc valves and Starr-Edwards valves.
therapy in valvular heart disease. In: Schlant R, Alexander
1998:1867–74. Reprinted with permission from the McGraw-Hill
AVR indicates aortic valve replacement; and MVR, mitral valviological) than with one in the aortic position (100,106,553–
55). With either type of prosthesis or valve location, the risk
f emboli is probably higher in the first few days and months
fter valve insertion (556), before the valve is fully endotheli-
lized (480).
. Mechanical Valves
ll patients with mechanical valves require anticoagulation.
or mechanical prostheses in the aortic position, the INR with
arfarin therapy should be maintained between 2.0 and 3.0 for
ileaflet valves and Medtronic Hall valves and between 2.5 and
.5 for other disc valves and Starr-Edwards valves. For pros-
heses in the mitral position, the INR should be maintained
etween 2.5 and 3.5 for all mechanical valves. There is a
ifference of opinion regarding the Starr-Edwards valve in the
ortic position, with the minority opinion recommending that
NR be maintained between 2.0 and 3.0. In patients with
ortic mechanical prostheses who are at higher risk of throm-
oembolic complications, INR should be maintained at 2.5 to
.5, and the addition of aspirin should be considered (see
elow). These include patients with atrial fibrillation, previous
hromboembolism, and a hypercoagulable state. Many would
lso include patients with severe LV dysfunction in this
igher-risk group (557).
The addition of low-dose aspirin (75 to 100 mg per day)
o warfarin therapy (INR 2.0 to 3.5) not only further
ecreases the risk of thromboembolism (485,558–562) but
lso decreases mortality due to other cardiovascular diseases.
slight increase in the risk of bleeding with this combina-
ion should be kept in mind (558,563). The addition of
spirin (75 to 100 mg per day) to warfarin should be
trongly considered unless there is a contraindication to the
se of aspirin. This combination is particularly appropriate
erapy in Patients With Prosthetic
arfarin
R 2.0–3.0)
Warfarin
(INR 2.5–3.5) No Warfarin
lass I Class IIa
lass I
Class I
Class I
lass IIa Class IIb
Class IIa
lass I
lass IIa
Class IIa
lass I
be individualized (see special situations in text). In patients
. Risk factors: atrial fibrillation, left ventricular dysfunction,
tional normalized ratio (INR) should be maintained between
ified from McAnulty JH, Rahimtoola SH. Antithrombotic
ditors. Hurst’s The Heart. New York, NY: McGraw-Hill,c Th
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ACC/AHA Practice Guidelines August 1, 2006:598–675n patients who have had an embolus while undergoing
arfarin therapy, those with known vascular disease, and
hose who are known to be particularly hypercoagulable. As
n example, such combination therapy is recommended by a
ommittee concerning the use of antithrombotic therapy in
omen during pregnancy (484). The method of anticoag-
lation in pregnant patients is controversial and is discussed
n Section V-F.
It is important to note that thromboembolic risk is
ncreased early after insertion of the prosthetic heart valve.
he use of UFH early after prosthetic valve replacement,
efore warfarin achieves therapeutic levels, is controversial.
any centers start UFH as soon as the risk of increased
urgical bleeding is reduced (usually within 24 to 48 h), with
aintenance of aPTT between 55 and 70 s. After an overlap
f UFH and warfarin for 3 to 5 days, UFH is discontinued
hen an INR of 2.0 to 3.0 is achieved. In some patients,
chievement of therapeutic INR must be delayed several
ays after surgery because of mitigating complications.
. Biological Valves
ecause of an increased risk of thromboembolism during
he first 3 months after implantation of a biological pros-
hetic valve, anticoagulation with warfarin is often used,
specially when the valve is in the mitral position (556),
lthough most centers use only aspirin for biological valves
n the aortic position. The risk is particularly high in the first
ew days after surgery, and many centers start UFH as soon
s the risk of increased surgical bleeding is reduced (usually
ithin 24 to 48 h), with maintenance of aPTT between 55
nd 70 s. After an overlap of UFH and warfarin for 3 to 5
ays, UFH may be discontinued when an INR of 2.0 to 3.0
s achieved. After 3 months, the tissue valve can be treated
ike native valve disease, and warfarin can be discontinued in
ore than two thirds of patients with biological valves
102,556,564). In the remaining patients with associated
isk factors for thromboembolism, such as atrial fibrillation,
revious thromboembolism, or hypercoagulable condition,
ifelong warfarin therapy is indicated to achieve an INR of
.0 to 3.0. Many would also recommend continuing anti-
oagulation in patients with severe LV dysfunction (ejection
raction less than 0.30) (557).
. Embolic Events During Adequate Antithrombotic
herapy
n the patient who has a definite embolic episode(s) while
ndergoing adequate antithrombotic therapy, the dosage of
ntithrombotic therapy should be increased, when clinically
afe, as follows:
Warfarin, INR 2.0 to 3.0: warfarin dose increased to
achieve INR of 2.5 to 3.5;
Warfarin, INR 2.5 to 3.5: warfarin dose may need to
be increased to achieve INR of 3.5 to 4.5;
Not taking aspirin: aspirin 75 to 100 mg per day
should be initiated;Warfarin plus aspirin 75 to 100 mg per day: aspirin
dose may also need to be increased to 325 mg per day
if the higher dose of warfarin is not achieving the
desired clinical result;
Aspirin alone: aspirin dose may need to be increased
to 325 mg per day, clopidogrel 75 mg per day added,
and/or warfarin added.
. Excessive Anticoagulation
n most patients with INR above the therapeutic range,
xcessive anticoagulation can be managed by withholding
arfarin and monitoring the level of anticoagulation with serial
NR determinations (480). Excessive anticoagulation (INR
reater than 5) greatly increases the risk of hemorrhage.
owever, rapid decreases in INR that lead to INR falling
elow the therapeutic level increase the risk of thromboembo-
ism. Patients with prosthetic heart valves with an INR of 5 to
0 who are not bleeding can be treated by withholding
arfarin and administering 1 to 2.5 mg of oral vitamin K1
phytonadione) (480,565). The INR should be determined
fter 24 h and subsequently as needed. Warfarin therapy is
estarted and adjusted dose appropriately to ensure that the
NR is in the therapeutic range. In emergency situations, the
se of fresh frozen plasma is preferable to high-dose vitamin
1 (566), especially parenteral vitamin K1, because use of the
atter increases the risk of overcorrection to a hypercoagulable
tate. Low-dose intravenous vitamin K (less than 1 mg)
ppears safe in this situation (567).
. Bridging Therapy in Patients With Mechanical Valves
ho Require Interruption of Warfarin Therapy for Non-
ardiac Surgery, Invasive Procedures, or Dental Care
lass I
. In patients at low risk of thrombosis, defined as those
with a bileaflet mechanical AVR with no risk factors,*
it is recommended that warfarin be stopped 48 to 72 h
before the procedure (so the INR falls to less than
1.5) and restarted within 24 h after the procedure.
Heparin is usually unnecessary. (Level of Evidence: B)
. In patients at high risk of thrombosis, defined as
those with any mechanical MV replacement or a
mechanical AVR with any risk factor, therapeutic
doses of IV UFH should be started when the INR
falls below 2.0 (typically 48 h before surgery), stopped
4 to 6 h before the procedure, restarted as early after
surgery as bleeding stability allows, and continued
until the INR is again therapeutic with warfarin
therapy. (Level of Evidence: B)
lass IIa
It is reasonable to give fresh frozen plasma to patients
with mechanical valves who require interruption of
warfarin therapy for emergency noncardiac surgery,
invasive procedures, or dental care. Fresh frozen
CC
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of Evidence: B)
lass IIb
In patients at high risk of thrombosis (see above),
therapeutic doses of subcutaneous UFH (15 000 U
every 12 h) or LMWH (100 U per kg every 12 h) may
be considered during the period of a subtherapeutic
INR. (Level of Evidence: B)
lass III
In patients with mechanical valves who require in-
terruption of warfarin therapy for noncardiac surgery,
invasive procedures, or dental care, high-dose vita-
min K1 should not be given routinely, because this
may create a hypercoagulable condition. (Level of
Evidence: B)
Risk factors: atrial fibrillation, previous thromboembolism,
V dysfunction, hypercoagulable conditions, older generation
hrombogenic valves, mechanical tricuspid valves, or more
han 1 mechanical valve.
The risk of increased bleeding during a procedure per-
ormed with a patient receiving antithrombotic therapy has
o be weighed against the increased risk of a thromboem-
olism caused by stopping the therapy. The risk of stopping
arfarin can be estimated and is relatively slight if the drug
s withheld for only a few days.
Management of antithrombotic therapy must be individ-
alized, but some generalizations apply (568). Antithrom-
otic therapy should not be stopped for procedures in which
leeding is unlikely or would be inconsequential if it
ccurred, for example, surgery on the skin, dental cleaning,
r simple treatment for dental caries. Eye surgery, particu-
arly for cataracts or glaucoma, is usually associated with
ery little bleeding and thus is frequently performed without
lterations to antithrombotic treatment. When bleeding is
ikely or its potential consequences are severe, antithrom-
otic treatment should be altered.
For patients with a bileaflet mechanical aortic valve and
o risk factors, warfarin should be stopped before the
rocedure so that the INR is less than 1.5 (which is often 48
o 72 h after warfarin is discontinued) (568,569) and
estarted within 24 h after a procedure. Admission to the
ospital or a delay in discharge to give heparin is usually
nnecessary.
Patients at high risk of thrombosis include all patients
ith mechanical mitral or tricuspid valve replacements and
atients with an AVR and any risk factors. Such risk factors
nclude atrial fibrillation, previous thromboembolism, hy-
ercoagulable condition, older-generation mechanical
alves, LV dysfunction (ejection fraction less than 0.30), or
ore than 1 mechanical valve (570–572). When UFH is
sed, it should be started when INR falls below 2.0 (i.e.,
8 h before surgery) and stopped 4 to 6 h before therocedure. UFH should be restarted as early after surgery as
leeding stability allows, and the aPTT should be main-
ained at 55 to 70 s until warfarin is therapeutic. LMWH is
ttractive because it is more easily used outside the hospital;
owever, concerns about the use of LMWH for mechanical
alves persists, and package inserts continue to list a warning
or this use of these medications (490).
High-dose vitamin K1 should not be given routinely,
ecause this may create a hypercoagulable condition. For
mergency situations, fresh frozen plasma is preferable to
igh-dose vitamin K1 (see Section IX-A-4).
. Antithrombotic Therapy in Patients Who Need Car-
iac Catheterization/Angiography
n an emergency or semiurgent situation, cardiac catheter-
zation can be performed in a patient taking warfarin, but
referably, the drug should be stopped so that INR is less
han 1.5. The drug should be restarted as soon as the
rocedure is completed. If a patient has more than 1 risk
actor that predisposes to thromboembolism, heparin
hould be started when INR falls below 2.0 and should be
ontinued when warfarin is restarted. After an overlap of 3
o 5 days, heparin may be discontinued when the desired
NR is achieved. If the catheterization procedure is to
nclude a transseptal puncture (especially in a patient who
as not had previous opening of the pericardium), patients
hould be removed from all antithrombotic therapy, and
NR should be less than 1.2.
. Thrombosis of Prosthetic Heart Valves
lass I
. Transthoracic and Doppler echocardiography is in-
dicated in patients with suspected prosthetic valve
thrombosis to assess hemodynamic severity. (Level of
Evidence: B)
. TEE and/or fluoroscopy is indicated in patients with
suspected valve thrombosis to assess valve motion
and clot burden. (Level of Evidence: B)
lass IIa
. Emergency operation is reasonable for patients with a
thrombosed left-sided prosthetic valve and NYHA
functional class III–IV symptoms. (Level of Evidence: C)
. Emergency operation is reasonable for patients with a
thrombosed left-sided prosthetic valve and a large
clot burden. (Level of Evidence: C)
. Fibrinolytic therapy is reasonable for thrombosed
right-sided prosthetic heart valves with NYHA class
III–IV symptoms or a large clot burden. (Level of
Evidence C)
lass IIb
. Fibrinolytic therapy may be considered as a first-line
therapy for patients with a thrombosed left-sided
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ACC/AHA Practice Guidelines August 1, 2006:598–675prosthetic valve, NYHA functional class I–II symp-
toms, and a small clot burden. (Level of Evidence: B)
. Fibrinolytic therapy may be considered as a first-line
therapy for patients with a thrombosed left-sided
prosthetic valve, NYHA functional class III–IV
symptoms, and a small clot burden if surgery is high
risk or not available. (Level of Evidence: B)
. Fibrinolytic therapy may be considered for patients
with an obstructed, thrombosed left-sided prosthetic
valve who have NYHA functional class II–IV symp-
toms and a large clot burden if emergency surgery is
high risk or not available. (Level of Evidence: C)
. Intravenous UFH as an alternative to fibrinolytic
therapy may be considered for patients with a throm-
bosed valve who are in NYHA functional class I–II
and have a small clot burden. (Level of Evidence: C)
ibrinolytic therapy for a left-sided prosthetic valve ob-
tructed by thrombus is associated with significant risks
cerebral emboli in 12% to 15% of cases) and is often
neffective. Fibrinolytic therapy in such patients is reserved
or those in whom surgical intervention carries a high risk
nd those with contraindications to surgery (573–580).
In patients with a “small clot” who are in NYHA
unctional class I or II, treatment with short-term intrave-
ous UFH therapy or continuous infusion of fibrinolytic
herapy may be considered (576–580). The size threshold
or this recommendation is difficult to define because of the
ack of large cohort studies and differing thresholds from
mall studies (ranging from 5 to 10 mm, as determined
y TEE) below which intravenous UFH or fibrinolytic
herapy is safe and effective (575,578–580). Factors that
dentify patients at risk for adverse outcomes of fibrinolytic
herapy include active internal bleeding, history of hemor-
hagic stroke, recent cranial trauma of neoplasm, diabetic
emorrhagic retinopathy, large thrombi, mobile thrombi,
ypertension (greater than 200 over 120 mm Hg), hypo-
ension or shock, and NYHA functional class III–IV
ymptoms. If fibrinolytic therapy is successful, it should be
ollowed by intravenous UFH until warfarin achieves an
NR of 3.0 to 4.0 for aortic prosthetic valves and 3.5 to 4.5
or mitral prosthetic valves. If partially successful, fibrino-
ytic therapy may be followed by a combination of subcu-
aneous UFH twice daily (to achieve an aPTT of 55 to 80 s)
lus warfarin (INR 2.5 to 3.5) for a 3-month period (576).
Patients with small thrombi who receive intravenous
FH as first-line therapy and who do not respond success-
ully may receive a trial of continuous-infusion fibrinolytic
herapy. If fibrinolytic therapy is unsuccessful or there is an
ncreased risk associated with fibrinolytic therapy, reopera-
ion should be considered. An alternative in patients who
emain hemodynamically stable is to convert intravenous
FH to combined therapy with subcutaneous UFH (twice
aily to an aPTT of 55 to 80 s) and warfarin (INR 2.5 to
.5) for 1 to 3 months on an outpatient basis to allow for
ndogenous fibrinolysis (576). If intravenous UFH, fibrino- eytic therapy, combined UFH/fibrinolytic therapy, or com-
ined UFH/warfarin is successful, warfarin doses should be
ncreased so that INR is between 3.0 and 4.0 (approximately
.5) for prosthetic aortic valves and between 3.5 and 4.5
approximately 4.0) for prosthetic MVs. These patients
hould also receive low-dose aspirin.
Thrombosis of mechanical tricuspid valve prostheses may
e treated with fibrinolytic therapy, although experience
ith this is limited (581,582).
. Follow-Up Visits
lass I
. For patients with prosthetic heart valves, a history,
physical examination, and appropriate tests should be
performed at the first postoperative outpatient evalua-
tion, 2 to 4 weeks after hospital discharge. This should
include a transthoracic Doppler echocardiogram if a
baseline echocardiogram was not obtained before hos-
pital discharge. (Level of Evidence: C)
. For patients with prosthetic heart valves, routine
follow-up visits should be conducted annually, with
earlier re-evaluations (with echocardiography) if there is
a change in clinical status. (Level of Evidence: C)
lass IIb
Patients with bioprosthetic valves may be considered
for annual echocardiograms after the first 5 years in
the absence of a change in clinical status. (Level of
Evidence: C)
lass III
Routine annual echocardiograms are not indicated in
the absence of a change in clinical status in patients
with mechanical heart valves or during the first 5
years after valve replacement with a bioprosthetic
valve. (Level of Evidence: C)
. First Outpatient Postoperative Visit
he first outpatient evaluation after valve surgery usually
ccurs 3 to 4 weeks after hospital discharge. By this time,
he patient’s physical capabilities and expected improvement
n functional capacity can be assessed. The workup on this
isit should include an interval or complete history and
hysical examination, ECG, chest X-ray, 2D and Doppler
chocardiography, complete blood count, blood urea nitro-
en/creatinine, electrolytes, lactate dehydrogenase, and
NR, if indicated. Echocardiography is the most useful
oninvasive test. It provides information about prosthesis
tenosis/regurgitation, valve area, assessment of other valve
isease(s), pulmonary hypertension, atrial size, LV and RV
ypertrophy, LV and RV size and function, and pericardial
ffusion/thickening. It is an essential component of the first
ostoperative visit because it allows an assessment of the
ffects and results of surgery, as well as serving as a baseline
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. Follow-Up Visits in Patients Without Complications
atients who have undergone valve replacement are not
ured but still have serious heart disease. The clinical course
f patients with prosthetic heart valves is influenced by
everal factors (550), including LV dysfunction, progression
f other valve disease, pulmonary hypertension, other car-
iac diseases, complications of prosthetic heart valves, and
linical heart failure. The interval between routine
ollow-up visits depends on the patient’s needs.
The asymptomatic uncomplicated patient needs to be
een only at 1-year intervals, at which time a complete
istory and thorough physical examination should be per-
ormed. No further echocardiographic testing is required
fter the initial postoperative evaluation in patients with
echanical valves who are stable and who have no symp-
oms or clinical evidence of LV dysfunction, prosthetic valve
ysfunction, or dysfunction of other heart valves (1). Once
egurgitation is detected, close follow-up with 2D and
oppler echocardiography every 3 to 6 months is indicated.
chocardiography is indicated in any patient with a pros-
hetic heart valve whenever there is evidence of a new
urmur or change in clinical status, when there are ques-
ions about prosthetic valve integrity and function, and
hen there are concerns about ventricular function.
. Follow-Up Visits in Patients With Complications
lass I
Patients with LV systolic dysfunction after valve
surgery should receive standard medical therapy for
systolic heart failure. This therapy should be contin-
ued even if there is improvement of LV dysfunction.
(Level of Evidence: B)
V dysfunction and clinical heart failure after valve replace-
ent may be the result of preoperative LV dysfunction that
ersists or improves only partially, perioperative myocardial
amage, other valve disease that has progressed, complica-
ions of prosthetic heart valves, and associated heart disease
uch as CAD and systemic hypertension. Any patient with
prosthetic heart valve who does not improve after surgery
r who later shows deterioration of functional capacity
hould undergo appropriate testing, including 2D and
oppler echocardiography and, if necessary, TEE and
ardiac catheterization with angiography to determine the
ause. Patients with postoperative LV systolic dysfunction,
ven if asymptomatic, should receive standard medical
herapy for systolic heart failure, and this therapy should be
ontinued indefinitely even if there is improvement in
ystolic function and/or symptoms. All patients should also
eceive primary and secondary prevention measures to re-
uce the risk of future cardiovascular events. N. EVALUATION AND TREATMENT OF CORONARY
RTERY DISEASE IN PATIENTS WITH VALVULAR
EART DISEASE
any patients with valvular heart disease have concomitant
AD, but there are only limited data regarding the optimal
trategies for diagnosis and treatment of CAD in such patients.
hus, management decisions are usually developed by blend-
ng information from the randomized studies of treatment of
AD and the smaller published series of patients undergoing
urgical treatment of valvular heart disease.
. Probability of Coronary Artery Disease in Patients
ith Valvular Heart Disease
he prevalence of CAD in patients with valvular heart
isease is determined by the same variables as in the general
opulation (583), and risk factors should be approached
ith the prevention and risk reduction strategies that have
een recommended for the general population (584).
Ischemic symptoms in patients with valvular heart disease
ay have multiple causes, such as LV chamber enlargement,
ncreased wall stress or wall thickening with subendocardial
schemia (585), and RV hypertrophy (586). Angina is thus
less specific indicator of CAD in patients with valvular
eart disease than in the general population.
Among patients with severe AS, angina is a common
ymptom in young patients with normal coronary arteries and
ongenital or rheumatic AS. On the other hand, CAD is a
ommon finding in older symptomatic men with AS. In
lderly patients (greater than 70 years old), angina is a strong
eterminant of CAD (sensitivity 78%, specificity 82%) (587).
alcification of the aortic valve is also associated with a high
resence of CAD (90%) (588). In general, because angina is a
oor marker of CAD in patients with AS, coronary angiogra-
hy is recommended in symptomatic patients before AVR in
en older than 35 years; premenopausal women older than 35
ears with coronary risk factors, as well as asymptomatic men
lder than 45 years; women older than 55 years; or those with
or more coronary risk factors.
CAD is less prevalent in patients with AR than in those
ith AS, and the prevalence of CAD in patients with MS
s lower than in patients with aortic valve disease, an
bservation explained principally on the basis of differences
n age and gender. Nonetheless, because of the impact of
ntreated CAD on perioperative and long-term postopera-
ive survival, preoperative identification of CAD is of great
mportance in patients with AR or MS and those with AS.
hus, in symptomatic patients and/or those with LV
ysfunction, preoperative coronary angiography is recom-
ended in men aged greater than 35 years, premenopausal
omen aged greater than 35 years with coronary risk
actors, and postmenopausal women.
The relation between MR and CAD is unique in that CAD
s frequently the cause of this valve lesion. The management of
hese patients is discussed in Sections III-F-4 and VII-B-1-c.
either angina nor heart failure symptoms are reliable markers
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ion to evaluate the cause and severity of MR, CAD is present
n an average of 33% (589,590). In patients undergoing
atheterization for acute ischemic syndromes, an average of
0% have associated MR (591). Those with chronic CAD and
R usually have lower LV ejection fractions and more
xtensive CAD than those without MR.
. Diagnosis of Coronary Artery Disease
lass I
. Coronary angiography is indicated before valve sur-
gery (including infective endocarditis) or mitral bal-
loon commissurotomy in patients with chest pain,
other objective evidence of ischemia, decreased LV
systolic function, history of CAD, or coronary risk
factors (including age). Patients undergoing mitral
balloon valvotomy need not undergo coronary an-
giography solely on the basis of coronary risk factors.
(Level of Evidence: C)
. Coronary angiography is indicated in patients with
apparently mild to moderate valvular heart disease
but with progressive angina (Canadian Heart Asso-
ciation functional class II or greater), objective evi-
dence of ischemia, decreased LV systolic function, or
overt congestive heart failure. (Level of Evidence: C)
. Coronary angiography should be performed before
valve surgery in men aged 35 years or older, premeno-
pausal women aged 35 years or older who have coronary
risk factors, and postmenopausal women. (Level of
Evidence: C)
lass IIa
Surgery without coronary angiography is reasonable
for patients having emergency valve surgery for acute
valve regurgitation, aortic root disease, or infective
endocarditis. (Level of Evidence: C)
lass IIb
Coronary angiography may be considered for patients
undergoing catheterization to confirm the severity
of valve lesions before valve surgery without pre-
existing evidence of CAD, multiple coronary risk
factors, or advanced age. (Level of Evidence: C)
lass III
. Coronary angiography is not indicated in young
patients undergoing nonemergency valve surgery
when no further hemodynamic assessment by cathe-
terization is deemed necessary and there are no
coronary risk factors, no history of CAD, and no
evidence of ischemia. (Level of Evidence: C)
. Patients should not undergo coronary angiography
before valve surgery if they are severely hemodynam-
ically unstable. (Level of Evidence: C) The resting ECG in patients with valvular heart disease
requently shows ST-segment changes due to LV hypertro-
hy, LV dilatation, or bundle-branch block, which reduces
he accuracy of the ECG at rest and during exercise for the
iagnosis of concomitant CAD.
Given the importance of determining the presence of
AD, coronary angiography remains the most appropriate
ethod for the definitive diagnosis of CAD. Noninvasive
maging is useful when CAD is suspected in patients with
ild valve stenosis or regurgitation and normal LV cavity
ize and wall thickness, but it has a limited role in patients
ith severe valvular heart disease.
In patients undergoing emergency valve surgery for acute
R, aortic dissection, or endocarditis with hemodynamic
nstability, cardiac catheterization, aortography, and coro-
ary angiography are rarely required, are associated with
ncreased risk, and might delay urgent surgery unnecessarily
136,139–142). Angiography should be considered only
hen the valve diagnosis cannot be determined by noninvasive
maging and when patients have known CAD, especially those
ith previous CABG (see Section III-B-1-b).
. Treatment of Coronary Artery Disease at the Time of
ortic Valve Replacement
lass I
Patients undergoing AVR with significant stenoses
(greater than or equal to 70% reduction in luminal
diameter) in major coronary arteries should be treated
with bypass grafting. (Level of Evidence: C)
lass IIa
. In patients undergoing AVR and coronary bypass
grafting, use of the left internal thoracic artery is
reasonable for bypass of stenoses of the left anterior
descending coronary artery greater than or equal to
50% to 70%. (Level of Evidence: C)
. For patients undergoing AVR with moderate stenosis
(50% to 70% reduction in luminal diameter), it is
reasonable to perform coronary bypass grafting in
major coronary arteries. (Level of Evidence: C)
s noted previously, more than 33% of patients with AS
ndergoing AVR have concomitant CAD, and more than
0% of patients older than 70 years have CAD. The
ddition of CABG to AVR has had little or no adverse
ffect on operative mortality. Moreover, combined CABG
nd AVR reduces the rates of perioperative myocardial
nfarction, operative mortality, and late mortality and mor-
idity compared with patients with significant CAD who do
ot undergo revascularization at the time of AVR. It has
ecome standard practice to bypass all significant coronary
rtery stenoses when possible in patients undergoing AVR.
he committee recommends this approach.
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oronary Artery Bypass Surgery
lass I
AVR is indicated in patients undergoing CABG who
have severe AS who meet the criteria for valve replace-
ment (see Section III-A-6). (Level of Evidence: C)
lass IIa
AVR is reasonable in patients undergoing CABG
who have moderate AS (mean gradient 30 to 50 mm
Hg or Doppler velocity 3 to 4 m per second). (Level
of Evidence: B)
lass IIb
AVR may be considered in patients undergoing
CABG who have mild AS (mean gradient less than
30 mm Hg or Doppler velocity less than 3 m per
second) when there is evidence, such as moderate-
severe valve calcification, that progression may be
rapid. (Level of Evidence: C)
atients undergoing CABG who have severe AS should
ndergo AVR at the time of revascularization. Decision
aking is less clear in patients who have CAD that requires
ABG when these patients have mild to moderate AS.
ontroversy persists regarding the indications for “prophy-
actic” AVR at the time of CABG in such patients. This
ecision should be made only after the severity of AS is
etermined by Doppler echocardiography and cardiac cath-
terization.
Confirmation by cardiac catheterization is especially im-
ortant in patients with reduced stroke volumes, mixed
alve lesions, or intermediate mean aortic valve gradients
between 30 and 50 mm Hg) by Doppler echocardiography,
ecause many such patients may actually have severe AS (as
iscussed in Section III-A-5). The more complex and
ontroversial issue is the decision to replace the aortic valve
or only mild AS at the time of CABG, because the degree
f AS may become more severe within a few years, neces-
itating a second, more difficult AVR operation in a patient
ith patent bypass grafts.
It is difficult to predict whether a given patient with CAD
nd mild AS is likely to develop significant AS in the years
fter CABG. As noted previously (see Section III-A-2), the
atural history of mild AS is variable, with some patients
anifesting a relatively rapid progression of AS with a
ecrease in valve area of up to 0.3 cm2 per year and an
ncrease in pressure gradient of up to 15 to 19 mm Hg per
ear; however, the majority may show little or no change
20,22–26,37,592–597). The average rate of reduction in
alve area is on average 0.12 cm2 per year (20), but the rate
f change in an individual patient is difficult to predict.
Retrospective studies of patients who have come to AVR
fter previous CABG have been reported in which the mean
ime to reoperation was 5 to 8 years (598–603). The aorticalve gradient at the primary operation was small, less than
0 mm Hg, but the mean gradient increased significantly to
reater than 50 mm Hg at the time of the second operation.
t is important to note that these reports represent selected
atients in whom AS progressed to the point that AVR was
arranted. The number of patients in these surgical series
ho had similar gradients at the time of the primary
peration but who did not have significant progression of
S is unknown.
Although definitive data are not yet available, patients
ith intermediate aortic valve gradients (30 to 50 mm Hg
ean gradient at catheterization or transvalvular velocity of
to 4 m per second by Doppler echocardiography) who are
ndergoing CABG may warrant AVR at the time of
evascularization (108–112), whereas patients with gradi-
nts below 10 mm Hg do not need valve replacement. The
egree of mobility and calcification are also important
actors predicting more rapid progression of aortic disease
nd should be taken into consideration, particularly in those
ith gradients between 10 and 25 mm Hg (29,108,112–
14,604–607).
. Management of Concomitant Mitral Valve Disease and
oronary Artery Disease
ost patients with both MV disease and CAD have
schemic MR, as discussed in Sections III-F-4 and VII-B-
-c. In patients with 1 to 2 MR, ischemic symptoms
sually dictate the need for revascularization. Patients with
ore severe ischemic MR usually have significant LV
ysfunction, and the decision to perform revascularization
nd MV repair is based on symptoms, severity of CAD, LV
ysfunction, and inducible myocardial ischemia.
In patients with MV disease due to diseases other than
schemia, significantly obstructed coronary arteries identi-
ed at preoperative cardiac catheterization are generally
evascularized at the time of MV surgery. There are no data
o indicate the wisdom of this general policy, but because
evascularization usually adds little morbidity or mortality to
he operation, the additional revascularization surgery is
sually recommended.
PPENDIX 1. Abbreviation List
CC  American College of Cardiology
CE  angiotensin-converting enzyme
HA  American Heart Association
PTT  activated partial thromboplastin time
R  aortic regurgitation
S  aortic stenosis
VR  aortic valve replacement
ABG  coronary artery bypass graft surgery
AD  coronary artery disease
CG  electrocardiogram
NR  international normalized ratio
MWH  low-molecular-weight heparin
V  left ventricularcontinued on next page
AM
M
M
M
N
R
T
T
U
2
R
662 Bonow et al. JACC Vol. 48, No. 3, 2006
ACC/AHA Practice Guidelines August 1, 2006:598–675PPENDIX 1. Continued
R  mitral regurgitation
S  mitral stenosis
V  mitral valve
VP  mitral valve prolapse
YHA  New York Heart Association
V  right ventricular
EE  transesophageal echocardiography
R  tricuspid regurgitation
FH  unfractionated heparin
D  2-dimensional
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